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Teratology PrimerPreface
The first edition of the Teratology Primer was published by the Teratology Society in 
June 2005. Thousands of copies have been distributed to colleagues and trainees. The 
fundamental information provided in the first edition is still valid, however, knowledge grows 
constantly. We have included new topics in this second edition and the chapters that appeared 
in the original Primer have been updated. 
The goal of this second edition of the Primer, like that of the first, is to give you in a few short 
pages, a sense of what this field is about. What is teratology? Do I want to be a teratologist? 
How are new chemicals evaluated for their reproductive risk? What exposures should we be 
concerned about? This Teratology Primer is meant to answer these questions and more. Topics 
range from how birth defects are diagnosed, to the impact of genes or environmental exposures, 
to ethical considerations, to the use of systems biology or computational approaches to predict 
teratogenic risk. 
The Primer was written by scientists who want to share their fascination for the development 
of complex organisms from a couple of microscopic cells, and for why and how, things don’t 
always go right in the process. Being a teratologist is having a front row seat for the most 
exciting and mysterious performances known to this planet. We hope that you will become as 
excited about working in this field as are the contributing authors. If you find yourself drawn to 
a topic and you want to learn more, we hope that you will contact the Teratology Society. You 
are the future of this field.
We are especially pleased that the timing of this second edition of the Teratology Primer 
coincides with the 50th anniversary of the Teratology Society. As we enter this new decade for 
the Society, we have decided to drop the traditional format of a paper bound book and move 
to an electronic only version for the Teratology Primer. The Primer will be freely available on 
the Teratology Society Web site (http://www.teratology.org) as a single PDF or as PDFs of 
individual chapters. This approach will allow for a wider scope of circulation of the Primer, 
permit more frequent updates of the content, and help save a forest of trees. 
It is our hope that this edition of the Teratology Primer lays the common foundation for basic 
scientists, clinician scientists, healthcare professionals, trainees, policy makers and anyone who 
has an interest in the discipline to acquire the knowledge that they seek. We have tried to give 
a balanced presentation of different views but not every scientist whose name is listed as a 
contributor to this book will agree with every statement made in the book.
We should like to acknowledge the dedicated support of headquarters staff for their roles in 
the production of this Primer. We thank the National Institute of Environmental Health Sciences, 
NIH for their financial support. Finally, we thank all the contributors and members of the 
Teratology Society for their valuable contributions and support in making this Primer possible. 
The Teratology Society 
Editors 
Barbara Hales, Anthony Scialli, and Melissa Tassinari 
2010 
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“What a piece of work is an embryo!” as Hamlet might 
have said. “In form and moving how express and admirable! 
In complexity how infinite!” It starts as a single cell, which 
by repeated divisions gives rise to many genetically identical 
cells. These cells receive signals from their surroundings and 
from one another as to where they are in this ball of cells 
—front or back, right or left, headwards or tailwards, and 
what they are destined to become. Each cell commits itself 
to being one of many types; the cells migrate, combine into 
tissues, or get out of the way by dying at predetermined times 
and places. The tissues signal one another to take their own 
pathways; they bend, twist, and form organs. An organism 
emerges. This wondrous transformation from single celled 
simplicity to myriad-celled complexity is programmed by 
genes that, in the greatest mystery of all, are turned on and 
off at specified times and places to coordinate the process. It 
is a wonder that this marvelously emergent operation, where 
there are so many opportunities for mistakes, ever produces 
a well-formed and functional organism. 
And sometimes it doesn’t. Mistakes occur. Defective 
genes may disturb development in ways that lead to death 
or to malformations. Extrinsic factors may do the same. 
“Teratogenic” refers to factors that cause malformations, 
whether they be genes or environmental agents. The word 
comes from the Greek “teras,” for “monster,” a term applied 
in ancient times to babies with severe malformations, which 
were considered portents or, in the Latin, “monstra.”
Malformations can happen in many ways. For example, 
when the neural plate rolls up to form the neural tube, 
it may not close completely, resulting in a neural tube 
defect—anencephaly if the opening is in the head region, or 
spina bifida if it is lower down. The embryonic processes that 
form the face may fail to fuse, resulting in a cleft lip. Later, 
the shelves that will form the palate may fail to move from 
the vertical to the horizontal, where they should meet in the 
midline and fuse, resulting in a cleft palate. Or they may 
meet, but fail to fuse, with the same result. The forebrain may 
fail to induce the overlying tissue to form the eye, so there is 
no eye (anophthalmia). The tissues between the toes may fail 
to break down as they should, and the toes remain webbed.
Experimental teratology flourished in the 19th century, 
and embryologists knew well that the development of bird and 
frog embryos could be deranged by environmental “insults,” 
such as lack of oxygen (hypoxia). But the mammalian uterus 
was thought to be an impregnable barrier that would protect 
the embryo from such threats. By exclusion, mammalian 
malformations must be genetic, it was thought. 
In the early 1940s, several events changed this view. 
In Australia an astute ophthalmologist, Norman Gregg, 
established a connection between maternal rubella (German 
measles) and the triad of cataracts, heart malformations, 
and deafness. In Cincinnati Josef Warkany, an Austrian 
pediatrician showed that depriving female rats of vitamin B 
(riboflavin) could cause malformations in their offspring—
one of the early experimental demonstrations of a teratogen. 
Warkany was trying to produce congenital cretinism by 
putting the rats on an iodine deficient diet. The diet did 
indeed cause malformations, but not because of the iodine 
deficiency; depleting the diet of iodine had also depleted it 
of riboflavin!  
Several other teratogens were found in experimental 
animals, including nitrogen mustard (an anti cancer drug), 
trypan blue (a dye), and hypoxia (lack of oxygen). The 
pendulum was swinging back; it seemed that malformations 
were not genetically, but environmentally caused. 
In Montreal, in the early 1950s, Clarke Fraser’s group 
wanted to bring genetics back into the picture. They had 
found that treating pregnant mice with cortisone caused cleft 
palate in the offspring, and showed that the frequency was 
high in some strains and low in others. The only difference 
was in the genes. So began “teratogenetics,” the study of how 
genes influence the embryo’s susceptibility to teratogens. 
F. Clarke Fraser
McGill University (Emeritus)
Montreal, Quebec, Canada
What is Teratology?
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“Achondroplasia Gladiator”—
Bibliotheque Nationale, Paris
[In “Congenital Malformatons”  
by J. Warkany, Year Book Medical 
Publishers, 1971]
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The McGill group went on to develop the idea that 
an embryo’s genetically determined, normal, pattern of 
development could influence its susceptibility to a teratogen— 
the multifactorial threshold concept. For instance, an embryo 
must move its palate shelves from vertical to horizontal 
before a certain critical point or they will not meet and 
fuse. A teratogen that causes cleft palate by delaying shelf 
movement beyond this point is more likely to do so in an 
embryo whose genes normally move its shelves late.
As studies of the basis for abnormal development 
progressed, patterns began to appear, and the principles 
of teratology were developed. These stated, in summary, 
that the probability of a malformation being produced by 
a teratogen depends on the dose of the agent, the stage 
at which the embryo is exposed, and the genotype of the 
embryo and mother.
The number of mammalian teratogens grew, and those 
who worked with them began to meet from time to time, to 
talk about what they were finding, leading, in 1960, to the 
formation of the Teratology Society. There were, of course, 
concerns about whether these experimental teratogens 
would be a threat to human embryos, but it was thought, 
by me at least, that they were all “sledgehammer blows,” 
that would be teratogenic in people only at doses far above 
those to which human embryos would be exposed. So not to 
worry, or so we thought. 
Then came thalidomide, a totally unexpected 
catastrophe. The discovery that ordinary doses of this 
supposedly “harmless” sleeping pill and anti-nauseant could 
cause severe malformations in human babies galvanized 
this new field of teratology. Scientists who had been quietly 
working in their laboratories suddenly found themselves 
spending much of their time in conferences and workshops, 
sitting on advisory committees, acting as consultants for 
pharmaceutical companies, regulatory agencies, and 
lawyers, as well as redesigning their research plans. 
The field of teratology and developmental toxicology 
expanded rapidly. The following pages will show how far we 
have come, and how many important questions still remain 
to be answered. A lot of effort has gone into developing ways 
to predict how much of a hazard a particular experimental 
teratogen would be to the human embryo (chapters 9–19). 
It was recognized that animal studies might not prove a drug 
was “safe” for the human embryo (in spite of great pressure 
from legislators and the public to do so), since species can 
vary in their responses to teratogenic exposures. A number 
of human teratogens have been identified, and some, 
suspected of teratogenicity, have been exonerated—at 
least of a detectable risk (chapters 21–32). Regulations for 
testing drugs before market release have greatly improved 
(chapter 14). Other chapters deal with how much such 
things as population studies (chapter 11), post-marketing 
surveillance (chapter 13), and systems biology (chapter 16) 
add to our understanding. And, in a major advance, the 
maternal role of folate in preventing neural tube defects 
and other birth defects is being exploited (chapter 32). 
Encouraging women to take folic acid supplements and 
adding folate to flour have produced dramatic falls in the 
frequency of neural tube defects in many parts of the world.
Progress has been made not only in the use of 
animal studies to predict human risks, but also to illumine 
how, and under what circumstances, teratogens act to 
produce malformations (chapters 2–8). These studies have 
contributed greatly to our knowledge of abnormal and also 
normal development. Now we are beginning to see exactly 
when and where the genes turn on and off in the embryo, to 
appreciate how they guide development and to gain exciting 
new insights into how genes and teratogens interact. The 
prospects for progress in the war on birth defects were never 
brighter.
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Human Birth Defects
What Birth Defects are Common in humans?   
how are They Diagnosed at Birth?
A malformation is a structural abnormality with surgical, 
medical, or cosmetic importance.	 About 2% of newborn 
infants have a malformation. The frequency increases to 3% 
at 1 year of age, as additional abnormalities are identified. 
The frequency of malformations is higher in spontaneous 
abortions than in liveborn infants, reflecting the fact that 
many of the most severe problems are incompatible with 
survival.
Defects in the formation of the heart are the most 
common birth defects and are recognized in about 15% of 
infants with birth defects. Heart defects are found by listening 
to the infant’s heart for the presence of a heart murmur. 
The examining physician decides whether or not to have 
additional studies, such as an echocardiogram, to identify a 
specific heart abnormality. Many heart defects are minor and 
transients and routine echocardiography would identify up to 
5% of babies as having an abnormality, even though only a 
small fraction of these children have a clinically important 
problem. Therefore, the rate of detection of birth defects is 
very dependent on how much effort is put into finding birth 
defects.
Other common abnormalities include extra fingers and 
toes (polydactyly), especially on the outer aspect of the hands, 
webbing between fingers and toes (syndactyly), defects in 
closure of the developing spine (myelomeningocele), club 
foot (talipes equinovarus and calcaneovalgus) cleft lip, cleft 
palate, and incomplete closure of the urethra of the male 
(hypospadias). Because these abnormalities are readily 
identifiable by examining the outside of the child, they 
are less prone to variation based on level of effort of the 
examining clinician.
Variation by Race and Ethnic Group:
Many common birth defects are much more common 
in individuals from one race or ethnic group in comparison 
to another. For example, the dangling extra finger along the 
fifth finger side of the hand occurs in 1% of African newborn 
infants in comparison to 10 times less (0.1%) in Caucasian 
infants born in the United States. Another example is spina 
bifida, more common among Hispanic infants than in 
African-American infants. A third example is the fact that 
Polynesian infants born in New Zealand have a much higher 
frequency of club foot deformity in comparison to Caucasian 
infants born in the same country.
how are Malformations Identified?
Many birth defects, such as polydactyly, syndactyly, 
hypospadias, club foot, cleft lip, and spina bifida, are 
diagnosed by the infant’s doctor in a “surface”  examination 
at birth. Often, the first signs of heart defects are a murmur 
heard in the initial examination. Many abnormalities of 
the kidneys, such as hydronephrosis, multicystic dysplasia, 
and absence of the kidney, can be identified in the routine 
prenatal screening by ultrasound at 18 to 20 weeks of 
pregnancy. There are often no signs of these “silent” urinary 
tract abnormalities at birth. The more testing applied to a 
pregnancy or a newborn, the more likely an abnormality will 
be found. Early medical or surgical treatment of some of 
these defects in important, so liberal use of diagnostic testing 
may be helpful. In other instances, diagnostic testing creates 
undue worry about a defect that may be transient or clinically 
unimportant.
Establishing the Diagnosis and apparent Cause
The physician examining a child with a common 
malformation like a heart defect, hypospadias, cleft lip or 
club foot, determines whether or not the abnormality is 
“isolated” or is one of several birth defects. Many isolated 
and common malformations are attributed to multifactorial 
Genetic Cause
      Dominant or recessive gene  3%
      Chromosomal aberrations 10%
      Multifactorial inheritance  23%
      Familial conditions 15%
Teratogens* and uterine factors** 5.6%
Twinning*** 0.4%
Unknown cause 43%
 100%
* Teratogens were insulin-dependent diabetes mellitus in the 
mother; anticonvulsant and anticoagulant drugs
** Uterine factors included amnion rupture which produced limb 
deformities
*** Twinning associated defects were conjoined twins
(from Nelson K and Holmes LB, 1989) 
Causes of Birth DefeCts
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inheritance, a process that is thought to include more than 
one genetic abnormality and other non-genetic factors. 
The practical significance of this type of inheritance is that 
there is an increased chance that the brothers and sisters 
or, when older, the sons and daughters, will have the same 
abnormality.
When a common malformation occurs in association 
with other malformations, it is more likely to be associated 
with a chromosome abnormality or is due to a genetic 
syndrome (chapter 6). Chromosome abnormalities are 
diagnosed by routine chromosome analysis or the new 
chromosome microarray testing. These tests identify extra 
chromosomes (trisomies), unbalanced translocations, and 
more subtle chromosome deletions and duplications. If a 
genetic syndrome is suspected, the testing available can 
be identified in the listings at www.genetests.org. A brief 
summary of most genetic disorders is provided by the on-line 
Mendelian Inheritance in Man, a catalog of autosomal 
dominant, autosomal recessive and X-linked disorders. For 
most malformations, the cause of the condition is unknown; 
however, an increasing number of genetic abnormalities are 
being described as causes of malformations.
Environmental exposures are occasional causes of 
birth defects. Although many parents of children with 
malformations feel guilty about an exposure to a medication 
or workplace chemical, in most cases, careful evaluation of 
the exposure history does not suggest exposure as a cause 
of the malformation. For most malformations, the cause of 
the condition is unknown; however, an increasing number 
of genetic abnormalities are being described as causes of 
malformations.
Treatments
The “isolated” malformations are typically corrected 
by surgical repair. However, one dramatic exception is the 
talipes equinovarus club foot deformity. The pioneering work 
of Ignacio Ponsetti, M.D., an orthopedist at the University of 
Iowa, showed that over 90% of the affected infants could be 
treated successfully with serial casting over the first few weeks 
of life. The treated infant continues to wear corrective braces 
for several weeks and then, only during naps and while 
asleep for three years. This non-surgical approach makes 
successful treatment more readily available in developing 
countries.
new Research Findings
Many investigators have been searching for the gene 
mutations associated with the common malformations. 
Several mutations have been identified and are a factor in 
the occurrence of cleft lip, cleft palate, heart malformations, 
club foot, hypospadias, and holoprosencephaly. In general, 
the testing for these associated mutations has been carried 
out by research laboratories and is not available in 
commercial laboratories. Investigators are also identifying 
non-genetic etiologic factors, such as nutritional deficiencies 
in the mother of an infant with gastroschisis, an abdominal 
wall defect.
Even though environmental exposures, including 
medications, are unusual as causes of malformations, 
a great deal of effort is expended in identifying possible 
teratogenic exposures. The evaluation of possible teratogenic 
exposures involves an interpretation of experimental animal 
and epidemiology studies. The identification of a new 
teratogenic exposure informs the at-risk pregnant woman 
and her clinician and offers the possibility of prevention of 
birth defects.
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What Is the Timeline of Important Events During Pregnancy  
That May Be Disrupted by a Teratogenic Exposure?
Critical Periods of DevelopmentChapter 2
Pregnancy is typically envisioned as consisting of three 
sequential trimesters, each lasting three months. Many 
events occur during prenatal development that are critical 
for the success of the pregnancy and, ultimately, the birth of 
a healthy child. These events can be described as milestones 
of pregnancy, or periods and phases during which essential 
events occur. Normal development of the conceptus plus 
its supporting membranes and placenta—can be adversely 
affected by poor maternal health and nutrition, genetic 
mutation, environmental exposures, or a combination 
of these factors. The focus of this chapter is the timing of 
important events that may be disrupted by a teratogenic 
exposure (Figure 2-1). Although there are critical periods 
in which the conceptus is highly susceptible to teratogenic 
exposure, in fact, the conceptus can be susceptible to 
exposure prior to and throughout in utero development and 
even postnatally. 
In addition to using trimesters to measure the progress 
of pregnancy, three periods of development are used as 
milestones: the period of the egg, the period of the embryo, 
and the period of the fetus. The period of the egg is 
generally defined as the time during pregnancy that precedes 
implantation—that is, the time from formation of the zygote 
until the blastocyst burrows into the wall of the receptive, 
hormonally primed, uterus. This is initiated by the end of 
the first week post fertilization. The conceptus at this stage 
appears grossly spherical. The second period, the period of 
the embryo, is roughly defined as the time from implantation 
through the 8th week of development. During this second 
period, part of the conceptus takes on the shape of what can 
be readily recognized as an embryo (Figure 2-2), a simple 
organism composed of a rudimentary head, trunk, and tail, 
projecting limb buds, a beating heart, obvious eyes, and 
a primitive segmentation. The remainder of the conceptus 
contributes to the extra-embryonic membranes, such as the 
amnion, which enclose and protect the embryo during its 
development, and to the fetal component of the placenta. 
The final period, the period of the fetus, extends from the 
beginning of the 9th week of gestation until birth. This period 
is characterized by rapid growth, and the differentiation of 
cells, resulting in the formation of distinct tissue types that 
become assembled into functional organ systems. 
Figure 2-2. Photographs of human embryos at five stages of 
gestation reproduced from the collection of the Congenital Anomaly 
Research Center, Kyoto University Graduate School of Medicine, 
courtesy of Dr. Kohei Shiota, Ms. Chigako Uwabe, and Dr. Shigehito 
Yamada. Shown (from left to right) are Carnegie Stages 9, 10, 13, 
17, and 23 during the period of the embryo. The Stage 9 embryo 
has initiated neurulation, which is largely completed by Stage 10 
with the exception that the cranial and caudal ends of the neural 
tube remain open as the neuropores. By Stage 13, body folding has 
established the tube-within-a-tube body plan of the early embryo, 
with a distinct head, trunk, and tail, and paddle-like limb buds. 
By Stage 17, the developing eyes are readily identifiable, and 
the limb buds now have bulbous distal plate-like structures that 
will form the hands and the feet. By Stage 23—the last stage in 
the period of the embryo—all external structures have taken on 
morphologies similar to those of the adult.
Figure 2-1. Timeline of important events during pregnancy that 
may be disrupted by a teratogenic exposure. Shown are the lengths 
of pregnancy in days (0–280, from conception or fertilization 
to birth), the span of the three trimesters (3 months each), the 
three periods of prenatal development (egg, embryo, and fetus), 
key developmental events (fertilization, cleavage, implantation, 
gastrulation, primary morphogenesis, organogenesis, and birth), 
and some outcomes of teratogenic exposure.
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Periods of development broadly define the structure 
of the developing organism at three different times during 
pregnancy. For example, the structure of the pre-blastocyst 
conceptus prior to gastrulation is rather different than the 
definitive structure of the embryo proper and its supporting 
tissues, which are elaborated during the period of the embryo. 
The embryo contains the rudiments of the organs of the fetus 
which makes the link between the structure of the embryo 
and fetus more intuitive, but, for example, the paddle-like 
limb buds present in the early embryo are non-functional 
and have a very different structure than that of the upper and 
lower limbs of the fetus, which at birth are fully functional. 
Just as the egg contains the precursor cells for the rudiments 
of the embryo, the embryo contains the precursor cells for 
all of the tissues and organs of the fetus. Precursor cells—
regardless of their period in development—are susceptible 
to disruption by teratogenic exposures, which can alter their 
survival, rate of proliferation, migratory activity, ability to 
differentiate, or to function properly.
Phases of development define not the structure of the 
developing organism, but the unique developmental events that 
are occurring at that time. Four major phases are recognized 
in the prenatal development of humans: gametogenesis; 
fertilization, cleavage, and blastulation; gastrulation	
and	formation of the tube-within-a-tube body plan; and 
organogenesis, with cellular and tissue differentiation 
and rapid growth. The gametes are generated during 
gametogenesis in the ovaries of the female and the testes of 
the male. During gametogenesis, germ cells (first identifiable 
in the yolk sac—an extra-embryonic membrane) migrate to 
the developing gonads, divide mitotically, and then initiate 
meiosis, which is completed postnatally after the onset of 
puberty, resulting in the generation of haploid oocytes and 
spermatozoa. 
During the second phase, fertilization, cleavage, and 
blastulation, the oocyte and spermatozoon fuse to produce 
a diploid zygote, which rapidly initiates a series of mitotic 
divisions (that is, undergoes cleavage) to produce a solid 
ball of cells called a morula. As the morula passes down 
the oviduct toward the uterus, it forms an internal cavity, 
transforming into a hollow cyst-like structure called the 
blastocyst. The blastocyst is capable of implanting into the 
wall of the uterus, initiating in utero development of the 
embryo. During implantation, the blastocyst differentiates 
two cell regions: the outer trophoblast, consisting of the cells 
that invade the uterine wall and contribute to the formation 
of the placenta, and the inner cell mass, the source of the 
embryo and its extra-embryonic membranes. 
As implantation is occurring, the embryo initiates the 
third phase, gastrulation, a process in which three distinct 
cell layers (germ layers) form, each of which gives rise 
to specific derivatives. The ectoderm forms the nervous 
system, the mesoderm forms most of the muscle and bone 
of the embryo, and the endoderm forms the lining of the 
gastrointestinal tract. These three germ layers are stacked 
upon each other like pancakes. This two-dimensional stack 
becomes sculpted into a three-dimensional embryo having 
a tube-within-a-tube body plan and containing rudiments 
of all of the major organ systems. How this body plan is 
achieved is referred to as primary morphogenesis and it 
involves localized changes in the shape, size, position, and 
numbers of cells in the three germ layers, generating tissue 
movements such as thickening, folding, delamination, and 
fusion. As a result of primary morphogenesis, specific organ 
rudiments are generated as well as an embryonic body 
that is now largely separated from its surrounding extra-
embryonic membranes. For example, the outer tube of the 
tube-within-a-tube body plan is the future body wall; it is 
generated by the expansion, folding, and fusion of the edges 
of the two-dimensional embryo. Its outer wall is in direct 
contact with amniotic fluid after formation of the amniotic 
cavity. Simultaneously, the inner tube of the tube-within-a-
tube body plan is formed: the future gastrointestinal tract or 
gut tube, lined with endoderm. 
Simultaneously, other primary morphogenetic events 
are occurring to generate the rudiments of the major organ 
systems. During a process called neurulation, a portion of the 
ectoderm thickens, then folds inward and fuses at its edges 
to form a third tube, the neural tube, the rudiment of the 
entire adult central nervous system. Some cells left over from 
the process of neurulation delaminate from the ectoderm to 
form neural crest cells, an important population of migratory 
cells that contribute to a number of organ systems such as the 
mesenchyme of the developing face, the cranial and spinal 
ganglion of the peripheral nervous system, and the septum 
that partitions the outflow tract of the heart into two major 
vessels that separate the systemic and pulmonary circulation: 
the aortic and pulmonary vessels. Mesodermal cells in the 
developing trunk of the embryo undergo segmentation to 
form transient structures called somites, which give rise to 
the muscles and bones of the trunk, as well as the adjacent 
dermis of the skin. Some cranial mesodermal cells condense 
into paired tubes that fuse to form the heart during the 
process of cardiogenesis. After the formation of a single 
heart tube, this rudiment rapidly loops upon itself, begins 
to beat and pump blood, and then partitions to form four 
rudimentary chambers: the right and left atria, and right 
and left ventricles. Still other mesodermal cells arrange into 
tubules, contributing to the developing urogenital system.
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The final phase, organogenesis, involves the growth 
and differentiation of precursor cells and tissues contained 
within each of the organ rudiments formed during primary 
morphogenesis. Of the four phases, organogenesis occurs 
over the longest period of time, extending from about four 
weeks of development (during the period of the embryo), 
throughout the fetal period, and even continuing postnatally 
for some organ systems.
Teratogenic exposure during any period or phase of 
development can have dire consequences (Figure 2-1). In 
general, disruption of the earliest developmental stages 
(gametogenesis; fertilization, cleavage, and blastulation) 
results in the loss of the conceptus (a miscarriage, often 
before the woman realizes she is pregnant). Disruption 
during primary morphogenesis and organogenesis may 
result in major structural anomalies, what is usually termed a 
birth defect, (e.g., a neural tube defect such as spina bifida, 
a ventral body wall defect such as gastroschisis, a heart 
defect such as the formation of a single outflow tract, a limb 
anomaly, such as phocomelia, or a facial cleft such as cleft 
lip or palate). Disruption during the late embryonic and fetal 
period generally results in abnormal organ differentiation, 
growth, and function (e.g., mental retardation, hearing loss, 
neonatal hypoglycemia, lung immaturity). Thus, the timing 
of a particular teratogenic exposure can result in different 
outcomes. Examples that illustrate this are discussed in later 
chapters.
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What are the Possible Consequences of Pre-Conception  
Germ Cell Exposures on Pregnancy Outcome?
Pre-Conception Germ Cell ExposureChapter 3
Certain exposures during pregnancy can 
damage the developing embryo or fetus. But can 
a pre-conception exposure of germ cells, either 
oocytes or spermatozoa, also result in adverse 
effects? 
Female Germ Cells: Oocytes
Few studies in this area have been done on 
oocytes although some studies have shown that 
exposure of female rats or mice, as adults, in 
the early post-natal window or during gestation, 
to chemicals such as 4-vinylcyclohexene or to 
therapeutic agents such as cyclophosphamide, 
can result in a reduction of primordial, primary, 
or antral follicles. In the mid-gestation female 
fetus, oocytes progress through meiotic prophase, 
undergoing the complex events of synapsis and 
recombination, and then enter a protracted arrest 
phase in late prophase. During this time window, 
in utero exposures to specific environmental 
chemicals may affect the ability of chromosomes 
to synapse, leading to chromosomal segregation 
errors. In the post-pubertal adult ovary, oocyte 
growth resumes to culminate in the completion 
of meiosis I and the ovulation of a metaphase II–arrested 
egg. Disturbances in growth may affect these processes 
and disrupt spindle formation and the alignment of 
chromosomes. However, it is laborious to obtain mature 
oocytes from the ovary and relatively few scientists have 
studied these processes. Due to our growing reliance on 
in vitro fertilization techniques, in vitro oocyte maturation 
procedures are of increasing interest. There are several studies 
that suggest that oocytes maturing in vitro are susceptible 
to chemical insults. It is clear that additional studies are 
needed to determine whether these exposures will result in 
adverse effects on embryo quality and whether exposures 
in vivo may have similar effects.
Targets in the Male Reproductive system
Spermatozoa are much easier to study. They are 
abundant, replenished daily, and easy to obtain; on 
average, a man produces 100 million sperm/day. Male 
germ cells undergo several mitotic and two meiotic divisions, 
followed by chromatin remodeling to repackage the haploid 
genome for delivery to the oocyte. Male germ cells show 
differential vulnerability to the action of chemicals and 
altered environmental conditions during these cell division 
and chromatin remodeling events.
The extent to which human paternal exposures contribute 
to infertility and abnormal pregnancy outcomes is not clear. 
In some studies, being a welder, painter, auto mechanic, or 
fireman has been associated with an increased risk of male 
infertility and adverse effects on progeny outcome, including 
increases in spontaneous abortions, birth defects, and 
childhood cancer. It is difficult to link paternally mediated 
adverse effects on pregnancy outcome to any specific 
chemical or combination of chemicals from these studies of 
occupational exposures. First, infertility and pregnancy loss 
are frequent in humans even without chemical exposures. 
Secondly, there is often little information available on dose, 
duration of exposure, or potential chemical interactions. 
One group that is an exception in this respect is the male 
survivors of childhood cancer; medical records document 
the selection and dose of chemotherapeutic agents and 
radiation therapy that these patients received. A large 
Figure 3-1.
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follow-up study has revealed that survivors who were not 
sterile were only half as likely to sire a pregnancy as their 
siblings. Radiation therapy of more than 7.5 Gy to the testes, 
higher cumulative alkylating agent dose, and treatment 
with cyclophosphamide or procarbazine were identified as 
risk factors. Indeed, one recent study has shown that the 
sperm generated two years after chemotherapy maintain a 
significant degree of chromatin damage. The establishment 
of a battery of chromatin quality tests would assist in 
counselling cancer survivors.
There are three mechanisms by which paternal exposure 
to a drug theoretically may adversely affect progeny outcome. 
In animal experiments, high doses of several drugs, including 
the anticancer alkylating agent cyclophosphamide, given 
to males before mating were found in the seminal fluid of 
male rats. Cyclophosphamide was transmitted to the female 
during mating, and caused a dose-dependent decrease in 
the number of early embryos. This effect could be due to 
direct exposure of the early conceptus or through an effect 
on sperm function. 
Since normal testicular function depends on hormonal 
signals coming from the pituitary, that is, in turn, controlled 
by the hypothalamus, interference with communication 
between the hypothalamic-pituitary complex and the testis 
may have adverse effect on spermatogenesis. Alternatively, 
chemicals may target the testis directly. Treatment of male 
rats with high doses of di(2-ethylhexyl) phthalate (DEHP), a 
commonly used plasticizer, reduces serum testosterone and 
increases serum luteinizing hormone (LH) levels; the reduction 
in testosterone is due to an effect on the testis rather than the 
hypothalamic-pituitary axis. Ethane dimethanesulphonate 
targets Leydig cells and epididymal principal cells. Sertoli 
cells are targeted by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 
(TCDD) or hexanedione. Disrupting the functions of these 
cells may alter germ cell quantity or quality; this would be 
anticipated to affect male fertility, but may or may not directly 
affect offspring. 
The third mechanism is a direct effect of the toxicant 
on the male germ cell, either during spermatogenesis in 
the testis or sperm maturation in the epididymis. Damage 
that arrests sperm production or maturation cannot affect 
offspring because the germ cells never achieve the ability 
to fertilize oocytes. But when spermatozoa are affected by 
drugs or chemicals and still retain their ability to fertilize 
eggs, trouble may arise. 
Male Germ Cells in the Testis or the Epididymis
Rat spermatogonia undergo several mitotic cell divisions 
to become spermatocytes and then two meiotic cell divisions 
to form spermatids. Development of spermatids, called 
spermiation, includes a condensation of nuclear elements, 
the development of a propulsion mechanism, the shedding 
of most of the cytoplasm, leading to the production 
of spermatozoa. The kinetics of progression through 
spermatogenesis are very tightly controlled. Therefore, we 
can deduce the stage of spermatogenesis affected by a 
toxicant based on the time from treatment of the male to 
adverse effects after mating. 
For example, in rats, an effect on progeny outcome during 
the first week after exposure of males to a drug or X-rays 
means that spermatozoa in the epididymis were affected. 
Exposure 2–4 weeks prior to conception represents an effect 
on germ cell first exposed as spermatids, and exposure 5–6 
weeks before conception represents an effect on germ cells 
first exposed as spermatocytes. Exposures more than seven 
weeks prior to conception represent an effect on germ cells 
first exposed as spermatogonia or stem cells. 
Spermatogonia are susceptible to exposure to a wide 
range of certain drugs, including many anti-cancer drugs; 
these exposures reduce sperm numbers and increase the 
percentage of abnormal sperm among surviving cells. In 
mice, exposure to chlorambucil, an anti-cancer drug, causes 
a peak in mutations in offspring when germ cells are exposed 
as spermatids. Spermatids and spermatozoa are most 
sensitive to mutations induced by acrylamide and lethality 
induced by ethylnitrosourea. The treatment of male mice 
with clinically relevant doses of anticancer drugs, including 
cyclophosphamide and procarbazine, results in statistically 
significant, dose-dependent increases in expanded simple 
tandem repeat mutations in the germ line.
Cyclophosphamide has very different effects that 
depend on both the timing of exposure and the dose. 
When spermatogonia are exposed to cyclophosphamide, 
a small increase in external malformations and growth 
retardation is seen in developing rat fetuses. But when 
spermatids or spermatozoa are exposed to chronic low-dose 
cyclophosphamide, postimplantation losses are increased, 
but no malformations or growth retardation is seen. 
Cyclophosphamide is particularly interesting because effects 
on postimplantation loss and malformations and even some 
behavioral abnormalities occur not only in offspring but also 
in the second generation of the treated rats. 
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Spermatozoa acquire the ability to fertilize an egg while 
passing through the epididymis. Either radiation or drugs 
can affect spermatozoa in the epididymis and vas deferens. 
Methyl chloride increases embryo death, possibly by causing 
inflammation in the epididymis; an anti-inflammatory 
agent reverses the effect. Cyclophosphamide increases 
post-implantation loss only when the exposed spermatozoa 
originate in the head or body of the epididymis, but not 
the tail. 
Responses of the Male Germ Cell to Insult
The response of the germ cell to insult depends on both 
timing and the extent of damage (Figure 3-1). Damage may 
be completely repaired, in which case everything proceeds 
normally. Damage may be partially repaired, in which case 
spermatogenesis may continue and the “wounded” sperm, 
with its load of damaged chromatin (DNA + associated 
proteins), could fertilize an oocyte. DNA repair within the 
oocyte may rescue the zygote. Studies in rodents have 
revealed that fertilization with a damaged male germ cell 
triggers a DNA damage response in the zygote; gammaH2AX, 
a post-translationally modified histone that marks sites of 
DNA damage, accumulates in the male genome. If repair 
fails or is incomplete, abnormal progeny may result. Another 
possibility is that the insult overwhelms repair processes and 
the damaged male germ cell dies by a form of suicide called 
apoptosis. Drug-induced apoptosis is most pronounced in 
spermatogonia and spermatocytes, both pre-meiotic germ 
cells that have DNA repair mechanisms. Spermatids and 
spermatozoa, that are post-meiotic germ cells, cannot repair 
DNA and seem to lose the ability to die by apoptosis. Losing 
suicidal capability is not a good thing, because damaged 
spermatids and spermatozoa could soldier on to transfer 
damaged DNA to an oocyte. The ability of spermatozoon to 
fertilize an oocyte is not dependent of the quality of the DNA 
in its nucleus.
Conclusion
Over the past two decades, abundant evidence has 
demonstrated that male-mediated adverse progeny outcome 
is a real phenomenon in experimental animals, and several 
mechanisms responsible for these adverse outcomes are 
well described. Both genetic and epigenetic mechanisms 
have been suggested. 
Should we be concerned about progeny outcome after 
the exposure of men to chemical agents?  While to date, 
human studies have not shown an increase in birth defects 
among the children of men treated with cancer therapies or 
exposed to ionizing radiation, it is clear that there is an effect 
on fertility; some studies have shown an increase in germline 
mutations. More research is needed.
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What Is the Role of the Placenta—Does It Protect against  
or Is It a Target for Insult?
Chapter 4 The Role of the Placenta 
The placenta is the anchor, the conduit, and the 
controller of pregnancy—and it can also be a target for 
toxicant action. The placenta attempts to protect the embryo 
and fetus from insult; however, the placental protector can 
be compromised and also be the site of toxic action. 
The placenta is not just a barrier, but has many functions 
that are vital to the health of the embryo/fetus. The placenta 
encompasses not only the chorioallantoic placenta but all 
of its extraembryonic membranes (chorion/amnion) and 
the yolk sac. (Figure 4-1). The placenta and its membranes 
secure the embryo and fetus to the endometrium (uterine 
lining) and release a variety of steroid and protein hormones 
that characterize the physiology of the pregnant female. 
 Alterations in any of these functions can lead to 
pregnancy loss (miscarriage). Of particular concern is the 
relative hypoxic environment that is normally present during 
early embryonic development and the abnormal maternal 
blood flow, which can produce higher levels of oxygen 
and lead to miscarriage and pre-eclampsia/eclampsia, as 
noted in Figure 4-2. The placenta transports nutrients to the 
embryo/fetus and waste products away from the embryo/fetus 
but, during this exchange, foreign compounds can hitchhike 
across the placenta. The placenta stores chemicals and also 
serves as a site for biotransformation. Substances that may 
be benign to the pregnant woman can be transformed by 
metabolizing enzymes in the placenta to agents toxic to the 
embryo/fetus. Thus, the functions of the placenta that nourish 
and support the fetus can be compromised to result in 
placental toxicity, fetal nutrient deprivation, and production 
of toxic chemicals.
Patterns of placental development are similar among 
different animal species, but developmental time schedules 
may differ. The placentae themselves vary widely among 
species. Marsupials, for example, have only a yolk sac, while 
sheep have multicotyledonary (multi-lobed) placentation. 
Rats, mice, and rabbits, the principal species studied in 
teratology, all have yolk sac placentae, as do humans, but 
the functions of the yolk sacs are very different. In rodents 
and rabbits, the yolk sac everts (turns inside out) and 
becomes an important port of entry for molecules (e.g., 
immunoglobulins) into the embryo and fetus throughout 
pregnancy, even though a chorioallantoic placenta develops 
Figure 4-1. Placental Structure in the Mouse. Figures depict early development of the mouse conceptus at embryonic 
days (E3.5, E7.5, E12.5). In the fetus, the visceral yolk sac (vYS) inverts and remains active throughout the entire gestation 
providing for transfer of selective large molecules, e.g., immunoglobulins IgG and vitamin B12. Abbreviations: Al, allantois; 
Am, amnion; Ch, chorion; Dec, decidua; Emb, embryo; Epc, ectoplacental cone; ICM, inner cell mass; Lab, Labyrinth; 
pYS, parietal yolk sac; SpT, spongiotrophoblast; TCG, trophoblast giant cell; Umb Cord, umbilical cord; vYS, visceral 
yolk sac; C-TGC, maternal blood canal trophoblast giant cell; P-TGC, parietal trophoblast giant cell; S-TGC, sinusoidal 
trophoblast giant cell; SpA-TGC, Spiral artery-associated trophoblast giant cell; Cyan-trophectoderm and trophoblast 
lineage, Black- inner cell mass and embryonic ectoderm; Gray -endoderm, Red-maternal vasculature, Purple-mesoderm, 
Yellow-decidua, Pink-fetal blood vessels in labyrinth. (From Hu and Cross, Int. J. Dev. Biol. 54:341–354, 2010.)
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during the last half of pregnancy to provide gas and small 
molecule exchange. In contrast, the yolk sac shrinks and 
becomes vestigial (shrunken and nonfunctional) in humans 
during the latter part of the first trimester.
In laboratory species, immunoglobulins, critical for 
immune function in the neonate (IgG), are transported only 
through the visceral yolk sac; in humans, transport occurs 
via receptors in the chorioallantoic placenta. Both the yolk 
sac of the rodent as well as the chorioallantoic placenta of 
the human are important sites for degrading proteins and 
providing amino acids to the embryo and fetus. Trypan blue 
and other agents that interfere with protein degradation can 
kill the rodent embryo or fetus or can cause birth defects. 
Many agents, including cadmium, can alter 
placental function (see Table 4-1). Injecting 
cadmium in a pregnant rat close to giving birth 
causes the fetus to die and the placenta to 
degenerate within 24 hours. Directly injecting 
fetuses with cadmium near term doesn’t kill 
them, although they do develop hydrocephalus 
(head enlargement due to excess cerebrospinal 
fluid in the ventricles of the brain). Cadmium 
was previously thought to affect primarily the 
kidney, but it turns out that, at least in rats, 
cadmium is even more highly concentrated 
in the placenta. Human placentae definitely 
concentrate cadmium and can degenerate 
because of exposure. Early in pregnancy, the 
effects of cadmium on the placenta can lead 
to miscarriage; women affected by exposures 
to high concentrations of cadmium can have 
repeated pregnancy losses. The ability of 
the placenta to sequester cadmium protects 
the fetus or embryo for a while, but when a 
pregnant woman is exposed to substantial 
amounts of cadmium, the placenta—and with 
it, the fetus—may die.
One source of cadmium is cigarette 
smoke and may be one reason why smoking 
can compromise the growth of the conceptus. 
Smoking is associated with pregnancy loss, 
premature delivery, and decreased birth 
weight. Smokers’ placentas have very high 
levels of cadmium compared with those of 
nonsmokers, and these levels may contribute 
to the adverse outcomes that are associated 
with cigarette smoke.
The placenta can prevent or at least 
delay the transmission of viruses that infect the mother. 
Experiments have shown that a variety of viruses, including 
cytomegalovirus (CMV), human immunodeficiency virus 
(HIV), Coxsackie B, and Echo 11 cannot directly cross the 
placenta. However, these viruses may infect certain cells 
within the placenta. Whether or not the placenta is infected 
determines whether the embryo/fetus eventually becomes 
infected. 
In vitro models using dual perfusion of the human 
placenta, explant culture, and cell cultures have been useful 
to assess transfer of agents as well as effects on the placenta. 
Studies using human placental perfusions have been used in 
lieu of rodent studies for human proteins when FDA approval 
for these types of new agents has been necessary. 
Figure 4-2. Oxygen tension plays an important role in guiding the differentiation 
process that leads to cytotrophoblast invasion of the human uterus. (A) The early 
stages of placental development take place in a relatively hypoxic environment that 
favors cytotrophoblast proliferation rather than differentiation along the invasive 
pathway. Accordingly, this cell population (light green cells) rapidly increases in 
number as compared with the embryonic lineages. (B) As development continues, 
cytotrophoblast cells (dark green cells) invade the uterine wall and plug the maternal 
vessels, a process that helps maintain a state of physiological hypoxia. As indicated 
by the blunt arrows, cytotrophoblast cells migrate farther up arteries than veins. 
(C) By 10 to 12 weeks of human pregnancy, blood flow to the intervillous space 
begins. As the endovascular component of cytotrophoblast invasion progresses, the 
cells migrate along the lumina of spiral arterioles, replacing the maternal endothelial 
lining. Cytotrophoblast cells are also found in the smooth muscle walls of these 
vessels. In normal pregnancy the process whereby placental cells remodel uterine 
arterioles involves the decidual and inner third of the myometrial portions of these 
vessels. As a result, the diameter of the arterioles expands to accommodate the 
dramatic increase in blood flow that is needed to support rapid fetal growth later 
in pregnancy. It is likely that failed endovascular invasion leads in some cases to 
miscarriage, whereas an inability to invade to the appropriate depth is associated 
with pre-eclampsia/eclampsia and a subset of pregnancies in which the growth of 
the fetus is restricted. (From Red-Horse et al, J. Clin. Invest. 114:749, 2004.)
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Following delivery, the baby gets all of the attention. The 
placenta is neglected, often assigned to the trash; however, 
detailed pathological assessments of the placenta can not 
only be critical for determining what happened in utero but 
also may be helpful in predicting what may be health issues 
for the child. During pregnancy, the placenta is the star of 
the show. Teratology would be incomplete as a science 
without attention to this important organ.
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SOME XENOBIOTICS OBSERVED TO ALTER PLACENTAL AND YOLK SAC FUNCTION
AGENT EFFECT
DRUGS OF ABUSE
Cocaine In humans, reduces amino acid uptake and causes reperfusion injury. 
Ethanol (alcohol) In humans, alters membrane fluidity, and inhibits nutrient transport; in animals, ethanol inhibits 
pinocytosis.
Narcotics In humans, narcotics decrease protein incorporation and decrease amino acid uptake.
Smoking Smoking, in humans alters histology, induces monoxygenases, and increases cadmium levels, and 
doubles or triples the rate of PROM (premature rupture of membranes). Nicotine decreases glucose 
utilization, decreases lactate production, decreases amino acid uptake, and increases acetylcholine 
release, benzo(a)pyrene induces monoxygenases and alters protein hormone secretion.
DRUGS
Colchicine In humans, reduces amino acid uptake, inhibits differentiation. In animals, inhibits pinocytosis.
Enalapril In animals, causes a pathologically hypocellular, small placenta.
Verapamil In humans, increases COMT (catechol-O-methyl transferase) enzyme activity, and decreases MAO 
(monoamine oxidase) activity.
Indomethacin In humans, stimulates progesterone secretion. 
Anti-HIV drugs Zidovudine and nucleoside analogs, in humans, inhibit cell proliferation and differentiation, and alter 
release of progesterone, HCG (human chorionic gonadotropins), and HPL. 
Chloroform In animals, causes placental necrosis.
Ritodrine In humans, decreases CAMP.
Table 4-1. 
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METALS
Cadmium In humans, causes placental necrosis, loss of placental integrity, reduced release of protein hormones, 
inhibition of trophoblast proliferation, and induction of metallothionein. In animals, cadmium causes 
placental necrosis, increased mitochondrial calcium, and altered enzymes. Cadmium accumulates 
rapidly in both humans and animals; the effect is reversible with zinc.
Arsenic Affects lipid peroxidation in humans.
Mercury In humans, alters membrane fluidity and impairs amino acid transport. In animals, inhibits transport of 
zinc and copper.
Nickel In animals, inhibits glutathione s-transferase and reduces glutathione reductase.
Pesticides/ 
Environmental 
Chemicals
In humans, chlordane, p,p-DDT and DDE cause alterations in cholinesterase. In humans, methoxychlor, 
mirex, lindane, p,p DDT and DDE  all inhibit Ca2+ ATPase. Dinitrophenol, in animals, inhibits pinocytosis 
and inhibits vitamin B12 uptake. Dinitrophenol/iodoacetamide, in humans, inhibits glucose metabolism, 
inhibits amino acid transport, produces placental leakiness, and decreases ATP levels.  
In animals, dinitrophenol/iodoacetamide inhibits vitamin B12 uptake. 
OTHER
Trypan blue In animals, inhibits pinocytosis, inhibits lysosomal enzymes,and reduces  
receptor mediated endocytosis. Zinc does not reverse the effect.
Choline 
acetyltransfer-ase 
inhibitor 
(2-benzolethyl- 
trimethyl  
ammonium)
In humans, inhibits amino acid uptake, lowers choline acetyltransferase, lowers acetylcholine levels,  
and decreases acetylcholine release.
Antisera Yolk sac antiserum, in animals, inhibits pinocytosis and inhibits intralysosomal digestion of 
macromolecules. Kidney antiserum, in animals, decreases amino acid transport.
Cortisol In animals, alters solvent transfer
Ethylnitrosourea  In animals, induces choriocarcinoma.
Hydralazine In humans, inhibits monoamine oxidase (MAO) and cathechol-O-methyl transferase (COMT) 
Hypochlorous acid In humans, causes oxidant damage of collagen type I in chorioamnion. 
Iodoacetate In animals, inhibits pinocytosis.
Kepone In humans,inhibits Ca2+ ATPase.
Leupeptin In animals, inhibits lysosomal proteolysis but does not inhibit pinocytosis.
Lipooxgenase  
inhibitors
In humans, nordihydroguairetic acid (NDGA) inhibits HCG secretion. In animals,  
N-hydroxy-n-methyl-7-propoxy-2-naphtalin ethanamine alters morphology.
Hyperglycemia In animals, reduces protein uptake.
Ouabain In humans, inhibits Na, K, and ATPase, and inhibits amino acid transport.
N-acetoxy-2— 
acetylamino- 
fluorene
In animals, causes localization of DNA adducts.
Phthalate In humans, inhibits cell proliferation and increases trophoblast apoptosis
Phorbol In humans, stimulates HCG production. 
Polychloro- 
biphenyls (PCBs)
In animals, decreases amino acid transport.
Polycyclic aromatic 
hydrocarbons
In humans, induces AHH (arene hydroxyl hydrolase) and monoxygenases; alters protein secretion
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Serotonin In animals, decreases sodium transfer
Somatomedin  
inhibitors
In animals, inhibits pinocytosis, alters protein processing.
Sucrose In animals, alters ultrastructure.
Suramin In animals, inhibits pinocytosis.
Trifluoperazine In humans, inhibits Ca2+ATPase.
Vitamin E  
deficiency
In animals, causes placental necrosis.
Table 4-1. Compounds presented in this table have been shown to adversely affect either the chorioallantoic placenta or the visceral 
yolk sac. Limitations in the data set are the often high concentrations of the compounds being used; few doses are used and the stage of 
gestation may vary. Thus, this table is presented to the reader as a compilation of responses; however, the reader is referred to the original 
research for specific responses and doses. This table was adapted and updated from Slikker and Miller, 1994.
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Can Prenatal Exposures have Long-Term Effects  
on the Brain and Behavior?
Effects on Brain and BehaviorChapter 5
For decades fetal injuries were conceived largely in 
terms of structural birth defects. Effects on the central 
nervous system (CNS) were ignored unless the brain was 
visibly abnormal. As we all know from personal experience, 
cognitive development is a long, slow process requiring 
decades. Yet today, the idea that chemicals can damage 
the developing brain (neurobehavioral teratogenesis/ 
developmental neurotoxicity) is an accepted fact. What 
changed?  What changed was that a series of environmental 
and drug exposures were shown to damage the developing 
brain.
The first example was identified after mercury 
contaminated Minamata Bay, Japan. The mercury was 
transformed to methylmercury in plants and was progressively 
concentrated as it worked its way up the food chain and 
accumulated in the fish. People around the bay who ate 
the fish began showing symptoms, the most severe of which 
were among children exposed in utero (mental retardation, 
cerebral palsy, blindness, and other CNS impairments). 
Methylmercury poisoning has since been reported in other 
places; each time the most severely affected were prenatally 
exposed children. Even women who ingested moderate 
amounts had affected children despite being unaffected 
themselves, demonstrating that the developing CNS is more 
vulnerable than the adult CNS.
The heavy metal lead is among the best known 
chemicals to cause CNS impairment after developmental 
exposure. Adverse effects are seen after prenatal or 
childhood exposure or a combination of both. As research 
has advanced, CNS effects have been found at lower and 
lower levels and an entirely safe level of lead remains to be 
determined. Lead is illustrative because: (1) it is a pervasive 
compound, the effects of which are still felt decades after 
removal from products, (2) it is a worldwide problem, and 
(3) its effects occur over a long period of development, 
thereby illustrating how protecting the brain is a long-term 
and complex proposition. Other environmental agents that 
cause developmental neurotoxicity include the heavy metal 
cadmium, the transition metal manganese, polychlorinated 
biphenyls, and some pesticides.
What about drugs? Drugs are designed to have 
biological effects so it is no surprise that some drug exposures 
are teratogenic. It has taken longer to determine that some 
are developmental neurotoxicants. 13-cis-retinoic acid 
(Accutane) is for the treatment of severe acne. In utero exposure 
causes birth defects (retinoid embryopathy), and many of the 
children also had low IQs. In animal experiments, Vitamin 
A (another retinoid) is known to cause neurobehavioral 
impairments hence the effects of 13-cis-retinoic acid might 
have been predicted. The effects of 13-cis-retinoic acid on 
intelligence and birth defects were not always aligned; i.e., 
some children had severe birth defects and several mental 
impairments, but others had barely detectable birth defects 
and large IQ reductions. When the associations between birth 
defects and CNS effects are not concordant or nonexistent, 
proving connections between school performance and 
emotional problems identified later in life is far more difficult. 
For this to occur, detailed animal experiments and long-term 
human studies are required. Government regulations now 
expect companies to test animals for CNS effects before 
they are approved if a potential for adverse CNS effects 
is possible.
The effects of 13-cis-retinoic acid are striking but the 
medications are used by relatively few. A larger problem 
occurs in epilepsy. Approximately 1% (~3 million) of the 
population has epilepsy and most are treated with antiepileptic 
drugs (AED). The use of AEDs is associated with birth defect 
syndromes. One example is valproate (Depakote), an 
AED that when taken during pregnancy leads to 1–2% of 
exposed infants born with neural tube defects, and a higher 
percentage born with the Fetal Valproate Syndrome. The 
syndrome includes characteristic facial features (dysmorphic 
facies) and impaired intellectual development. Recent studies 
suggest it also may increase rates of autism. What about 
other more commonly used drugs, such as antidepressants 
or statins?  While it is reassuring that no evidence of fetal 
neurotoxicity has yet appeared for these, determination of 
safety during pregnancy through well designed prospective 
human studies and specifically focused animal studies still 
need to be done.
Two recreational drugs that are problematic when 
overused are alcohol and tobacco. Both have been shown 
to result in life-long neurobehavioral effects. At the extreme, 
prenatal alcohol exposure can cause Fetal Alcohol Syndrome, 
characterized by three clusters of effects: (a) growth 
impairment (pre- and postnatal), (b) facial dysmorphogenesis, 
and (c) CNS effects. The latter include changes in structure 
(visualized using brain imaging techniques) and behavioral 
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abnormalities (intellectual impairment, attention deficit 
hyperactivity disorder (ADHD), emotional instability, and 
antisocial behaviors). There are also less severe effects of 
alcohol, called fetal alcohol effects, in which one or two of 
these clusters of effects are observed rather than all three. 
Cigarette smoking is associated with intrauterine growth 
retardation, as is widely known, but studies also show 
that exposed children have IQ reductions of ~10 points, 
primarily of verbal abilities. Animal experiments verify that 
prenatal nicotine affects offspring behavior.
What about illegal drugs? We think of cocaine, 
methamphetamine, LSD, heroin, and PCP as powerful drugs 
with destructive consequences, so can we assume they 
damage fetal brain development? We know these drugs 
cross the blood brain barrier because they are psychotropic. 
It turns out that the blood brain barrier is far more restrictive 
than the placenta, so these drugs easily reach the fetus; 
some (methamphetamine) even accumulate more in the 
fetus than in the mother. Despite this, effects on development 
have been difficult to pin down. None of these exposures has 
been shown to cause birth defects, but animal studies now 
show that prenatal cocaine alters dopamine systems which 
are involved in attention, including the principal dopamine 
receptor, D1, such that the receptor is less available to 
interact with dopamine when it is released into the synaptic 
cleft. Changes are also seen in the neurotransmitter GABA 
and in pyramidal neurons in the cerebral cortex. In children 
prenatally exposed to cocaine, problems of attention are 
prominent, which is consistent with a dopamine effect. 
Cocaine-exposed children also show IQ reductions (~4 
points), which, while not easy to notice in one individual, 
have implications across a population. If the bell-shaped 
distribution of IQs shifts downward for thousands of children 
each year, there could be a large impact on schools that 
educate them and employers that train them. Patterns of use 
are important too; women using higher doses, using more 
drugs (polydrug abuse), with use for a longer time during 
gestation, and with less prenatal care have worse outcomes. 
Prenatal marijuana has also been documented to result in 
reductions in visual processing and impulse control.
More recent is the problem of methamphetamine abuse, 
which leads to changes in brain structure, neurotransmitters, 
spatial memory, and language development after prenatal 
exposure. Between 1994 and 2006, pregnant women 
entering drug treatment programs in the U.S. who identified 
methamphetamine as their primary drug of abuse rose 
from 8% to 24%. A human prospective prenatal study of 
this drug has begun and recent animal experiments reveal 
long-term effects on brain neurochemistry and behavior, 
including impaired spatial memory and enduring changes 
in dopamine and serotonin after developmental exposure to 
methamphetamine.
For exposures that are teratogenic, the first trimester, 
perhaps even before pregnancy is recognized, is the 
major period of vulnerability. For the CNS, the period of 
vulnerability starts during the first trimester and lasts through 
adolescence. There are many reasons for this extended period 
of sensitivity, one of which is the phenomenal complexity of 
the brain (Figure 5-1). Developmental neurotoxic effects are 
often described as subtle. While this is accurate to the extent 
that it is a comparative statement, for example, ADHD is 
subtle compared to a life-threatening cardiac defect, it is not 
accurate when it is used to imply that such effects are less 
important. While developmental neurotoxic effects may not 
be life threatening, they may have an important impact on 
how people are able to navigate through life. As we think 
about drug and chemical safety, the impact of CNS damage 
should never be forgotten.
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Figure 5-1. From review by S. Danzer with permission (Danzer, 
2008). Photomontage of confocal microscopy images showing 
principal neurons of the hippocampus. Images are from an adult 
Thy1-GFP-expressing mouse. Red = dentate granule cells, Purple 
= CA3 pyramidal cells, Yellow = CA1 pyramidal cells.  d = dentate 
granule cell layer; H = hilus; sl = stratum lucidum; CA3 = CA3 
pyramidal cell layer; CA1 = CA1 pyramidal cell layer. Scale bar = 
300 μm.
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how Do Genes affect the Risk of having a Child with a Birth Defect?
Genes and Birth DefectsChapter 6
Every infant born in the 
U.S. has at least a 2%–3% 
risk of being born with a 
major malformation or 
deformation, and an even 
higher risk (approximately 
10%) of being born with 
internal anomalies or 
functional deficits that may 
not become apparent until 
later in life. The cause of 
most congenital anomalies 
is unknown. Approximately 
40–50% of malformations 
fall into the group of those 
defects with unknown 
cause(s). It has previously 
been estimated that genetic 
causes (anomalies arising 
from alterations in genetic 
material) account for at 
least 25% of all human 
malformations. As we 
have learned more about 
the human genome and 
developed new techniques, 
the proportion of birth 
defects attributed to genetic 
causes has increased.
There are numerous 
types of genetic alterations, the most common of which are 
mutations (changes to the DNA sequence of genes) and 
chromosomal defects (e.g., extra or missing chromosomes, 
or parts of chromosomes, Figure 6-1). Genetic alterations 
leading to malformations can be inherited, or can occur 
spontaneously due to random mutations of DNA. To date, 
genetically mediated malformations have not been found 
to result from exposure to any environmental agents, even 
those agents that have been shown to be capable of causing 
damage to genetic material in individual cells (mutagen). 
Radiation is a highly potent mutagen, but even after the 
atom bombs were exploded over Japan, a careful study of 
the exposed population over the subsequent generations 
demonstrated no increase in birth defects or genetic diseases 
in offspring caused by new mutations, despite the significant 
radiation exposure (chapter 21). Environmental causes of 
human malformations (defined as any external influence 
on fetal development, i.e., not genetic) are thought to be 
rare. It is estimated that only approximately 1% of all human 
malformations are related to drug exposures, chemicals, or 
radiation.  
A birth defect can occur singly as an isolated defect. 
Multiple birth defects can also occur in one individual. 
When multiple birth defects, especially defects affecting 
varied organs and systems appear together and are seen 
in different individuals in different families in a recurrent 
pattern or combination, they are generally accepted to 
have a common underlying cause, and are designated a 
Figure 6-1.
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birth defect syndrome. One example is Down syndrome, 
or trisomy 21, caused by the presence of all or part of 
an extra chromosome 21. The risk of having a child with 
Down syndrome is increased with increasing maternal age. 
Paternal age may also be a factor when the mother is 35 or 
older. Even with well-defined and refined syndromes, there 
is inherent variability in the manifestations of these birth 
defect syndromes, both in the type and severity of the various 
structural abnormalities that may appear. As a particular 
pattern of defects or syndrome is seen in other patients 
and as more is learned about a syndrome over time, initial 
descriptions are refined. Patients with the same syndrome will 
manifest varying degrees of common core features, as well 
as occasional unusual or infrequent (but related) features. 
The purpose of syndrome identification and refinement is to 
enable clinicians to recognize these features as suggesting a 
specific condition, with a common underlying cause, natural 
history, and prognosis. Syndrome diagnosis assists clinicians 
in, among other things, patient counseling and treatment. 
There are two broad classes of birth defect syndromes, 
genetic and non-genetic. Genetic syndromes result from some 
change in the genetic material of the conceptus, occurring 
prior to or around the time of conception. Suggested reading 
at the end of this chapter describes the general approach for 
determining the difference between these two broad classes 
of birth defect syndromes has been delineated in more 
detail. An alteration in the genetic material of the cells may 
cause a genetic disease or genetic birth defect syndrome. 
While the same genes and the same genetic alteration will 
generally appear in each cell of the body, not all genes are 
expressed (i.e., activated) within each tissue in the body. The 
expression (or lack of expression) of each gene or group of 
genes in a given tissue is often controlled by other genes, 
and is responsible for different functions in different cells. 
When an error occurs in genetic material affecting a specific 
gene(s), even though the error appears in each cell of the 
body, it will only affect those cells (and thus organs) in which 
those genes are expressed. The functional capabilities of 
other genes, not affected by the error, help to determine 
much of the individual variability among different people 
with the same syndrome. 
Thus, syndromes occur within the context of the underlying 
genetic background for each individual. Among children 
with Down syndrome, parental background for common 
genetically determined traits like stature, intelligence, and 
pigmentation always come through in the child with the 
syndrome, so that the tallest children with Down syndrome 
come from the tallest parents. Because there are underlying 
genetically determined susceptibilities for many common 
birth defects, this helps to explain why different individuals 
with the same syndrome do not have the exact same 
combination of birth defects. 
The type and location of each specific genetic alteration 
within a given gene will help to determine the variability and 
severity within a specific syndrome. Likewise, it is believed 
that all humans carry some genetic alterations that do not 
cause problems, either because the function of that particular 
gene product is covered by the other member of the gene 
pair, because that particular mutation does not alter the 
function of the gene product that it encodes, or because 
the particular mutation occurs in a non-essential part of the 
genetic material.
Genetic alterations can occur in either the sperm or the 
egg, or both, prior to or at the time of conception. If there is 
an alteration in the genetic material of the sperm and/or the 
egg, when the sperm fertilizes the egg at conception, each 
cell that derives from that fused egg/sperm cell (zygote) will 
carry that mistake. It is also possible that the genetic material 
of the sperm and egg could be “normal,” but shortly (within 
hours, or at most days) after conception, a mistake occurs 
during cell replication. This type of cell replication error 
would result in “mosaicism,” meaning that only some cells of 
the body will carry the error or mutation (i.e., those cells that 
derive from the cell where the error first took place). Even 
when such a mosaic genetic error occurs after conception, 
the error must occur shortly after conception, since after 
the first week there would be far too many cells without the 
mutation for manifestations of the genetic alteration to be 
apparent. Some genetic mutations may not be compatible 
with survival of the early embryo and result in an early 
spontaneous abortion. A mutation that occurs within the male 
or female germ cells could actually result in the occurrence 
of a dominantly inherited syndrome, even though neither 
parent shows signs of the same syndrome.  This is estimated 
to occur in 1–3% of cases.
Genetic disorders can also be inherited from the affected 
individual’s normal parent(s). Within the 25,000–30,000 
pairs of genes in the human genome, one member of each 
pair, or one allele, is derived from each parent. Because 
genes work in pairs, a person can have a functional gene or 
allele and a defective gene, and still be “normal.” Usually 
the functional version of the gene pair, where one gene 
is defective, allows that gene to perform its specific task. 
The gene that does not function in these cases is called 
a recessive gene. Carriers for Tay-Sachs disease, cystic 
fibrosis, or sickle cell disease can be without the condition 
but carry the defective gene because it is only in one copy. 
In normal carrier parents these recessive genes only become 
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apparent when each parent has the same recessive gene, 
and the child inherits both non-working genes (one mutant 
gene from each parent). The risk for two carrier parents to 
have a child with a recessive disorder is 25%. 
Dominant conditions result when there is one defective 
gene in a gene pair, and the normal member of that gene 
pair cannot complete a specific developmental task by 
itself. These dominant conditions usually result in a pattern 
of birth defects, a specific birth defect, or a risk for specific 
types of cancer because these genes affect developmental 
pathways or basic cell replication pathways. When a person 
has a mutation in one of these genes, the chance of passing 
it to an offspring is 50%; thus, such dominant autosomal 
conditions are inherited in families. When such conditions 
appear for the first time in a family, they reflect a sporadic, 
new occurrence of the condition. In many instances, random 
or spontaneous mutations, or chromosomal errors, can lead 
to genetic birth defects and genetic birth defect syndromes. 
Spontaneous mutations are not uncommon. When neither 
parent has the dominant genetic problem seen in their child, 
it is termed a de novo (new) or sporadic occurrence. It is 
estimated that between 3.0 and 7.5% of all malformations 
in humans are the result of such fresh dominant mutations in 
genetic material.
Individuals exposed to some highly mutagenic 
chemotherapy drugs do not produce offspring with more 
than the expected incidence of birth defects and other genetic 
diseases. To the extent of our current scientific knowledge, 
mutations leading to birth defects occur in the normal 
course of cell division. There is one exception: advancing 
age. Advancing paternal age is associated with an increased 
risk for structural chromosomal defects and gene mutations 
in the male. It is commonly accepted that fresh dominant 
mutations occur more commonly in the sperm than in the 
egg. The susceptibility of sperm stem cells to genetic damage 
may be an important factor in the accumulation of genetic 
damage since men produce spermatozoa continuously 
throughout their reproductive lives. In contrast, oocyte 
development arrests before birth (chapter 3). The male germ 
cell begins to show effects of aging at 30 years, and most 
in vitro fertilization centers will discourage a man older than 
40 years from donating his sperm. 
Clearly genes, and genetic alterations, play a role in the 
risk of having a child with a birth defect. Tests are available 
to screen prenatally for some of these genetic alterations 
(chapter 9). Furthermore, while the genetic make-up of the 
offspring is critical, the environment also plays a role in 
determining cell fates. The extent to environmental exposures 
and interactions between genes and the environment 
affect the risk of birth defects are active areas of research 
(chapter 7). 
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how Do Gene-Environment Interactions  
affect the Risk of Birth Defects?
Gene-Environment InteractionsChapter 7
A key concept in teratology is that there are individual 
differences in sensitivity to teratogenic exposures. Only a 
small percentage of infants with known teratogenic exposures 
display any adverse effects. After years of study, we have 
come to appreciate the fact that the more common birth 
defects represent the interaction between multiple genes with 
small effects and environmental factors (gene-environment 
interaction), disrupting development to a degree beyond 
which these factors could have produced individually. 
Genetic variation affects food tolerances and may also 
influence dietary requirements. A good example is the striking 
finding about the critical role of a simple vitamin, folic acid, 
in normal embryonic development. Neural tube defects 
(NTDs) are common congenital malformations, occurring 
in approximately 1 per 1000 liveborn infants and known 
to have both an environmental and genetic component to 
their development. Epidemiologic and experimental studies 
demonstrate the benefit of folic acid supplementation in 
preventing NTDs and other congenital anomalies, though 
how it provides these benefits is not known (chapter 32). 
There are some NTDs that are not preventable by 
folic acid supplementation, suggesting that a “genetic 
subpopulation” may exist that is either less responsive to folic 
acid supplementation or has a different underlying cause 
for these malformations. Researchers have investigated 
variants in genes associated with folate metabolism and 
transport as potential risk factors for NTDs. These genes 
include: folate receptor alpha (FRα); reduced folate carrier 
(SLC19A1); 5,10-methylenetetrahydrofolate reductase 
(MTHFR); cystathionine β-synthase (CBS); methionine 
synthase (MTR); methionine synthase reductase (MTRR); 
methylenetetrahydrofolate dehydrogenase (MTHFD1); 
betaine-homocysteine methyltransferase (BHMT); and 
thymidylate synthase (TYMS). Interactions between maternal 
folate intake and variations in folate genes (e.g., MTHFR 
C677T, MTRR A66G, and SLC19A1 A80G) have been 
suggested by these studies. For example, in a population-
based case–control study conducted in California, infants 
with an 80GG genotype of SLC19A1 gene born to mothers 
who did not take vitamin supplementation during early 
pregnancy had a significantly higher risk of developing 
spina bifida.
Another example of gene-environmental interaction 
involves anticonvulsant drugs, long recognized as causing 
birth defects in infants exposed in utero. However, only about 
11% to 20% of these infants will exhibit neurodevelopment 
impairment with or without structural defects, while about 
3% to 10% will be born with structural malformations alone. 
In animal studies, there are clear differences in 
anticonvulsant-induced NTD susceptibility between strains. 
It is likely that a similar situation exists for humans, where an 
estimated 1% to 2% of infants exposed in utero to valproic 
acid will be born with spina bifida or other forms of NTDs. 
Detoxification enzymes involved in metabolizing drugs and 
pollutants, as well as toxic compounds produced by the 
mother or fetus, may play a role. Variant forms of both Phase 
1 (cytochrome P450 enzymes) and Phase 2 (e.g., epoxide 
hydrolase, glutathione transferases, sulfotransferases, and 
N-acetyl transferases) enzymes are likely to increase risk of 
malformations, because poor metabolizers may experience 
a “build-up” of toxic chemicals in susceptible embryonic 
tissues or because enhanced, rapid metabolizers for Phase 
1 enzymes may produce more toxic intermediates than the 
Phase 2 enzymes can handle. Many Phase 1-generated 
intermediates are chemically reactive and bind to protein or 
DNA, and may be teratogenic, mutagenic, or carcinogenic. 
Graphic from Khoury MJ, Morris J. Pharmacogenomics  
& Public Health: The Promise of Targeted Disease Prevention.
www.cdc.gov/genomics/ info/factshts/pharmacofs.htm
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Only a few clinical studies have investigated some of 
these enzyme variants with respect to risks of structural birth 
defects. Recently, the MTHFR C677T genotype was studied 
regarding the rates of major malformations following in utero 
exposure to antiepileptic drugs. Neither the “risk allele” (T) 
nor the antiepileptic drug-exposure alone had a significant 
impact on the rate of serious malformations in the offspring, 
but when these two factors co-existed, the risk increased, 
suggesting that genetic testing may help predict which 
infants are at the greatest risk of developing birth defects 
from exposure to anticonvulsant drugs. 
A final example of gene-environment interaction is 
cigarette smoking and the risk for having an infant with 
an orofacial cleft. Maternal smoking during pregnancy is 
associated with cleft lip and/or palate (CL/P). Several animal 
studies have also demonstrated the adverse effects of cigarette 
smoking on development of cleft lip and/or cleft palate. 
Gene-environment interactions have been investigated 
between maternal smoking and more than 2 dozen genes, 
including nitric oxide synthase 3 (NOS3), aryl hydrocarbon 
receptor (AhR) pathway genes, several detoxification genes 
(CYP1A1, EPHX1), glutathione transferase gene family 
(GSTs), arylamine N-acetyltransferase gene family (NATs), 
hypoxia-induced factor-1 (HIF1), folate pathway genes (eg 
MTHFR), muscle segment homeobox1 (MSX1), and other 
developmental genes. The most-studied gene in this area is 
transforming growth factor α (TGFA). A large study involving 
both nonsmoking and smoking pregnant women found that 
heavy smokers who carried the rare ‘risk’ variant of this gene 
were twice as likely to have a baby affected with cleft lip 
or palate than nonsmoking women with the more common 
gene variant. Infants who possessed the rare gene variant 
were six times as likely to have cleft lip or palate when the 
mother was a heavy smoker. 
Although medicine is still far from individualized 
preventive measures for birth defects, understanding how 
specific environmental factors interact with an individual’s 
genetics, or “genotype,” may yield critical clues that will 
ultimately lead to new approaches to prevent preventable 
birth defects.
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Do Teratogenic Exposures act through Common Pathways  
or Mechanisms of action?
Chapter 8 Common Pathways for Teratogenic Exposure
The term mechanism of action refers to the interactions 
of an agent with the organism that lead to an adverse effect. 
Mechanisms of action are diverse: agents can interact with a 
receptor, bind to DNA or protein, degrade cell membranes 
or proteins, inhibit an enzyme, or modify proteins. If enough 
of these interactions between an exogenous agent and the 
organism occur at a biochemical level, changes can occur in 
the cells and tissues and can lead to changes in cell function, 
cell fate, or result in cell death. Abnormal development 
results if the damage is extensive. Different agents can act 
through the same mechanism of action; producing similar 
effects. For example, there are a large number of vitamin A 
derivatives (retinoids) that are used for therapeutic purposes; 
in the embryo, retinoids interact with the same family of 
retinoic acid receptors. These agents differ in potency (i.e., 
the dosage needed to produce an effect) but not in the 
outcome (malformation or death) they produce.
Receptor Interactions
Receptors are proteins within or on the surfaces of 
cells that are targeted by hormones or other signaling 
molecules. Receptors perform the same function for cells 
as our senses perform for our bodies: they inform the cell 
about its environment and, when activated, bring about 
changes in cell function. Some teratogens act by interacting 
with receptors, either mimicking the endogenous signaling 
molecule or by interfering with the signaling molecule’s 
ability to interact with its receptor. Examples include 
retinoic acid and diethylstilbestrol (DES), a potent estrogen 
that was once given to pregnant women in an effort to 
prevent miscarriage. Retinoic acid, is essential for normal 
development, and interacts with its receptors that are 
expressed in certain embryonic structures; too much or too 
little retinoic acid causes defects in those structures. DES binds 
to estrogen receptors and causes defects in male and female 
reproductive organs, as well as a rare form of vaginal cancer 
in about one of every thousand women whose mothers took 
DES during pregnancy. The retinoic acid receptor and the 
estrogen receptor are part of a family of nuclear receptors 
called cytosolic receptors; many other receptors in this family 
are known or suspected to be targets for teratogens, such as 
the androgen receptor and the thyroid hormone receptor.
Covalent Binding to Dna or Protein
Some agents are chemically reactive or are metabolized 
by the body to chemically reactive forms. These reactive 
forms create covalent bonds to important biomolecules, 
changing the function of these molecules. For example, 
cyclophosphamide, a drug used to treat cancer, is metabolized 
to phosphoramide mustard, a reactive intermediate that 
covalently binds DNA and other important molecules in the 
cell, impairing the function of these molecules and ultimately 
the function of the cell.
Peroxidation
Chemicals that generate highly reactive substances 
like hydrogen peroxide can oxidize molecules, particularly 
the lipids that form the foundation for cell membranes. 
Disruptions to the cell membrane often lead to cell death.
Enzyme Inhibition, Interference with sulfhydryl Groups
Enzymes are proteins that catalyze chemical reactions, 
such as the reactions that break down sugars to produce 
energy for the cell, or that synthesize the large molecules 
needed for cell structure and function. Inhibiting the function 
of an enzyme may have teratogenic consequences. For 
Graphic courtesy of Barbara F. Hales.
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example, methotrexate, a folic acid antagonist used to 
treat cancer, psoriasis, rheumatoid arthritis, and ectopic 
pregnancy, interferes with the synthesis of the nucleotides 
needed to make DNA, as well as with other metabolic 
processes that require folic acid.
Sulfhydryl groups, which contain sulfur and hydrogen 
and are found on the amino acid cysteine, are important 
in creating the three-dimensional structure of proteins: two 
sulfur atoms that are distant from each other link together 
to form a disulfide bridge, creating a loop in the protein. 
Sulfhydryl groups are used to hold essential minerals like 
zinc in place in proteins. Sulfhydryl groups are also important 
in caspases and other enzymes involved in programmed 
cell death, a normal developmental process. Cadmium, 
mercury, and other heavy metals can interact with sulfhydryl 
groups, disrupting the function of the proteins that contain 
them.
Modification of Proteins
Some proteins require modification in order to carry 
out their function, and these modifications can be another 
target of teratogenic exposures. For example, a signaling 
protein called sonic hedgehog (Shh) must first be clipped 
into two fragments, with the signaling fragment having a 
cholesterol molecule added to it in order for it to function 
normally. Shh functions to delineate the ventral portion of 
the central nervous system. Defects of the central nervous 
system in which the ventral portion is poorly defined, such 
as holoprosencephaly or cyclopia, arise when Shh does not 
function correctly. A number of different agents have been 
shown to interfere with Shh function, including cyclopamine 
(an alkaloid in certain range plants in the Western U.S.) and 
some but not all inhibitors of cholesterol synthesis. These 
agents appear to act by interfering with the cholesterol 
modification of Shh. Mutations of one particular gene 
in the cholesterol synthesis pathway can cause identical 
abnormalities, as does mutation of Shh itself, an example 
of how different mechanisms at a biochemical or molecular 
level can have common outcomes.
Progression of Mechanistic Events to Pathology
If the mechanistic events are sufficiently widespread, they 
may result in changes at the cell and tissue level. Different 
exposures can cause the same cascade of events that result in 
abnormal development. For example, the edema syndrome 
results when embryos are exposed to low oxygen levels. 
Heart rate and blood pressure drop, sodium and potassium 
concentrations in the plasma change, and fluid seeping out 
of blood vessels causes hollow organs to swell and blisters 
to form in solid structures. The distortions caused by fluid 
accumulation disrupt development. But other agents can 
cause the edema syndrome as well; trypan blue (a biological 
stain) and other agents that affect the nutrition of the early 
embryo cause similar effects.
Apoptosis is a form of programmed cell death that 
occurs in embryos during normal development as a means 
of sculpting limbs and other structures, to get rid of extra 
cells or cells that have served their purpose and to remove 
damaged cells. Apoptosis in normal cells that have not 
completed their useful lifespan can cause major problems. 
Zinc deficiency and ethanol (the alcohol in beer, wine, and 
liquor), for example, extend the size of areas in the developing 
embryo undergoing cell death beyond what is normal. Other 
chemicals, such as deoxycoformycin, an antimetabolite that 
inhibits nucleotide synthesis, produce apoptosis in areas 
where it does not normally occur. Research into teratogenic 
mechanisms and pathogenesis is advancing as great strides 
are made in our understanding of the molecular processes 
that control embryonic development. Teratologists have 
only begun to study how chemical agents interact with these 
processes. 
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What Tests are available to screen Prenatally for Birth Defects?
Screening for Birth DefectsChapter 9
There are two kinds of tests used in clinical medicine, 
screening tests and diagnostic tests. Screening tests identify 
people in the general population who have a higher than 
average risk of a disease of interest. Diagnostic tests address 
the question of whether a particular individual is affected. 
Often in obstetrics, a screening test is applied to all pregnant 
women to find those women at particular risk of having a 
baby with a congenital abnormality. Diagnostic tests are 
then used for those women to see which of them in fact is 
carrying an affected child. Most diagnostic tests in pregnancy 
are invasive and have a risk for pregnancy complications 
and fetal loss, so we do not want to do them on everyone. 
Screening tests, therefore, refine the population for which 
diagnostic tests may be worth the risk.
The ability of screening tests to correctly predict 
abnormalities varies depends on the incidence of the 
condition in the general population and the reliability (its 
ability to accurately deliver a result) of the test. Ideally, the 
test should have few false positive results (predicting that 
a normal pregnancy is abnormal) and few false negatives 
(predicting that an abnormal pregnancy is normal). 
The background risk for birth defects in liveborn babies 
is 2–3% at birth. No prenatal screen or diagnostic test that 
is currently available can identify all of this risk. Available 
prenatal screening and diagnostic tests use ultrasound, 
maternal serum, amniotic fluid, chorionic villi, or fetal blood. 
Each test has specific indications and risks (Table 9-I).
Ultrasound 
Ultrasound, also called sonography, uses the reflection 
of sound waves to make an image of tissue-interfaces. 
These images can be highly detailed, almost photographic 
depictions of the embryo and fetus. Ultrasound can confirm 
a live pregnancy, establish gestational age, and identify twins 
and other multiple gestations. Ultrasound can also detect 
fetal abnormalities and is often the only useful prenatal 
test following a potential or known teratogenic exposure. 
Ultrasound is useful for evaluating fetal growth and 
development, but cannot determine the underlying cause 
of an abnormality. Ultrasound also cannot provide much 
information about neurological functioning of the fetus. 
Ultrasound is used for both screening and diagnosis. 
For example, during the first trimester, thickening of a 
fluid compartment in the embryo’s neck is associated with 
an increased risk of certain chromosome abnormalities 
(Figure 9-1). The test is called nuchal translucency and is 
not diagnostic, because some embryos with increased 
neck fluid are normal. If ultrasound images show increased 
nuchal translucency, this abnormal screening test can be 
followed by a diagnostic test for chromosome abnormalities 
(discussed below). In other cases, ultrasound can be 
diagnostic. For example, the accuracy of ultrasound in 
detecting anencephaly (incomplete head development) is 
approximately 100%.
Table 9-1.  
PREnaTaL DIaGnOsTIC sCREEns anD TEsTs
saMPLE TEsTs InDICaTIOns RIsks
Maternal serum AFP 
Multiple-analyte 
screens
Open NTD, abdominal wall defects Down 
syndrome, Trisomy 18, aneuploidy
Bruising, pain at site of blood 
withdrawal
Amniotic fluid 
(amniocentesis)
Karyotype AFP DNA, 
enzyme, hormone 
analysis
Maternal age ≥ 35, Abnormal MSAFP or triple 
screen  
Indicated as result of genetic counselling
≤1:200 risk for miscarriage
Chorionic villi (CVS) Karyotype DNA, 
enzyme, hormone 
analysis
Maternal age ≥ 35 Indicated as result of genetic 
counselling   
Earlier diagnosis desired
≤1:100 risk for miscarriage
Fetal blood (fetal 
blood sampling)
Karyotype DNA 
testing
1 to 3 in 100 risk for fetal loss
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It has become common practice in the U.S. for pregnant 
women to have at least one or two ultrasound examinations. 
The first scan is performed in the first trimester to confirm 
gestational age and the number of fetuses. This first scan 
can also measure nuchal translucency and can identify 
some malformations. A second ultrasound examination 
is performed at 18–20 weeks gestation. This ultrasound 
includes an anatomic survey that can identify about half 
of the structural malformations. Sometimes the second 
ultrasound will be followed by a more detailed examination 
at a later gestational age to further define suspected structural 
abnormalities. For example, fetal echocardiography, a 
specialized ultrasound examination of the fetal heart, can be 
used to characterize heart abnormalities with good accuracy.
Maternal serum screening
Maternal serum alpha-fetoprotein (MSAFP) measurement 
at 15–20 weeks’ gestation is used to determine if the fetus 
is at risk for an open neural tube defect. Alpha-fetoprotein 
(AFP) is secreted by the fetal liver and excreted in the fetal 
urine, but some AFP crosses the placenta and can be 
measured in maternal serum. The median values of AFP in 
amniotic fluid and maternal serum change with gestational 
age, so results are expressed as multiples of the median, or, 
cutely enough, MoM. 
Elevated MSAFP can be due to any of several factors. An 
abnormal fetal condition such as an open neural tube defect 
or abdominal wall defect can result in cause excessive AFP 
in the amniotic fluid, or an abnormal maternal-placental 
interface could allow excessive AFP to cross into the maternal 
circulation. Because AFP rises throughout pregnancy, 
inaccurate gestational age could cause an MSAFP level to 
seem high. Multiple gestations can also increase MSAFP, 
because more than one fetus is generating AFP. A less 
common reason for elevated amniotic fluid and maternal 
serum AFP levels are some rare inherited renal and skin 
diseases. Even if no reason can be found for an elevated 
MSAFP, the pregnancy would be considered at increased 
risk for preterm delivery or other adverse outcomes.
Nowadays, a “triple screen” or “quadruple screen” is often 
done, which combines a test for MSAFP with measurement 
of two or three other molecules. These chemicals currently 
include estriol, human chorionic gonadotropins (HCG), and 
inhibin-A, but the search for new and more predictive analytes 
or combinations of analytes is an area of active research. 
Initially designed to identify pregnancies at increased risk 
for trisomy 21 (Down syndrome), these multiple-analyte 
screens are also useful for detecting trisomy 18 and other 
less common aneuploidies (abnormalities of chromosome 
number). For the multiple-analyte screens, maternal blood 
is drawn between 15–20 weeks of gestation, at which time 
median values for each marker are well established. 
There are also protocols involving maternal blood 
sampling earlier in pregnancy, and first trimester screening 
with a nuchal translucency measurement and maternal blood 
testing is commonly offered to pregnant women. Establishing 
gestational age is critical for accurate interpretation because 
the medians for each marker change by the week. Results 
also have to be adjusted for maternal age. 
Diagnostic Testing
Because diagnostic testing in pregnancy is usually 
invasive, it is reserved for situations where the risk of 
an abnormal result exceeds the risk associated with the 
procedure.
Three different procedures can diagnose chromosomal 
abnormalities. The earliest test that can be done is chorionic 
villus sampling (CVS), which is performed between 10 
and 12 weeks of gestation. CVS involves suctioning bits 
of placental tissue, called chorionic villi, through a needle 
or a thin tube. These bits of placental tissue usually have 
the same chromosomes as the embryo. The cells from the 
chorionic villi are grown in culture and their chromosomal 
complement is analyzed. CVS is performed under ultrasound 
guidance; samples can be obtained either through the 
cervix or through the abdomen, depending on the operator 
preference and location of the embryo in the uterus. The 
risk of miscarriage is generally described as 1/100, but is 
considerably lower with more experienced operators. The 
advantage of CVS is that it can diagnose an abnormality 
earlier in pregnancy than any other test. However, CVS can 
only be used for chromosomal abnormalities; as we will see, 
amniocentesis can also be used for evaluating open neural 
tube and other defects.
Poor quality image, 
original is needed
Figure 9-1. Ultrasound image of a normal 
first trimester embryo in profile. The “+” signs 
mark the nuchal translucency measurement.
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Amniocentesis, the sampling of amniotic fluid, is 
commonly performed in the second trimester (Figure 9-2); 
chromosomal analysis is performed on amniocytes, which 
are cells that originated in the fetal skin and have the 
same chromosomes as the rest of the fetus. AFP levels in 
amniotic fluid are used to test for open neural tube and a 
few other kinds of defects. Amniocentesis performed under 
continuous ultrasound guidance is described to patients as 
having an approximate 1/200 risk for miscarriage, although 
the actual risk in experienced hands is much lower. First 
trimester amniocentesis is possible, but carries a greater risk 
of miscarriage. Amniocytes or amniotic fluid can also be 
used for DNA-based mutation analysis or enzyme analysis in 
the diagnosis of many inherited diseases. Tests for unusual 
genetic diseases are only done when the fetus has been 
determined by genetic counselling/history taking to be at risk 
for a specific condition.
The third way to do a chromosomal analysis is by taking 
a blood sample directly from the fetus after 18 weeks of 
gestation. This procedure involves the removal of blood from 
the umbilical vein, preferably close to the placental insertion 
site, and is associated with a 1–3% risk of fetal loss. 
Fetal cells are present normally in the maternal circulation. 
If isolated, these cells have potential to be useful in prenatal 
diagnosis, as a method that involves no risk to the fetus. 
However, the volume of fetal cells in the maternal circulation 
is very small, and there is some evidence that fetal cells may 
persist in maternal cells for many years, significantly beyond 
the pregnancy. Fetal cells sampled in a woman’s second 
pregnancy, then, might be contaminated with cells from the 
woman’s first child. A better alternative to harvesting fetal 
cells from maternal blood may be the identification of fetal 
DNA in maternal blood. DNA is shorter-lived than whole 
cells. Harvesting of fetal DNA offers an opportunity to test 
the fetus by drawing blood from the mother, a procedure 
that carries little if any risk. This test is not yet in clinical use, 
but may be a common practice in the future.
are These Tests Useful?
The usefulness of a test depends on what you want the 
test to tell you. Prenatal screening tests are limited in terms of 
the conditions detected and cannot be expected to give yes or 
no answers; they simply identify a population at greater than 
average risk of a given disorder. For example, chromosome 
abnormalities occur in about 1 in 1000 pregnancies in the 
general population. A woman with a triple screen result 
showing a 1 in 250 chance of an affected pregnancy has 
a higher than average risk and she may choose to have 
diagnostic testing. Notice, however, that the screening test 
does not give a normal/abnormal result. After all, 99.6% 
(249/250) of women with this “abnormal” result will have 
an unaffected pregnancy.
Even diagnostic testing is limited to chromosome 
analysis and AFP testing, and cannot guarantee a perfect 
baby. An anomaly that is detected early gives a pregnant 
patient and her partner the option to continue or terminate 
the pregnancy. When a decision is made to continue the 
pregnancy, medical management may be altered, and 
fetal surgery is sometimes possible for certain structural 
anomalies. Knowing about a problem in advance may be 
helpful to the family.
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Figure 9-2. Removal of amniotic fluid for diagnostic screening. 
Amniocentesis is performed under continuous ultrasound 
guidance. A needle is inserted through the maternal abdomen into 
the amniotic sac; the placenta is avoided, if possible. The tip of 
the needle is visible by ultrasound and is monitored throughout 
the procedure. Once the needle is within the amniotic sac, care 
is taken to avoid the fetus and umbilical cord. (In contrast, a fetal 
blood sampling targets the umbilical cord). A small amount of fluid 
is removed and discarded to avoid any possible contamination 
with maternal cells during insertion of the needle. Then the sample 
of fluid for analysis is removed. After needle removal, the fetal 
heart rate is checked by ultrasound.
Janine E. Polifka
University of Washington
Seattle, Washington
Anthony R. Scialli
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Sources of Information for Pregnancy SafetyChapter 10
Growing public awareness about birth defects has 
sent many people planning to have children to health care 
professionals with questions about how their exposures 
to drugs and environmental agents might affect their 
pregnancies. The number of published teratology and 
developmental toxicology studies published has increased 
over the years and the task of synthesizing and communicating 
accurate information has become more challenging. 
Most risk evaluations that are done are based on the 
general population’s likelihood of having an adverse event. 
Parents need help in understanding what their individual risk 
for an adverse pregnancy outcome is relative to that for the 
general population. For pregnant women who are exposed 
inadvertently, there is also a great need to understand 
the possible risks to the fetus. Approximately 15–20% of 
recognized pregnancies end in spontaneous abortion and 
between 2 and 3% of pregnancies result in a child with a 
major birth defect and/or mental retardation. Too often, 
counseling emphasizes the risks associated with drug 
therapy without balancing the discussion with the benefits to 
the mother and baby of treating an illness in the pregnant 
woman. A healthy mother helps to ensure a healthy fetus, and 
letting pregnant women remain ill because of fear of drug 
risks may not be the wisest course. To determine whether 
drug exposure increases a woman’s risk above background 
levels, health care professionals must integrate scientific 
information available on the agent and medical factors. 
A patient’s family or medical history may carry more risk 
than the drug in question, and complete knowledge of the 
pregnant woman’s health status, family history, pregnancy 
history, and occupational history, is helpful when evaluating 
teratogenic risk.
What sources of information are best? When health 
care practitioners have questions about medica-tions during 
pregnancy, they usually consult the product labeling. For 
drugs, product labeling is developed at the time a new 
product is approved by regulatory agencies such as the 
Food and Drug Administration (FDA) in the U.S. and the 
European Medicines Agency (EMA) in the European Union. 
The labeling describes the chemistry, pharmacology, and 
toxicology of the drug. It provides information on which 
uses (indications) and for which patient populations the 
drug has been approved and what the recommended doses 
are. The label includes results from both clinical studies 
and experimental animal studies to describe the safety and 
effectiveness of the drug. The pregnancy section of the label 
for a new drug is based almost entirely on laboratory animal 
data. It is a real challenge to practitioners and pregnant 
patients to understand the information in the labeling and 
determine the individual risk that taking the drug might have. 
The pregnancy section of the labeling in the U.S. currently 
contains a standardized rating system for pregnancy effects 
with five categories, each of which is given a letter (A, B, C, 
D, and X) [Table 10-1]. These categories were introduced by 
the FDA in 1979 in an effort to make pregnancy information 
easier to understand by practitioners, but the categories 
Table 10-1.
ThE CaTEGORIEs
Category a means that adequate controlled studies in women 
have failed to show a risk to the fetus. Virtually nothing is  
Category A.
Category B means either (1) experimental animal studies 
show risk but human studies do not, or (2) experimental 
animal studies are negative and adequate human studies do 
not exist. 
Category C means either (1) experimental animal studies 
show fetal risk or (2) there is no information one way or the 
other.
Category D means that there is evidence of risk to the human 
fetus (not necessarily from human studies, by the way), but 
that the benefit may outweigh the risk.
Category X means either (1) that there is evidence of risk to 
the human fetus, but the benefit would never outweigh the 
risk or (2) the drug has no conceivable utility in pregnancy.
Category B is a funny one, because if part (1) is fulfilled 
(adequate human studies do not show fetal risk), why is 
the drug not Category A? If part (2) is fulfilled, you have 
to wonder whether the experimental animal studies were 
adequately done. The way experimental animal studies are 
performed, a selection of doses is used in pregnant rodents 
or rabbits; the highest dose tested is supposed to result in 
some degree of maternal toxicity. Usually the top dose results 
in impairment of weight gain by the pregnant animal. In the 
face of impaired maternal weight gain during pregnancy, 
there ought to be an effect on the offspring (often a parallel 
impairment of offspring weight gain). This effect on offspring 
should count as fetal toxicity.
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have not been successful. The category system is erroneously 
interpreted as representing a gradation of risk and has not 
helped practitioners because the category designation does 
not communicate accurately what is known about the effects 
of a medication on pregnancy nor does it tell practitioners or 
patients what action to take. 
If you look closely at the definitions, you can see why 
the gradation of risk idea is inaccurate. Category C might 
be assigned to a drug that has been tested in some animal 
studies that may or may not have been adequate to assess 
potential risk, or the drug might be a C because there is little 
or no information in either animal or human studies. The 
majority of drugs fall into this category. Category X might 
be assigned to a drug that does not cause birth defects 
but simply has no conceivable use during pregnancy. Birth 
control pills are a great example of a Category X drug that 
has been shown not to increase the risk of birth defects. Birth 
control pills have been much better tested than some drugs 
in Category B or C and are in Category X only because there 
is no reason to take birth control pills during pregnancy.
Just as the categories do not describe a gradation of risk, 
the severity of effect is not indicated by the category level. 
For example, the anticonvulsant phenytoin is a Category D 
drug and is associated with birth defects in about 10% of 
exposed pregnancies. Lovastatin, a Category X drug based 
on lack of a perceived use for it during pregnancy, has not 
been associated with birth defects in exposed pregnancies. 
The difference between D and X may be simply whether there 
could be a reason to prescribe the drug during pregnancy, 
in spite of the presumed risk. Human data are available 
for only about 60% of Category X drugs. In other words, 
the Category X listing can be determined for presumed risk 
based on experimental animal studies plus a lack of a reason 
to use the medication during pregnancy. 
In 1994, the Teratology Society issued a recommendation 
that the category system be abandoned in favor of a plain-
text explanation of the available information on toxicity 
during development or on reproduction. Society members 
viewed the categories as hazardous to the fetus in potentially 
causing the termination of wanted pregnancies through 
inaccurate and incomplete information. The FDA also 
recognized the need to change the labeling and, in response 
to the Teratology Society, the Organization of Teratology 
Information Specialists (OTIS), and other concerned groups’ 
published a draft Proposed Rule: Pregnancy and Lactation 
Labeling that eliminates the pregnancy categories in favor 
of inclusion of plain text information relevant to determining 
risk. Based on the many comments received about the draft 
Rule, the FDA is in the process of finalizing the Rule, which 
will mandate changes in the pregnancy section of the labels 
for new drugs and eventually for all drugs.
What are other resources available for clinicians? The 
drug labeling itself will never provide all the information 
that might be needed to help make informed decisions for 
the pregnant patient. Other resources include textbooks, 
computerized databases, and teratogen information services. 
Textbooks that provide information regarding the reproductive 
effects of environmental agents can be found in the Suggested 
Reading section that follows. Peer-reviewed journals publish 
original studies, review articles, editorials, and information 
on upcoming conferences. Computerized databases contain 
information on thousands of agents, including medications, 
and summarize information from scientific studies. These 
databases are available on the Internet. For links to some 
of these databases, see the website list in the beginning 
of this Primer or go to the Teratology Society Web site at 
http://www.teratology.org/scientists.asp#tox.
Teratology Information Services (TIS) are comprehensive, 
multidisciplinary resources that provide free, up-to-date 
information about the reproductive effects of environmental 
agents to both health care providers and their patients. 
Most TIS have at least one full time teratogen information 
specialist and are directed by individuals with a medical or 
doctoral degree and expertise in clinical teratology. TIS are 
usually located at major medical universities or state health 
departments and can access a variety of resources, including 
medical libraries, online reproductive databases, and 
consultants in teratology-related fields such as toxicology, 
pharmacology, occupational medicine, genetics, radiation 
biology, infectious diseases, perinatology, and epidemiology. 
Although TIS operate independently, OTIS was formed more 
than 15 years ago to facilitate education and training in this 
area and to establish quality-assurance criteria. Through 
OTIS, teratology information specialists are in a unique 
position to quickly respond to public concerns that may be 
raised when research findings reach the popular press before 
health care providers can critically evaluate them. For more 
information and a list of TIS in North America, the OTIS 
Web site is at http://www.otispregnancy.org.
suggested Reading
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation 
(8th Ed.). Philadelphia, Pa.: Lippincott Williams & Wilkins, 2008.
Evaluating Chemical and Other Agent Exposures for Reproductive 
and Developmental Toxicity. Subcommittee on Reproductive and 
Developmental Toxicity, Committee on Toxicology, Board on 
Environmental Studies and Toxicology, National Research Council. 
Washington, DC:  National Academy of Sciences, 2001. Online 
at the National Academies Press Web site: http://www.nap.edu/
books/0309073162/html/.
Teratology Primer
10-29
Sources of Information for Pregnancy Safety
Friedman JM, Hanson JW. Chapter 39. Clinical Teratology. 
In Rimoin DL, Connor JM, Pyeritz R, and Korf B. (eds) Emery and 
Rimoin’s Principles and Practice of Medical Genetics, 4th edition. 
London: Churchill Livingstone, 2002.
Koren G, (ed.)  Medication Safety in Pregnancy and Breastfeeding: 
The Evidence-Based, A-to-Z Clinician’s Pocket Guide. New York: 
McGraw-Hill Companies, Inc., 2007.
Kweder SL. Drugs and biologics in pregnancy and breastfeeding: 
FDA in the 21st century. Birth Defects Research (Part A) 2008: 
82:605–609.
Polifka JE, Faustman EM: Developmental Toxicology: Web 
resources for evaluating risk in humans. Toxicology 2002:173: 
35–65. 
Polifka JE, Friedman JM:  Medical Genetics:  1. Clinical teratology 
in the age of genomics. CMAJ 2002: 167(3):265–273.
Schaefer C, Peters P, Miller RK (eds): Drugs During Pregnancy 
and Lactation: Treatment Options and Risk Assessment, 2nd ed. 
Burlington, Mass.: Academic Press, 2007.
Shepard TH, Lemire RJ: Catalog of Teratogenic Agents, 12th ed. 
Baltimore, Md.: The Johns Hopkins University Press, 2007.
Teratology Public Affairs Committee. FDA Classification of Drugs 
for Teratogenic Risk. Teratology 1994: 49:446–447.
Teratology Public Affairs Committee Position Paper: Pregnancy 
Labeling for Prescription Drugs: Ten Years Later. Birth Defects 
Research (Part A) 2007: 79:627–630
11-30
Sonja A. Rasmussen1 
National Center on Birth Defects and  
    Developmental Disabilities,
Centers for Disease Control and Prevention 
Atlanta, Georgia
Gary M. Shaw
Stanford University School of Medicine
Palo Alto, California
how Do Epidemiologic studies Contribute to the  
Identification of Teratogenic Exposures?
Chapter 11 Epidemiology and Identification of Teratogens
Epidemiology is the study of the 
distributions of, and risk factors for, diseases 
in human populations. Epidemiologists 
use a variety of designs and statistical 
procedures to identify and assess risk 
factors. Although clinical observations 
from a single case or case series sometimes 
play a role in understanding the effects of 
a particular exposure during pregnancy, in 
most circumstances, it is difficult to know 
whether the observed outcome is due to 
the pregnancy exposure or if the exposure 
is incidental. However, these clinical 
observations may raise clues that can be 
addressed in epidemiologic studies.
Epidemiologists who study potential 
teratogenic exposures typically conduct 
observational studies on populations. 
Unless a particular exposure or procedure 
is thought to be beneficial, most studies 
cannot ethically be experimental in their 
design, e.g., randomized controlled trials. 
In experimental studies, the investigator 
has much more control over the many 
exposures study subjects may encounter, 
whereas in observational studies, the 
investigator is relegated to being an 
observer of factors to which subjects in 
a study population are exposed. In some instances, many 
of these exposures are not known or cannot be adequately 
controlled. Thus, observational epidemiology studies offer 
associations and do not establish causation. 
The two primary types of observational studies that 
epidemiologists have at their disposal are cohort and 
case-control studies. The cohort study approach starts with 
one group of individuals in a defined population exposed 
to a particular agent and compares the risk of disease/
outcome in that group to a second group of individuals from 
the population not exposed to the same agent (Figure 11-1). 
Cohort studies may include the entire population of interest 
or at least a large segment of the population, and often 
require long periods of follow-up time to reliably establish 
the risk of disease/outcome between the two groups. The 
second main type of observational study design—the 
case-control study—includes all cases of the disease of 
interest in the defined population, but only a random sample 
of the non-diseased population (Figure 11-2). That is, the 
epidemiologist determines the ratio of cases to controls that 
are included in the study, and compares the frequency of the 
specified exposure/factor between cases (with the disease of 
1The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease 
Control and Prevention.
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Figure 11-1. Study design of a cohort study: Pregnancies (exposed and unexposed to 
the agent of interest) are identified from all pregnancies in a defined population. Birth 
outcomes (whether the baby has a birth defect or not) are determined. The rate of 
infants with birth defects among exposed pregnancies is then divided by the rate of 
infants with birth defects among unexposed pregnancies to determine the relative risk. 
Adapted from Fletcher et al., 2005.
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interest) and controls (without the disease 
of interest). These types of studies tend to 
be more economical than cohort studies 
because one does not have to enroll as 
many individuals as would be needed in a 
cohort study, many of whom will never get 
the disease/outcome that is of interest.
Associations in these observational 
studies are assessed by calculating “risk 
estimates” for the exposed group relative 
to the unexposed group. The typical 
measure used in cohort studies to estimate 
the size of the association between a 
factor of interest and a disease/outcome 
of interest is known as the relative risk—
see Figure 11-1. A relative risk of 1.0 
indicates that the risk of disease in the 
group exposed to the risk factor is the 
same as the risk of disease in the group 
not exposed. Relative risks more than 1.0 
indicate that the risk of disease is higher in 
the exposed group, whereas relative risks 
less than 1.0 indicate that the risk is lower 
in the exposed group when compared to 
the unexposed. The typical measure used 
in case-control studies to estimate the size 
of the association between an exposure 
or factor of interest and a disease/
outcome of interest is known as the odds ratio—see 
Figure 11-2. The odds ratio is an approximation of the 
relative risk when the outcome is rare, and its interpretation 
is similar to the relative risk. That is, an odds ratio of 1.0 
indicates no association between factor and disease, an 
odds ratio >1.0 indicates an increased risk association and 
an odds ratio <1.0 indicates a decreased risk association. 
Confidence intervals are a measure of statistical precision of 
the relative risk or the odds ratio. Confidence intervals that 
contain 1.0 indicate that relative risk or odds ratio estimates 
do not differ statistically from the no-effect value of 1.0.
Conducting epidemiologic studies and drawing 
inferences from such observational studies requires the 
epidemiologist to be aware of methodologic issues pertinent 
to the exposure and the disease being studied. These issues 
include ascertainment of defects, grouping of defects, choice 
of control groups, confounding, and chance:
Ascertainment—Some birth defects are much more 
easily identified, for example, severe heart defects, such 
as hypoplastic left heart syndrome, are more likely to be 
ascertained than less severe heart defects, such as ventricular 
septal defects and atrial septal defects. These less severe 
defects are much more difficult to ascertain uniformly in 
a population because they may be asymptomatic in early 
life. Ascertainment of a defect needs to be nearly complete 
and consistent because if there is variability within a study 
on how well defects are ascertained between exposed and 
unexposed individuals, the observed result may be spurious. 
Grouping of defects—Human birth defects comprise 
many different developmental systems and structures, 
reflecting manifold differences in underlying pathogenesis and 
etiologies. Typically teratogenic exposures do not increase 
risks of all birth defects. Even specific groups of defects, e.g., 
heart defects, are heterogeneous in anatomy, development, 
and epidemiologic factors. Combining different birth defect 
types for analyses is a valid approach only if the defects being 
lumped have an underlying pathogenesis that is similar. 
Control groups—A very important consideration in 
case-control studies is the selection of the control group. An 
appropriate control group in a study of a specific birth defect 
is a random sample of mothers/babies who would have been 
included in the case group if their child had the birth defect 
being studied. In the circumstance with a medication that is 
indicated for a limited set of underlying conditions, a further 
approach might be to choose a control group that had the 
underlying condition, but did not use the medication. The 
Figure 11-2. Study design of a case-control study: All infants with birth defects are 
identified from a defined population and a sample of infants without birth defects is 
selected from the same defined population. Information is assessed about exposure 
during pregnancy after the pregnancy is complete and the outcome is known. The odds 
ratio, which estimates relative risk when the outcome is rare, is calculated as the odds 
of exposure among cases divided by the odds of exposure among controls. Adapted 
from Fletcher et al., 2005.
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latter may not be practical nor may it be ideal because those 
with the underlying condition may differ in severity of the 
condition.
Confounding—Studies investigating whether a specific 
birth defect is associated with a particular exposure need to 
accurately assess whether other factors associated with the 
exposure such as maternal age contribute to the results. For a 
factor to be a confounder, it must be associated with both the 
exposure and the outcome. If these other factors are known 
and have been measured, they can be addressed analytically 
with statistical methods such as logistic regression.
Chance—As noted above, the confidence interval 
provides a guide to determining the likelihood that a 
result occurred by chance. Another way to determine such 
likelihood is by using p values. The p value is an estimate 
that the differences observed occurred by chance alone, 
assuming that there is no difference between exposed 
and unexposed women. Typically, p values of <0.05 are 
considered statistically significant, although it should be 
recognized that the selection of 0.05 as a cutoff is arbitrary 
and other values may sometimes be more appropriate.
Bias—In addition to chance, it is important to consider 
whether some sort of study bias is an alternative explanation 
of the results that have been observed. Bias can be introduced 
in a variety of ways, e.g., mother’s recall of an exposure, 
incomplete case ascertainment, and confounding. If bias 
is present, it will cause observed results to differ from the 
truth. Investigators who use observational studies need to be 
particularly aware of such biases because the “treatment” or 
exposure under study was not assigned randomly. Statistical 
methods sometimes, but not always, can be used to address 
some biases. One factor to consider in case-control studies 
is whether the results observed could be due to recall bias, 
the tendency for a woman who had a baby with a birth defect 
to be more likely to recall prenatal exposures than a woman 
who had a normal baby. 
Absolute Risk vs. Relative Risk—Another issue to 
consider is what study results mean for an individual woman 
with a particular exposure. It is important to recognize that 
an elevated relative risk or odds ratio needs to be put into 
context by taking into account the frequency at which the 
outcome occurs. For example, a relative risk of 3 means that 
an exposed woman is at a three-fold risk of the particular 
outcome. If the outcome is rare (1 in 100,000), her absolute 
risk if exposed to the medication is 3 in 100,000 (1 in 
33,333), whereas if the outcome is more common (1 in 
100), her absolute risk would be 3 in 100, or 3%.
Epidemiologic studies provide a valuable approach 
to better understand effects of certain exposures during 
pregnancy. However, many factors need to be considered 
and results from such studies must be combined with existing 
information before assuming that the effect observed in a 
study is valid and meaningful for an individual woman.
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Women often need to take medications at some point 
during their pregnancy. Most drugs have not been evaluated 
in clinical trials that knowingly enroll pregnant women. A 
woman, as any other patient, should expect that any medicine 
prescribed during pregnancy has had an evaluation of risks as 
well as benefits. What are the ethical considerations for testing 
drugs during pregnancy? Ethical rules applied to medical 
practice and research are often referred to as medical ethics 
and include human participant protections, patients’ rights, 
informed consent and privacy/confidentiality. Ethical issues 
arising from advances in biological and medical sciences 
that are subsequently applied to human life, e.g., genetics, 
genetic testing, stem cell research, pharmacogenomics and 
personalized medicine, DNA databases and sample storage 
are referred to as bioethics (Figure 12-1). Both medical 
ethics and bioethics apply to clinical research. 
The fundamental ethical principles and codes that are 
instituted for the protection of human subjects are found in 
3 key documents. The Nuremberg Code in 1947 stated that 
“certain types of medical experiments on human beings, 
when kept within reasonably well-defined bounds, conform 
to the ethics of the medical profession generally. … and that 
certain basic principles must be observed in order to satisfy 
moral, ethical, and legal concepts.” This code became the 
prototype to assure that research involving human subjects 
would be carried out in an ethical manner. In the 1979 
Belmont Report and in the 2008 version of the Declaration 
of Helsinki, these principles were further defined, clarified 
and updated.
The Belmont Report summarizes the basic ethical 
principles according to the nature and definition of informed 
consent, the assessment of risk-benefit criteria in research 
involving human subjects, and their fair selection for 
research. The basic ethical principles for research involving 
human subjects are respect for persons (protection of 
pregnant women and fetuses through informed consent and 
additional safeguards), beneficence (prior evaluation of the 
risks of medications and/or medical procedures in pregnant 
women and fetuses), and justice (appropriate distribution of 
the benefits and burdens of research) (Table 12-1). 
Respect for Persons embodies the ethical concepts that 
individuals should be treated as autonomous persons and 
that those with diminished autonomy should be protected. 
This protection speaks to vulnerable populations, i.e., those 
that are limited in their scope of options, that are often 
frequently subjected to coercion in their decision making 
ability, or that may be compromised in their ability to give 
Figure 12-1.
ThE BELMOnT REPORT, 1979
PRInCIPLE aPPLICaTIOn
Respect for persons 
Individuals should be treated 
as autonomous agents; those 
with diminished autonomy 
are entitled to protection
Informed consent  
Subjects, to the degree that 
they are capable, must be 
given the opportunity to 
choose what shall or shall not 
happen to them  
The consent process must 
include three elements: 
information, comprehension 
and voluntariness
Beneficence  
Human subjects should not 
be harmed; Research should 
maximize possible benefits 
and minimize possible harms
assessment of risks and 
benefits  
Nature and scope of risks and 
benefits must be assessed in a 
systematic manner 
Justice  
The benefits and risks of 
research must be distributed 
fairly 
selection of subjects  
There must be fair procedures 
and outcomes in the selection 
of research subjects 
Table 12-1. The Belmont Report established three basic ethical 
principles—respect for persons, beneficence and justice—which 
are the cornerstone for regulations involving human subjects.
Medical Ethics and Bioethics
Medical Ethics
 Ethical rules applied to
issues in medical practice
and research
 Human participant
protections
 Patients' rights
 Informed consent
 Ethical review
 Privacy/confidentiality
Bioethics
 Ethical issues due to
advances in biological and
medical science applied to
human life
 Genetics, genetic testing
 Stem cell research
 Pharmacogenomics,
Personalized Medicine
 DNA databases, sample
storage
Teratology Primer
12-34
Ethics for Clinical Trials
informed consent. Vulnerable groups include pregnant 
women, human fetuses and neonates, children, prisoners, 
and persons with impaired decisional capacity.
In practice, respect for persons requires that individuals, 
to the degree that they are capable, be given the opportunity 
to choose what will or will not happen to them. This choice 
is provided through the three standard elements of informed 
consent: information, comprehension, and voluntariness. 
Respect for persons also safeguards the individuals’ right to 
withdraw at any time from research.
Beneficence refers to the efforts to ensure the well-being 
of the individual and is related to nonmaleficence, the 
obligation to do no harm. The Hippocratic maxim “do no 
harm” is a fundamental principle of medical ethics, but in 
the realm of research, refers to no harm regardless of the 
benefits that might come to others. The practical application 
of beneficence is the assessment of risks and benefits and 
the careful analysis of the design as well as alternative ways 
of obtaining the benefits sought in the research. Risks and 
benefits of research not only affect the individual subjects 
but possibly affect the families of the individual subjects and 
society. Hence, there is a requirement that risks to subjects 
be outweighed by the sum of both the anticipated benefit to 
the subject, if any, and the anticipated benefit to society in 
the form of knowledge to be gained from the research.
Justice is framed in the question: Who ought to receive 
the benefits of research and bear its burdens? This concept 
speaks to the fairness in distribution. Injustice implies denial 
of a benefit to which a person is entitled or undue imposition 
of a burden without good reason. The principle of justice 
gives rise to the requirement that there be fair procedures for 
the selection of research subjects. 
In many of the early writings on the ethics of research 
involving human subjects, the burdens of research fell largely 
on the poor and on unwilling prisoners, while the benefits 
of improved medical care came primarily to the wealthy. 
Justice in the selection of subjects requires that potentially 
beneficial research be equitable and not based on classes 
of vulnerable subjects to bear burdens without the benefits 
of the research. 
In 1991, a uniform set of regulations for the protection 
of human subjects was issued as the Federal Policy for the 
Protection of Human Subjects, informally known as the 
“Common Rule.” The Common Rule applies to all federally 
funded research and requires that for research with human 
subjects, the entity conducting the research must assure 
the federal government that it will provide and enforce 
protections for research conducted under its sponsorship, 
assess research proposals as to risks and potential benefits 
to subjects, ensure requirements for selecting subjects and 
obtaining informed consent are met, and establish and 
delegate to an Institutional Review Board (IRB) the authority 
to review and oversee human subjects protections for all 
research conducted.
The main elements of the Common Rule are often 
referred to by the specific section of the Rule. Subpart A 
covers the requirements for assuring compliance by research 
institutions, obtaining and documenting informed consent, 
and IRB review of research; Subpart B covers additional 
protections for pregnant women, in vitro fertilization, and 
fetuses; Subpart C addresses the ethical use of prisoners; 
and Subpart D covers the use of children in research.
Ethical Issues: Prenatal screening and Exposure
Advances in medical technology allow pregnant women 
to undergo genetic testing of their unborn child as part of 
routine prenatal care to potentially detect individuals at 
increased risk for an abnormal pregnancy outcome. A patient 
can then choose to continue or terminate the pregnancy, 
which leads to difficult ethical decisions regarding the 
best interests of all parties involved. Genetic technology 
can lead to positive/negative eugenics regarding gender 
and phenotypic trait selection (designer babies), in some 
situations resulting in loss of genetic diversity in the gene 
pool.
Prenatal exposure to many compounds, infectious 
diseases, stress and nutrition has the potential to negatively 
affect the developing fetus with preventable defects that can 
last a lifetime. It is the ethical responsibility of the mother to 
protect the developing child through appropriate behavior 
and medical care.
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Post Marketing Surveillance 
Once a new medication is marketed, if the medication 
is used at all by women who are in their childbearing years, 
there are likely to be pregnant women who take the drug. 
This pregnancy exposure can occur unintentionally during 
the early weeks of pregnancy before a woman knows that 
she is pregnant. A pregnant woman may also take a new 
medication intentionally for some disease or condition 
that requires treatment. Without human pregnancy clinical 
trial data to establish the safety of a medication for the 
developing fetus, post-marketing surveillance studies are an 
increasingly common method for gathering data on potential 
teratogenicity as quickly and as efficiently as possible. 
One type of post-marketing surveillance study is a 
called a “pregnancy registry.” Pregnancy registries are 
studies in which pregnant women who have taken a specific 
medication are asked to enroll in the registry. Information 
is collected about the woman’s pregnancy, her medication 
and other exposures, and the outcome of that pregnancy. 
Information is typically collected on all pregnancy outcomes, 
whether the pregnancy ends in miscarriage, stillbirth, or a 
live born baby or babies, and information is collected on 
any complications that occur, including birth defects. The 
number of specific poor outcomes, such as babies born with 
birth defects, among women who took the drug of interest 
is evaluated to determine if these events are more frequent 
than expected and if it is plausible that the excess number of 
affected infants might be due to a teratogenic effect. 
Every pregnant woman has a small, 2–3% risk of having 
a child with a birth defect regardless of the medications she 
takes. In order to determine if a specific new drug exposure 
might be increasing that risk, pregnant women exposed to 
the drug under study are compared to another group of 
pregnant women. This reference group can be the general 
population of pregnant women, or can be a comparison 
group of pregnant women who are enrolled in the registry 
but who have not taken the medication under study. 
The objective of a pregnancy registry is to determine as 
early as possible after a drug is marketed whether or not 
there is any indication of a teratogenic risk in humans. This 
approach is appealing to pregnant women and their health 
care providers because it has the potential to provide clues 
about safety issues or teratogenic potential so that the best 
treatment decisions can be made. 
A pregnancy registry may be the most efficient method 
for post-marketing surveillance if a drug is used for a very 
rare condition or is used only infrequently in the population 
of women who might become pregnant. A pregnancy registry 
can also be a good method for identifying a new human 
teratogen if the medication causes a very unique and severe 
pattern of birth defects or a very high incidence of specific 
birth defects. 
However, because new medications might be infrequently 
used in pregnant women and because pregnancy registries 
rely on women and/or their health care providers to volunteer 
for the study, the number of women who enroll in any given 
registry often is very small. Small numbers of participants 
can limit the ability of a pregnancy registry to conclusively 
detect human teratogens, particularly if the drug only 
affects a small proportion of exposed pregnancies. Thus, 
an important function of a pregnancy registry is to identify 
potential “signals” or suggestions of an excess risk, and to 
call for additional studies to confirm or refute that signal. By 
the same token, pregnancy registries can never definitively 
establish safety but can provide some reassurance that a 
specific drug does not carry a high risk for a severe pattern 
of birth defects.
Another approach to post-marketing surveillance takes 
advantage of the technological advances in electronic 
claims data and medical and pharmacy records storage. 
Large databases that include pregnancy information, such 
as linked prescription and birth records can compare 
pregnancy outcomes between pregnant women who have 
been prescribed a new drug of interest and those who have 
not within the same healthcare database. This approach 
offers many of the advantages of a pregnancy registry at 
potentially far less cost, and need not rely on volunteers to 
enroll. 
Some limitations of healthcare database studies include 
the difficulty in determining if the drug that was prescribed 
was actually taken by the mother and when and oftentimes 
lack of access to information on other important exposures 
such as whether or not the mother smoked cigarettes or 
drank alcohol during pregnancy. In addition, just as with 
pregnancy registries, if the drug of interest is infrequently 
prescribed to women of childbearing age, even very large 
databases may have access to only small numbers of 
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pregnant women exposed to any particular drug. Therefore, 
large databases may still have difficulty in identifying new 
teratogens unless the risk is high for a severe and easily 
recognizable teratogenic effect.
Despite the challenges of performing post-marketing 
surveillance for human teratogenicity, the public health need 
for such information is great. In the absence of randomized 
clinical trials, synthesis of information from post-marketing 
studies along with population-based studies, pre-clinical 
developmental toxicity studies, and other predictive 
techniques, as described in this Primer, are needed to 
optimize the capacity to recognize a potential teratogenic 
effect with a new pharmaceutical agent or conversely 
to provide reassurance that a new drug does not pose a 
substantial risk. 
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No pregnant woman wants to take chances with the 
health of her baby, and women expect that medications 
prescribed during pregnancy have been tested for safety 
for the embryo or fetus. Product labels for drugs contain a 
section on use in pregnancy. What is different about this 
section compared to the rest of the drug label is that it is 
almost always entirely composed of data from animal studies 
rather than data from human clinical trials. Most drugs are 
not tested in pregnant women, and during initial testing, 
women at risk of pregnancy are intentionally avoided. Only 
post-menopausal women or women who are using effective 
contraception are normally enrolled in drug trials before 
reproductive toxicology tests are conducted. After these tests 
are completed, reproductive age women are included in 
large-scale clinical trials. 
Since the 1960’s, testing in experimental animal models 
has been required to estimate prenatal risk in humans. 
These studies are typically performed in one rodent and one 
non-rodent species. Rats and rabbits are the most often used, 
unless it is known that one or the other is not considered an 
appropriate model. In recent years, there is increased use of 
primate models to test biologic drugs because the traditional 
rat and rabbit models are not relevant. Worldwide, the 
International Conference on Harmonization (ICH) guidelines 
for testing pharmaceuticals are followed. Similar guidelines 
and regulations from the U.S. Environmental Protection 
Agency (EPA) and the European Organization for Economic 
Cooperation and Development (OECD) govern the testing 
for potential exposures to chemicals in the environment.
The studies that follow these ICH guidelines are intended 
to test the potential for adverse effects from pre-conceptional 
exposure through exposure via the milk in newborn animals. 
Developmental toxicity is evaluated in two of these studies. The 
first is the embryo-fetal toxicity study, which exposes pregnant 
female animals during the period of organogenesis, typically 
defined as the period from implantation to palate closure. 
Rats are dosed on gestational days 6–17 and the fetuses are 
examined on day 21, just prior to term. Rabbits are dosed 
on gestational days 7–19 and the fetuses are examined on 
gestational days 29 or 30. Fetuses are examined for external 
malformations and internal malformations of the organs 
(viscera) and skeleton. Growth is evaluated by body weight 
and in some cases by crown-rump (body) length. The doses 
used in these studies are carefully selected to cover a range 
of concentrations including exposures at or above expected 
human exposures. Animals are exposed to at least three 
different doses and outcomes are compared with a control 
group, exposed only to water or another inactive vehicle. 
The agent is tested over a range of doses up to a dose that 
stresses the system by producing some degree of maternal 
toxicity. The highest dose of the agent is usually chosen 
as one that will produce maternal toxicity, for example, a 
small decrease in pregnancy weight gain. The lowest dose 
of the agent is one that is close to the anticipated human 
exposure level. Middle doses are chosen between these two 
levels. The lowest dose of the agent that produces abnormal 
development is called the LOAEL (lowest observed adverse 
effect level). The next lower dose is called the NOAEL (no 
observed adverse effect level). These levels can be compared 
to the anticipated human exposure level. In general (in the 
absence of other modifying information about the toxicity of 
the agent), if the anticipated human exposure level is 100 
times lower than the NOAEL, adverse effects on human 
development are considered unlikely. Some researchers 
believe that this 100-fold “safety margin” is unnecessarily 
1The information and conclusions found in this chapter are those of the author and do not necessarily reflect the views or policies of the FDA.
Graphic courtesy of Barbara F. Hales.
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high, and that much smaller margins, perhaps between 
4-fold and 100-fold, would be just as protective. In instances 
where no abnormal effects on the offspring, even when 
the agent is given at maternally toxic levels, the evidence 
suggests that abnormal effects on human development are 
unlikely. Any testing scheme, however, cannot categorically 
define a medicinal product, as safe or unsafe because this 
expectation ignores the importance of the exposure level in 
determining toxicity. A chemical that is toxic at one dose will 
be nontoxic at another dose.
Embryo-fetal toxicity studies evaluate the potential for 
structural malformations and developmental delays of the 
offspring but are not designed to assess effects on function. 
Another ICH guideline study is used to do this. The pre- and 
post-natal study covers exposure during both the prenatal 
and early postnatal stages of development. Rats are dosed 
from gestational day 6 (pre-natal) through lactation day 21, 
the day of weaning (post-natal). Physical endpoints used in 
developmental toxicity studies are examined in this study, 
but additional tests are done as well. Body weight changes 
in pups are measured to evaluate growth. Offspring are 
observed for the achievement of functional developmental 
landmarks, including the development of the air righting 
reflex (the ability for the pup to land on its feet). Vision and 
hearing are tested, and water mazes and other tests evaluate 
learning and memory. Once the animals attain sexual 
maturity, functional reproductive ability is evaluated by 
mating the offspring. The dams are observed to evaluate the 
potential impact of exposure on parturition and the ability to 
care for her young during the lactation period. 
The data from all of these studies form the basis for 
assessing risk during pregnancy. Data from animal models 
are not absolutely predictive of human risk but do provide 
a good assessment of potential problems. The ability of 
a drug to cause developmental toxicity is usually related 
to the concentration in blood and tissues. Concentrations 
that cause developmental toxicity in one species will usually 
cause developmental toxicity in other species, although 
the malformations may be different across species. Study 
outcomes include death or malformations (cleft lip/palate, 
spina bifida, etc.), but it is much more common for studies 
to indicate effects on overall development, such as lower 
fetal body weights, delayed skeletal ossification, or delayed 
maturation of the kidneys or other organs. 
Completion of these studies is only half the task; 
appropriate interpretation of these data is key and should 
be done by scientists trained in the concepts and principles 
of teratology. It is extremely important to factor in maternal 
toxicity when interpreting findings, because illness or stress 
in a dam will affect her pups (chapter 24). Malformations or 
significantly delayed fetal development without any effects on 
the dam may indicate a direct effect of the drug on the fetus. 
It is also important to know the baseline incidence of specific 
malformations in animal models to determine the effects 
of an agent over the spontaneous background risk. Data 
are also reviewed to determine if there is a dose-response 
relationship, meaning that the incidence and severity of 
adverse outcome increases with increasing dose. Assessing 
patterns is important in assessing risk. A study that shows no 
effect of low and high doses, but shows an effect at a middle 
dose, is less convincing than a study that relates increasing 
risk to increasing dose. Understanding the pharmacologic 
action of the drug and the mechanisms for toxicity are also 
important. If, for example, the malformations observed are 
unique to the species tested, then the data may not be relevant 
to human risk. Finally, risks must be weighed against benefits. 
A drug that is a member of a class known to be teratogenic 
in animal experiments would carry a warning against use in 
pregnancy, but in a pregnant woman with a chronic disease, 
it may be important to use the drug in spite of the possible 
risk. In these circumstances, testing remains an important 
part of the risk evaluation to characterize the margin of 
safety for humans. To date, there has not been a single 
example of a chemical that produces harm to the developing 
human without producing adverse effects on development 
in rats or rabbits at doses high enough to produce maternal 
toxicity. In other words, human embryos and fetuses are 
not uniquely sensitive provided that the agent has been 
tested at sufficiently high doses in experimental animals. 
The converse is not true: if a drug or chemical produces 
toxicity in experimental animal studies, it is not necessarily a 
risk at typical human exposure levels. There are many drugs 
and chemicals that produce abnormal development at the 
Graphic courtesy of Anthony R. Scialli.
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high doses used in experimental animal studies but not at 
the exposure levels encountered by humans. Experimental 
animal testing is designed to be conservative for use of drugs 
in pregnancy. 
While human data on developmental toxicity is 
increasingly included in drug labels, the majority of the 
drugs approved for use in the United States still have no 
human data in the pregnancy section of their label. For most 
drugs, clinical trials are not conducted in pregnant women. 
Consequently, we must rely on animal data to understand 
potential risk for both newly approved drugs and existing 
drugs. The pregnancy section of the drug label is often the 
major source for the information used by the clinician in 
estimating risk (chapter 10). Developmental toxicity studies in 
animals provide informative but complex data for assessing 
potential risks of drug use in human pregnancy. Extrapolation 
of information from reproductive toxicology studies to 
humans requires more data than is normally available in the 
product label. Animal studies are designed to elicit adverse 
events in order to provide a margin of safety for human use. 
Individual factors, including genetic background and the 
risks of the underlying disease being treated are weighed in 
order to make rational decisions about the use of any drug 
during pregnancy.
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Chapter 15 In Vitro Detection of Teratogens
Can In Vitro Methods Contribute to the Identification 
of Teratogenic Exposures? 
Barbara F. Hales
McGill University
Montreal, Quebec, Canada
Teratogenic effects range from embryo death to 
malformations, from growth problems to long-term functional 
impairments such as mental retardation. The advantage of 
experimental animal tests in teratogenicity risk assessment 
is that the pregnant animal comprises all of the potential 
endpoints for adverse effects of an exposure—i.e., the 
mother, placenta and embryo. So, how can in vitro methods 
contribute to the identification of teratogenic exposures?  
All in vitro teratogenicity tests have a biological compo-
nent that can undergo differentiation or organogenesis in 
vitro. This biological component could be cultured cells, an 
organ, or a whole embryo. Each of these levels of complexity 
has both advantages and disadvantages. The European 
Centre for the Validation of Alternative Methods (ECVAM; 
http://ecvam.jrc.it/) has led an initiative to establish and 
validate in vitro tests for embryotoxicity. The ideal in vitro ter-
atogenicity test should be rapid, reproducible, inexpensive, 
technically easy to perform, and not involve experimentation 
on animals. Cell culture involves few animals, especially if 
the cells have been maintained in culture over many genera-
tions as in established cell lines. A whole organ or embryo 
culture system, however, is more likely to involve all the 
processes in development that are likely to be susceptible 
to interference after a teratogenic exposure. No one system 
is perfect for every context, and a combination of several 
tests may be recommended. The advantage of in vitro testing 
is that exposure can be controlled very precisely. Species 
differences in how a chemical is metabolized can be 
overcome by adding the metabolite or an appropriate 
metabolizing system. 
This chapter will focus on three mammalian embryotoxicity 
test systems: the culture of embryonic stem cells, limb bud or 
limb bud micromass cultures, and whole embryo cultures. 
Many signalling pathways that control embryo development 
occur across species, so non-mammalian systems, using 
embryos of zebrafish, for example, may also have potential 
to evaluate teratogenic risk. 
Embryonic stem Cells
Embryonic stem cells are pluripotent cells, capable 
of differentiating into a wide variety of cell types, that are 
derived from the blastocyst inner cell mass (Figure 15-1). In 
the embryonic stem cell test, the effects of a test chemical 
on a mouse embryonic stem cell line (D3) are compared 
to those on adult fibroblast 3T3 cells. The endpoints 
measured are the ability of the chemical to inhibit growth 
of the embryonic stem cells or their differentiation into 
cardiac myocytes (muscle cells), for example, compared to 
their effect on adult 3T3 cells. Thus, this test compares the 
effects of a test chemical on embryonic cells relative to adult 
cells, and also looks at the ability of the chemical to inhibit 
differentiation. The use of established cell lines means that 
additional vertebrate animals are not needed. 
Limb Bud or Limb Bud Micromass Cultures
In the limb bud culture system (Figure 15-2), fetal limbs, 
usually from mice, are removed on day 11 or 12 of gestation 
and cultured for 6 to 9 days, with or without the agent 
under study. During culture the limbs undergo extensive 
changes in morphology (size and shape), and biochemical 
differentiation, which can be assessed quantitatively. 
Changes in size and shape can be measured using a scoring 
system or image analysis. Measurable biochemical changes 
include DNA, RNA, and protein content as well as creatine 
phosphokinase (related to muscle development) or alkaline 
phosphatase (involved in pre-bone formation).
Figure 15-1. The embryonic stem cell test evaluates the 
embryotoxicity of a chemical on the basis of its ability to inhibit 
embryonic stem cell differentiation and its cytotoxicity to 
embryonic relative to adult cells.
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The limb bud micromass culture system is based on the 
ability of undifferentiated limb bud mesenchyme cells to form 
foci, or clusters, of differentiating chondrocytes (cartilage 
cells). Cell proliferation, differentiation, and interactions 
between cells, or between cells and the extracellular matrix, 
are all implicated in this process. Limb buds are isolated 
from day 14 rat embryos, and made into a cell suspension, 
which is placed into wells (plates or trays dotted with small 
round indentations). The cells are incubated for 5 days with 
medium and a test chemical; control wells contain only 
medium. The total number of viable cells, differentiated cells 
and foci are determined. Chemicals that reduce the number 
of foci, or the number of cells within foci, are considered 
potentially problematic.
Whole Embryo Cultures
In the mammalian whole embryo culture system (Figure 
15-3), rat or mouse embryos with intact yolk sacs are 
removed during early organogenesis and cultured in rat 
serum. During culture, the embryos undergo tremendous 
growth and differentiation, advancing from the early somite 
stage to 30 to 45 somites by the end. The embryos turn 
and rotate, the neural tube closes, and the brain, heart 
and other organs begin to develop. The effect of chemicals 
on the number of dead and live embryos and the number 
of malformed versus normal embryos is noted, but many 
other measurements are taken as well. Effects on yolk sac 
diameter, crown-rump length, head length, and number of 
somite pairs are scored. Biochemical criteria, including DNA 
content, gene expression, protein content, and hemoglobin, 
are also usually assessed. Malformations induced in intact 
animal models by cadmium, retinoic acid, and hydroxyurea 
cause very similar effects in whole embryo culture, although 
adding chemicals directly to an embryo’s environment 
may not replicate the effects of maternal exposure to and 
metabolism of an agent. 
Use of non-Mammalian Embryos in a screening assay
Embryogenesis in the zebrafish (Danio rerio) is very 
similar to that of higher vertebrates. Zebrafish females can 
lay hundreds of eggs per week in the lab. The shell of their 
eggs is transparent, making them easy to study. The embryos 
development very rapidly, in just a few days, and are easy to 
handle. Thus, it is not surprising that screening assays using 
zebrafish embryos are attractive as an alternative method for 
the analysis of developmental toxicity. 
Role of In Vitro Methods or non-Mammalian Embryos 
in the Identification of Teratogenic Exposures
The ECVAM international validation study concluded 
that the whole embryo culture test, the micromass test 
on limb bud cells, and the embryonic stem cell test were 
scientifically validated and acceptable tests for regulatory 
use. Test chemicals were classified correctly at a rate that 
often exceeded 70%; for agents that were strongly toxic to 
the embryo, these tests were almost 100% predictive. The 
ECVAM Scientific Advisory Committee recognized that these 
methods could not replace intact animal tests for assessing 
reproductive toxicity, but concluded that they could provide 
suitable means for reducing and refining the use of animal 
Figure 15-2. Limb buds removed from mouse embryos on day 12 
of gestation were cultured for six days in a roller bottle system with 
chemically defined medium in the absence (A) or presence (B) of 
retinol acetate (10IU/ml) and stained with toluidine blue.
Figure 15-3. In the whole embryo culture system gestation day 
10.5 rat embryos (A) are cultured in a roller bottle system in the 
presence of rat serum for up to two days (B). In (C) compare the 
control embryo on the left to the embryo exposed in vitro to a DNA 
damaging agent, 4-hydroperoxycyclophosphamide, on the right. 
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procedures. Thus, in vitro tests have a role in screening 
chemicals, but are not viewed as replacements for in vivo 
whole animal developmental toxicity tests.
Are there instances in which in vitro tests or 
non-mammalian embryos are more useful than current in vivo 
mammalian animal tests in identifying teratogenic exposures? 
Scientists have begun to acquire new information about the 
genes that regulate developmental events, and about the 
chemical messenger systems involved in establishing spatial 
information or position in the early embryo. In vitro systems 
will be particularly useful in investigating the role of a specific 
gene or gene family during organogenesis. Transgenic 
animal (one whose genome contains gene(s) from another 
species) approaches are laborious and frustrating, especially 
because sometimes deleting the gene of interest kills the 
embryo. In vitro approaches may help to determine the role 
of specific signaling molecules or pathways. 
The National Research Council vision, described in 
“Toxicity Testing in the 21st Century” is the future of toxicity 
testing will be built on the use of cell-based assays and the 
knowledge of pathways by which cells respond to toxicants. 
Moving from effects of a chemical on the behavior of cells 
in a culture dish to predicting the ability of this substance to 
increase the incidence of birth defects in vivo, in animals or 
humans, is quite a challenge. In the mean time, it is likely 
that in vitro assays will complement but not completely 
replace in vivo animal testing. These assays can be valuable 
in elucidating mechanisms by which teratogenic exposures 
affect development, and may be particularly useful in testing 
chemicals that are metabolized in a species-specific manner. 
In vitro tests should be useful as screening tests to winnow 
compounds for further research and development. 
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Development is a collection of interacting and dynamic 
processes that form an embryo, fetus, and ultimately a 
child. Much of what we understand has come about through 
study of isolated individual events occurring at an organ, 
cellular, or molecular level but in the dynamic events such 
as those that form an embryo, fetus, and ultimately a child, 
the interplay of individual events must also be understood. 
Systems biology seeks to study the relationships and 
interactions between various parts of a biological system 
(metabolic pathways, organelles, cells). This approach can 
contribute to our understanding of normal development and 
how it may be perturbed by a teratogenic exposure. 
Teratologists think as systems biologists, either 
consciously or intuitively. In order to understand development, 
the conceptus is thought of as the maternal-child unit from 
the very start of life. While this approach is not unique to 
teratologists as many systems biologists and engineers model 
and understand processes as a whole and thereby optimize 
their understanding of dynamic systems by looking at 
interacting processes leading to an end state (developmental 
maturity), it is unique that teratologists have developed both 
disciplinary and scientific approaches that allow for such an 
integrated examination of normal and altered development.
Early embryologists used hierarchical and temporal 
approaches to understand the origin of tissues and cells. 
For example, as the developing organism moves from the 
blastula to gastrula to neurula stages, or when organs form 
from three tissues, ectoderm (neural plate, neural crest 
and epidermis), mesoderm (dorsal –cephalic and trunk 
notochord and somites, ventral-blood islands and lateral 
plate organs including heart and kidney), and endoderm 
(yolk cells and alimentary canal organs such as lungs, liver, 
and stomach). Such tissue hierarchies are highly relevant for 
predicting impacts across species.
Systems biology provides a framework to follow the 
interconnectedness and dependencies of the different 
processes of development. Recent research has emphasized 
the importance of using cell, organ, and embryo cultures to 
understand the details of tissue and cell interactions; however, 
only by looking at how these interactions build upon levels of 
biological complexity, moving from genetic and epigenetic, 
molecular, cellular, multicellular, tissues, organs, organ 
systems, to whole organisms, can we understand overall 
development. There is genomic conservation so observations 
made at these levels are highly conserved and relevant for 
similar levels across species. Examples include the relatively 
few (17) cell signaling pathways that have been characterized 
in all bilateral organisms that are able to explain most of 
development. For example, hedgehog signaling pathways, 
present in both vertebrate and Drosophila development, 
direct spermatogenesis in vertebrates and oogenesis in 
Drosophila. Hence, there is both a conserved but also a 
species-specific component that requires a systems approach 
in order to interpret impacts.
Recent advances in computational approaches 
have allowed systems biologists to become increasingly 
sophisticated in their ability to quantify impacts at one 
level for outcomes observed at more complex levels, birth 
and functional development (chapter 18). In particular, 
such computational approaches have shown promise for 
answering more detailed questions about mode of action 
for teratogenic exposures, for improving cross-species 
extrapolation, for quantitative structure activity relationships, 
and for improving our understanding of gene-environmental 
interactions and responses. A systems biology approach also 
allows for evaluation across levels of potential biological 
observation at the molecular, cellular, organ, conceptus, 
or population level and can allow for better extrapolation 
across biological levels of observation. There has been 
tremendous progress made in use of cell systems and organ 
culture to examine various effects on development. Linking 
the knowledge about the toxicokinetics and dynamics 
of chemical impacts has allowed for better prediction of 
potential for impacts at the organism level.
An important implication of a systems biology 
approach is that in order to understand normal as well 
as altered development, teratologists are needed from 
diverse scientific and clinical disciplines. Clinicians such 
as obstetricians who are teratologists follow the course 
of pregnancy and may see birth defects early in gestation 
using ultrasound imaging. Dysmorphologists are trained 
to look at developmental processes and to diagnose 
syndromes and alterations in development that represent 
deviations from such processes resulting in malformations. 
Developmental biologists study details on the mechanisms 
of organ and tissue development. Molecular biologists look 
at comparable cellular and molecular processes in order to 
follow alterations that result in birth defects. Developmental 
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toxicologists and pharmacologists study how chemicals or 
drugs can alter normal development and cause birth defects 
and developmental toxicity. An integration of knowledge 
from these many disciplines using the principles of systems 
biology will speed the understanding of teratogenic risk and 
an increased ability to minimize or prevent birth defects.
In order to properly understand the big picture, 
everyone should fear becoming mentally clouded and 
obsessed with one small section of truth.   
Xun Zi
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Chemical Structure and Teratogenic RiskChapter 17
The structure of a chemical determines its size, shape 
and physiochemical properties. These characteristics 
in turn influence the effect of a chemical on biological 
systems including developing organisms. Going from this 
assertion to the description of chemical characteristics that 
influence developmental toxicity represents a challenge 
in computational toxicology, a subset of computational 
biology. However, because of the substantial strides in 
chemistry, computer sciences, biostatistics, mathematics, 
and developmental biology it is now possible to imagine 
that the structure of a chemical will allow us to predict its 
potential developmental toxicity (chemoinformatics). These 
areas of research offer exciting opportunities for the young 
scientist to change the way we think about developmental 
toxicology and may allow us to predict drugs and chemicals 
that can produce birth defects. 
Chemists and biologists began exploring the relationship 
between biological activity and chemical properties more 
than 150 years ago, observing that the toxicity of chemicals 
was related to their lipid solubility. Within a group of 
chemicals, physicochemical parameters such as solubility 
and structural features like the presence of nitrogen or oxygen 
can be used to explore relationships with biological activity 
such as developmental toxicity. Because our understanding 
of (Quantitative) Structure Activity Relationships ((Q)SAR) 
has grown, the pharmaceutical industry uses (Q)SAR models 
in drug discovery and in the design of new medicines. 
Regulatory agencies around the world have also invested 
in the development of (Q)SAR resources such as datasets of 
chemicals and biological activity and (Q)SAR tools allowing 
scientists to explore the relationships between chemical 
characteristics and biological responses. 
Chemicals can be characterized by size, shape and 
physicochemical properties as well as structural attributes. 
Physicochemical parameters are classified as electronic, 
hydrophobic, or steric. Electronic parameters describe a 
molecule’s potential for engaging in interactions with other 
molecules. Chemical reactions are an example of this 
kind of intermolecular interaction. Hydrophobicity (water 
avoidance) is a description of where the compound can 
be found when it distributes between water or the more 
oil-friendly n-octanol. Hydrophobicity is important in both 
Figure 17-1. Convergence between chemoinformatics and bioinformatics (chapter 19) allows us to better understand how 
chemicals produce developmental toxicity. One example of this was an observation in the 1950’s that sheep grazed on the 
field lilly Veratrum californicum during early gestation (gestation days 10–15, normal gestation is ~150 days) had a higher risk 
of delivering a lamb with cyclopia and holoprosencephaly. Ingestion of Veratrum californicum prior to day 10 had no effect on 
embryonic development and intake after day 15 produced fetal death and limb malformations. The molecules which produce 
these malformations have structural similarity to cholesterol, suggesting that jervine and cyclopamine might alter cholesterol 
concentrations during embryonic development, producing the malformation. The potency to produce malformations is jervine 
~100, cyclopamine ~50 and cholesterol ~0. Research has demonstrated that jervine and cyclopamine interact with Sonic 
Hedgehog protein altering its ability to interact with the Patched receptor and change the critical gradients necessary for normal 
brain and eye formation. 
Jervine Cyclopamine Cholesterol
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drug development and toxicology because it may correlate 
with how well a compound is absorbed and transported to 
its site of action. Steric parameters include molecular volume 
and surface area, measures of a molecule’s “bulkiness” that 
may reflect size requirements at a receptor site or target 
molecule. Chemicals that have similar steric parameters 
may activate the same receptor. Many size, shape, and 
physicochemical properties have been characterized for 
chemicals that are thought to cause human developmental 
toxicity at commonly encountered exposure levels.
Chemicals can also be described by their structure, 
for example the number and type of atoms and the way 
they are connected. In analysis of chemical structures 
and developmental toxicity, the chemical is “fragmented” 
electronically into contiguous heavy atoms (atoms with 
molecular weights greater than hydrogen) from 2 to 10 
atoms in length and the distribution of those fragments 
among the chemicals is analyzed to determine if they appear 
more frequently in chemicals with that act as toxicants. 
Within the structure of a chemical there are fragments of 
connected atoms that may be predictive of the biological 
activity of the chemical. Other fragments may simply 
reflect scaffolding for the chemical, atoms contributing to 
the structure but not responsible for the biological activity. 
Chemical structure evaluation has been used in analysis and 
prediction of chemicals thought to alter endocrine function 
in developing or adult animals as well as for chemicals that 
produce developmental toxicity at some exposure level. 
Investigators using either physicochemical or structural 
features to explore developmental toxicity need to be 
extremely careful in constructing datasets and performing 
(Q)SAR analysis. This is especially critical as the mechanism 
or mode of action resulting in developmental toxicity 
following chemical exposure is not always well understood. 
In developing datasets for (Q)SAR analysis clear definition 
of the testing systems and developmental endpoints utilized 
(death, structural abnormality, functional abnormality or 
altered growth) is critical to allow other investigators the 
ability to analyze data and explore utility of the developed 
models. The criteria for assessment of the literature to create 
the developmental toxicity assessment must be explicitly 
described and the way the data in the dataset are utilized to 
make a prediction must be transparent.
The (Q)SAR validation approach starts with the 
assumption that chemicals can be characterized as 
toxic or nontoxic, either categorically or quantitatively. 
The principles and techniques of (Q)SAR have been 
applied to developmental toxicology. Several different 
chemical-biological relationships have been explored 
for chemicals with similar structures, including phenols, 
retinoids, aliphatic, heteroaromatic and carboaromatics, 
carboxylic acids, and bromochloro-haloacetic acids. Using 
a list of chemicals identified as developmental toxicants 
or nontoxicants in rats, mice, rabbits, and humans, SAR 
models correctly predicted results for 77–82% of randomly 
constructed test sets. Species-specific differences were 
observed for some structurally similar fragments. Carboxylic 
acid esters (e.g., COO-CH3 and COO-CH2-) for example, 
contributed to developmental toxicity in rats and mice, 
presumably by hydrolysis to the carboxylic acid. In humans, 
however, fragments referring to carboxylic acid esters were 
found to be benign in terms of developmental toxicity. 
(Q)SAR will never entirely replace research using animal 
models, and it remains to be seen whether these approaches 
can be reliable enough to have a place in assessing the 
developmental risk of new or unknown agents. There is 
exciting potential for further computational investigations of 
the relationship among chemical structure, physicochemical 
properties, and developmental toxicity endpoints. In the 
future, (Q)SAR will be an important tool for (a) achieving 
insights into mechanisms, (b) rapid and economical screening 
of compounds for hazard identification, (c) prioritizing 
chemicals for regulatory, research, and remedial actions, 
and (d) establishing guidelines for the design of industrial 
chemicals and pharmaceutical agents with minimal potential 
for human developmental toxicity.
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Computational Modeling for Environmental ExposuresChapter 18
Prenatal Vulnerability
Environmental causes of birth defects include maternal 
exposure to drugs, chemicals, or physical agents. 
Environmental factors account for an estimated 3–7% of 
birth defects although a broader contribution is likely based 
on the mother’s general health status and genetic blueprint 
(chapter 6). This chapter will focus on ‘environmental 
chemicals’ are natural and man-made compounds to which 
human populations are continually exposed as a matter of 
individual lifestyle, local geography and community life. The 
Centers for Disease Control and Prevention (CDC) National 
Health and Nutrition Examination Survey (NHANES) 
samples the U.S. population every two years to determine 
which chemicals get into people and at what concentrations 
[CDC, 2009]. NHANES measured 212 environmental 
chemicals in blood or urine. The National Children’s Study 
(NCS) which began its pilot program in 2009 will examine 
the effects of broad environmental influences on the health 
and development of 100,000 children across the United 
States, following these kids from before birth until age 21 
[http://www.nationalchildrensstudy.gov]. These ‘biomonitoring 
programs’ will help identify vulnerable populations and 
guide further assessment of chemical exposure sources. 
Yet, we are all exposed to many more chemicals daily. We 
also lack developmental effects data for most of the chemical 
landscape. The U.S. Environmental Protection Agency’s 
(EPA) Aggregated Toxicology Resource (ACToR) database 
indicates that developmental effects data is available for less 
than ~30% of 9,912 chemicals in commerce or relevant 
environmental interest. EPA’s Toxicity Reference Database 
(ToxRefDB) reveals potential developmental toxicity for 53 
of 283 (18.7%) environmental chemicals tested in pregnant 
rats or rabbits. It is clear that a new approach is needed if 
we are to be able to assess the potential for developmental 
toxicity of the remaining 70% of the chemicals of interest 
today. And there are more chemicals synthesized on a daily 
basis. 
Biological susceptibility
To understand developmental susceptibility, teratologists 
use “biological models” to extrapolate data from high-dose 
effects in animal studies to low-dose predictions in human 
populations. Two general kinds of predictive models are 
kinetic models and dynamic models.
Kinetic models predict what happens to the chemical 
once it enters the body: Absorption following oral intake, 
breathing dust or contact with the skin; Distribution and 
partitioning to different body compartments; Metabolism to 
chemical forms that are more or less biologically active; and 
Excretion from the body. ADME factors vary by individual, 
species, and chemical based on the particular xenobiotic 
(foreign chemical) metabolizing enzymes in the organ. 
Kinetic models can predict internal dose to a human embryo 
when the mother is exposed to low concentrations of the 
chemical for prolonged periods of time. Such information is 
necessary to determine the range of exposures that may be 
relevant for potential human toxicity. These models do not, 
however, address mechanisms.
Dynamic models predict what happens once a chemical 
or active metabolite reaches the target tissue. Because 
the embryo is a dynamic system, environmental chemicals 
may disrupt the timing of critical events in morphogenesis, 
growth, and differentiation. For example, cyclopamine, the 
natural plant product consumed by foraging sheep, blocks 
cholesterol esterification of the sonic hedgehog protein 
(SHH), disrupting forebrain development and in turn leading 
to formation of a single midline eye (cyclopia). In attempting 
to analyze a complex system like the embryo, teratologists 
face the challenge of untangling the pathway leading to 
a birth defect such as cyclopia into its primary initiating 
mechanism, a perturbation in the SHH pathway, from the 
myriad of secondary consequences leading to a birth defect. 
This information may be more readily available for drugs 
that have been designed with a specific therapeutic target 
1The United States Environmental Protection Agency through its Office of Research and Development funded and managed the research described 
and this paper has been subjected to Agency review and approved for publication. Reference to commercial products or services does not constitute 
endorsement.
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in mind than for environmental chemicals to which human 
exposure is unintended. 
Can in vivo databases that track exposure-disease 
correlations, as well newer technologies that permit 
‘high-throughput screening’ of the molecular and cellular 
pathways of toxicity help to fill in our knowledge gap 
with respect to the potential developmental toxicity of 
environmental chemicals?   
high-Throughput screening (hTs)
In 2007, the National Academy of Sciences recom-
mended an HTS paradigm to understand human toxicology 
of large numbers of chemicals. Automated technologies, 
originally developed for pharmaceutical screens, are now 
being used to profile cellular effects of thousands of chemical 
compounds in commerce or potentially entering the environ-
ment. In an HTS drug development paradigm, chemical 
libraries containing thousands of unique structures may be 
rapidly screened for target biological activity against specific 
cell lines in a high-throughput mode (Figure 18-1). Active 
compounds may be used as leads to design compounds 
that would have the desired in vivo efficacy; they are then 
evaluated in animal tests, clinical trials, and post-marketing 
surveillance. For example, the National Chemical Genomics 
Center (NCGC) of the NIH has the capacity for automated 
HTS of 100-200K compound libraries across tens of in vitro 
assays.
Applying the pharmaceutical HTS paradigm to toxicity 
testing turns the drug discovery process upside down (Figure 
18-1). Compounds of unknown or suspected human toxicity 
are tested through hundreds of in vitro assays. Computers 
are then used to look for patterns of biological activity 
across the assay portfolio and chemical library. These 
profiles may be compared with reference compounds of 
well-characterized biological activity or interrogated in 
different ways, looking for in vitro patterns of signals that are 
potentially diagnostic of in vivo toxicities. EPA’s ToxCast™ 
project is providing HTS data on 309 chemicals to examine 
predictiveness of 467 assays and data for ~1408 chemicals 
to evaluate potential toxicities based on weight-of-evidence. 
The broader “Toxicity Testing for the 21st century” (Tox21c) 
federal consortium is ramping up to test ~10,000 
chemicals of importance to commerce and the environment 
[http://www.epa.gov/ncct/toxcast/]. Alternative assays, such 
as embryonic stem cells and free-living zebrafish embryos, 
can be used to rapidly test chemical effects in systems 
undergoing morphogenesis, growth, and differentiation 
[http://www.alttox.org/].
Computational (In Silico) Models
Several challenges face this type of predictive modeling. 
These challenges cycle back to a need for computational 
models to merge high-throughput screening data with the 
vast literature on embryonic development. How does in vitro 
concentration-response correlate with internal dose-response 
kinetics, how do in vitro bioactivity profiles extrapolate from 
one cell-type or technology platform to another or how do 
individual targets of in vitro bioactivity link into pathways 
of developmental toxicity? A deep understanding of 
embryological development, intuition for new technologies 
and approaches to the study of birth defects, and a concern 
for environmental influences on human 
development are all driving the new 
vision on where environmental health 
protection needs to go. 
Whereas numerous models have 
been developed for cell signaling 
pathways in the embryo, fewer models 
exist for understanding how chemical 
lesions are propagated during 
developmental toxicity. Computational 
(in silico) models that execute a 
morphogenetic series of events may 
help in this regard, bridging the 
gap between in vitro profiling and 
in vivo response at different 
concentrations of chemical. The 
general idea is to model the cell of 
an embryonic tissue as an agent, 
i.e. the smallest fundamental unit 
capable of an autonomous decision. Figure 18-1. Paradigm for pharmaceutical HTS and toxicity testing.
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Individual agents and their interactions are coded into the 
model based on biological knowledge. The multicellular 
simulation is run and the emergent properties are recorded. 
These agent-based models can simulate the potential effects 
of environmental chemicals based on various inputs. The 
models can be exercised across conditions not practical 
experimentally due to cost, time, scale, or complexity. EPA’s 
Virtual Embryo will build computational (in silico) models 
that may make high-throughput screening data useful in 
a quantitative risk assessment of developmental toxicity 
[http://www.epa.gov/ncct/v-Embryo/]. So, to return to the 
original question, “Can computational models be used 
to assess the developmental toxicity of environmental 
exposures?” the answer may be not yet but the future is open. 
Much effort is bring expended today to realize this goal. 
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how Can We Use Bioinformatics to Predict Which agents  
Will Cause Birth Defects?
Bioinformatics and Detection of TeratogensChapter 19
The availability of genomic sequences from a growing 
number of human and model organisms has provided an 
explosion of data, information, and knowledge regarding 
biological systems and disease processes. High-throughput 
technologies such as DNA and protein microarray biochips 
are now standard tools for probing the cellular state and 
determining important cellular behaviors at the genomic/
proteomic levels. While these newer technologies are 
beginning to provide important information on cellular 
reactions to toxicant exposure (toxicogenomics), a major 
challenge that remains is the formulation of a strategy to 
integrate transcript, protein, metabolite, and toxicity data. 
This integration will require new concepts and tools in 
bioinformatics.
Bioinformatics applies principles of information sciences 
and technologies to make vast, diverse, and complex life 
sciences data more understandable. The applications of 
bioinformatics approaches may be particularly challenging 
in the embryo because of the complexity of the data, 
particularly with regards to the relative plasticity of precursor 
target cell populations in the embryo and the realization that 
morphogenetic processes have critical timing for inductive 
events and for regulative growth. No single technology is 
likely to resolve the complex problem of teratogenesis. 
Teratologists will need to maximize the amount and quality 
of input data from both experimental models and human 
epidemiological studies. High-throughput genomics has 
made many advances but cannot yet predict toxicity when 
the experimental parameters are unknown. 
Bridging Gaps
Data collected from research must be amenable to 
high performance computing. As emerging technologies 
continue to provide tools for comprehensive studies of large-
scale gene expression, they will continue to raise key issues. 
Foremost of these is the storage and access to vast digital 
information, the annotation of large-scale gene expression 
profiles, the interpretation of the causal and functional 
relationships between genes upwardly or downwardly 
regulated, and the ability to uncover biomolecular pathways 
across species in the context of disease. Bridging the gap 
between transcriptome regulation (all mRNA molecules-
transcripts- produced in a cell) and cellular function, for 
example, demands high-resolution data on cell function, 
gene promoter informatics, post-translational protein 
modifications, and biophysical interactions. Biologically 
significant changes at these information levels may go 
undetected by gene expression profiling alone and therefore 
must be integrated across the different technology platforms. 
Teratologists will increasingly learn to mine public data 
(knowledge) bases using bioinformatics tools that can deliver 
concept-driven outputs from data-driven inputs.
International efforts are underway to build a high quality 
public knowledge base for toxicogenomics, referred to as 
the Chemical Effects in Biological Systems (CEBS) database. 
Partners in the design and construction of this database 
include the National Center for Toxicogenomics and 
National Toxicology Program (NIH/NIEHS), the European 
Bioinformatics Institute, and the International Life Sciences 
Institute and Health and Environmental Sciences Institute. 
CEBS will provide an on-line repository for relevant data from 
molecular expression and conventional toxicology studies. 
By assimilating and refining information from multiple public 
databases and scientific literature, the knowledge base will 
provide a comprehensive resource on genes, gene clusters, 
pathways, toxicities, and diseases. 
Modeling frameworks represent the basis for 
computational algorithms that ultimately allow for 
data-driven simulations. For such predictive models to be 
effective, they must link adverse developmental outcomes 
to user-specified exposure scenarios, or vice-versa, through 
a cascade of biomolecular and physiological changes 
resulting from the interaction of chemicals with critical 
molecular targets in the embryo. We do not yet know 
whether mathematical models can accurately describe 
developmental processes and toxicities. The initial step is 
to discern unique molecular signature profiles to improve 
connections between input (exposure) and output (disease) 
endpoints as “complex systems” in the exposure-disease 
continuum. In nature, the organization of complex cellular 
systems requires fundamental inputs of energy, robustness, 
and control. Understanding this is at the cutting edge for 
addressing key questions in biology and medicine. 
Systems biology is defined broadly as the application of 
systems theory to biological problems, where systems theory 
refers to the analysis of composite systems that may divided 
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into subsystems to facilitate understanding and modeling 
(chapter 16). Central issues deal with the identification 
of component subsystems (modules), characterization of 
subsystem behavior (responses), and determination as to 
how different components are connected (networks) and how 
they relate to observable behavior of the system as a whole 
(controls). Mathematical models allow for the characterization 
of these subsystems. It remains to be determined whether 
this engineering-based approach will allow us to simulate 
mammalian development and mathematically characterize 
the adverse outcome scenarios in response to different 
environmental stressors. In moving toward the realm of 
digital biology there are certain generic questions with which 
we may begin. How do elements of system structure fit into a 
hierarchy for control? Given some members of the module, 
can we use bioinformatics to complete the list and identify 
pathways that predict the behavior of the altered (stressed) 
system? 
Birth Defects systems Manager (BDsM)
The ‘Birth Defects Systems Manager’ (BDSM) is a 
web-accessible data base designed to facilitate discovery of 
associations across developmental stages, organ systems, 
and disease phenotypes. BDSM contains embryo-based, 
high-content gene expression data from NCBI’s Gene 
Expression Omnibus (GEO). BDSM is being modified to 
become a machine-readable knowledge base that can 
supply data to support EPA’s new ‘Virtual Embryo’ project 
(http://www.epa.gov/ncct/v-embryo). The data query tool, 
QueryBDSM (Figure 19-1), allows specific queries across 
experiments to facilitate analysis of developmental genomics 
data and compare data generated across technology 
platforms and study types. To demonstrate, BDSM-derived 
data were used to compare expression profiles across six 
unrelated studies for developing systems. The analysis was 
restricted to 160 gene arrays in the BDSM library based 
on well annotated experiments published on normal 
mouse embryogenesis using Affymetrix/Agilent technology 
platforms. A virtual meta-chip was constructed for probes 
common to all five technology platforms represented in 
these studies, yielding 346 genes. The biggest limitation 
in combing different platforms is the small number of 
genes found in common between these platforms. Using 
tools available with BSDM, as shown in Figure 19-2, the 
gene-expression profiles correctly ordered the samples first 
by organ system and then by developmental sequence within 
each system. 
Figure 19-1. Workflow schema for the QueryBDSM module of BDSM. Individual 
files of normalized microarray data are selected from the GEO library. QueryBDSM 
determines the number of distinct microarray platforms in the sample queue and 
merges the data as follows: if all samples come from the same platform, then 
MetaSample is used; if multiple platforms are represented, then MetaChip is used. 
CIAeasy compares joint trends in expression data for the same samples run on 
different platform [Singh, Knudsen and Knudsen, 2007].
Figure 19-2. Hierarchy of molecular phenotypes in 
developing mouse embryos. In five GEO platforms 
(160 samples), 346 genes were found differentially 
expressed in BDSM profiles: preimplantation mouse 
embryo (GSE1749) [16], heart (GSE1479) GD10—
GD18 [14] nerve (GSE972) GD9.5—birth [3]; 
ovary (GSE1359) and testis (GSE1358) GD11.5—
birth [13]; orofacial (GSE1624) [9] and palate [2] 
between GD13-15. Each developing organ system 
was properly ordered by its natural chronology, 
based on the 346 gene-expression signature and 
an unsupervised clustering algorithm with Pearson 
correlation. Gene colors are mapped by K-means 
clustering (6 sets) [Singh, Knudsen and Knudsen, 
2007].
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Comparative bioinformatics analysis using QueryBDSM 
provides teratologists a tool to develop hypotheses 
connecting genetic perturbations to phenotype and enabling 
comparison to other developmental systems entered into the 
BDSM database.
Path forward
The U.S. National Library of Medicine’s Pubmed site 
includes 19 million citations and abstracts and continues to 
grow. The BDSM team is now working on assembling the 
literature’s unstructured data into a structured database 
and linking it to BDSM within a system that can then be 
used for testing and generating new hypotheses. This 
effort will generate data bases of entities (such as genes, 
proteins, metabolites, gene ontology processes) linked to 
PubMed identifiers/abstracts and providing information on 
the relationships between them. The end result will be an 
online/standalone tool that will help researchers to focus on 
the papers most relevant to their query and uncover hidden 
connections and obvious information gaps. 
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Chapter 20
The dose makes the poison. 
Paracelsus
If a compound causes birth defects, it should not 
be administered to pregnant women. However, it is not 
feasible to simply exclude drugs during pregnancy. Chronic 
conditions such as asthma, high blood pressure, epilepsy, 
and diabetes can also have adverse effects on pregnancy, so 
withholding drugs to treat these conditions during pregnancy 
can be bad for both the woman and the embryo or fetus. 
Additionally, pregnant women will continue to be exposed to 
various contaminants in their environments throughout their 
pregnancies.
It is generally accepted that low doses of some 
compounds may not pose a significant risk to the embryo 
or fetus. However, any agent may be harmful if the dose is 
high enough. Establishment of a safe level of exposure to a 
teratogenic agent is an important area of research, both for 
counseling women inadvertently exposed during pregnancy 
and for determining which drugs are appropriate for use in 
pregnancy. 
The idea that safe doses of known teratogens may exist 
is based on the threshold concept. This theory holds that 
embryotoxicity depends on multicellular injury and that 
there is a threshold dose below which no risk exists (for an 
example see chapter 21). Dose-response relationships in 
humans for most teratogenic agents are not known because 
drugs prescribed for a given condition are usually taken over 
a very small dose range. However, it has been suggested 
in several studies that doses of valproic acid above 1000 
mg/day are associated with an increased risk of birth defects. 
Valproic acid, originally approved to prevent seizures, but 
can also be prescribed for the treatment of bipolar disorder. 
If one assumes repair mechanisms are functioning to 
correct damage to embryonic cells, then it makes sense 
that an insult to the multicellular embryo can be overcome. 
Indeed, apoptosis, or programmed cell death, is a normal 
and necessary part of development. The knowledge that cells 
can be repaired or replaced supports the theory that there 
may be a threshold dose, below which no ultimate adverse 
effect occurs. 
There are some who do not agree with the concept of a 
threshold dose. Only about one third of the malformations 
that occur in humans can be traced to genetic or 
environmental causes. Most defects are categorized as 
spontaneous malformations, meaning that we don’t know 
what causes them. But if internal factors can cause birth 
defects, and environmental or drug-induced factors affect 
the same internal factors, then a drug-induced influence on 
that factor could tip the balance in the direction of embryo 
malformation. In this scenario, no safe level of exposure 
exists; instead, there is a continuum of probability for 
malformation, no matter how miniscule the drug exposure. 
An example could be a drug that alters the level of Vitamin 
A. Too little vitamin A produces birth defects and too much 
vitamin A produces birth defects. A drug that changes the 
level of vitamin A could tip the balance either way and cause 
a birth defect.
If the relationship between dose of an agent and its 
response is continuous, can there be a safe exposure to 
a teratogenic agent? If the relationship between dose and 
outcome is known from animal studies or from human cases 
of accidental exposure, then the uncertainty about risk of 
malformation can be reduced by administering lower doses 
that are unlikely to cause embryotoxicity. Safe doses may 
be estimated by using safety factors (reducing problematic 
doses by multiples, usually of 10) or by using quantitative 
biologically based dose-response models to mathematically 
estimate doses with a very low risk for the developing embryo. 
Is there a safe exposure?
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We can also use our knowledge about critical periods 
when the embryo is most vulnerable to possible teratogenic 
events, to reduce or eliminate exposures during those times. 
The critical period, however, is not the same for all drugs. 
For example, limb malformations caused by exposure to 
thalidomide appears to require exposure during the first 
trimester of pregnancy, while the teratogenic effects of 
angiotensin-converting enzyme inhibitors (a class of blood 
pressure medicines) occur during the second two-thirds of 
pregnancy. 
Protecting the embryo or fetus from the effects of toxic 
agents requires knowledge of the target site of the agent, the 
dose at which toxicity occurs, and the mechanisms by which 
toxicity occurs. If we know enough about these three areas, 
safe use of important medications may still be possible. 
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Many pregnant women are concerned about the 
potential reproductive and developmental risks of radiation 
exposures. With the advent of the Internet, consulting has 
become more rapid and efficient. In 2008, the pregnancy 
website of the Health Physics Society (HPS), ATE (Ask the 
Expert), received approximately 2,400,000 hits. Over 
700,000 prepared answers to questions were downloaded. 
Over 1,600 contacts were still anxious after reading the 
Website answers and requested a personal consultation. 
From this experience we have learned that many physicians 
and other counselors are not prepared to counsel patients 
concerning reproductive and developmental radiation risks. 
Approximately 8% of the contacts have provided inaccurate 
information that could have resulted in an unnecessary 
interruption of a wanted pregnancy.
Evaluating developmental risks requires attention to 
two important elements in order to provide scientifically 
and medically appropriate counseling. First, quality 
epidemiological studies are the foundation for determining 
human risks. It is rare that in vitro studies or animal studies can 
refute either negative or positive findings in epidemiological 
studies if an adequate and well-performed number of 
epidemiological studies are available. However, there have 
been instances when animal studies have been more reliable 
predictors of developmental effects. Secondly, biological 
plausibility is a powerful tool in evaluating alleged human 
risks; however, it is dependant on being knowledgeable in 
all the basic sciences and teratology principles.
There are five areas of radiation embryology with which 
counselors should be knowledgeable, as well as being 
familiar with the basic principles of teratology, in order to 
provide scientifically and medically appropriate counseling.
1. Can the fetus be harmed by ionizing radiation if it is 
not directly exposed? In other words if diagnostic 
radiological studies are performed on the head, neck, 
chest or extremities, is the embryo in the uterus at risk 
for an increase in adverse effects on development? 
The effects of radiation have been studied in animal 
models; these data indicate that radiation exposures 
in the diagnostic dose range (less than 0.1 Gy, or 10 
rad) do not increase the risk of adverse developmental 
effects because the exposure to the embryo is very small. 
Diagnostic radiological studies that do not expose the 
embryo will not increase the risk for birth defects or 
miscarriage above the background risk of 3% for birth 
defects and 15% for miscarriage.
2. Is mental retardation produced as a consequence of 
radiation during pregnancy a threshold phenomenon? 
There is no doubt that exposure of the developing 
human fetus to high doses (1–2 Gy) of ionizing radiation 
can result in mental retardation and microcephaly. 
The most vulnerable stage for the induction of mental 
retardation and severe microcephaly is reported to be 
from the 8th to 15th week of human gestation. During 
mid-gestation the brain can be depleted of neurons and 
when the neurons are killed at this stage they are not 
replaced, resulting in the induction of mental retardation 
and microcephaly. There is little disagreement about 
the vulnerability of the brain during organogenesis and 
fetogenesis. Although most radiation embryologists 
assumed that the exposures to diagnostic radiological 
studies were too small to produce mental retardation, 
there were few data in the human to confirm or refute 
this assumption. In 1984, Otake and Schull reanalyzed 
the data pertaining to the children who were irradiated 
in utero in Hiroshima and Nagasaki (RERF, Radiation 
Effects Research Foundation). They concluded that the 
most vulnerable period for the induction of mental 
retardation was from the 8th–15th week of gestation and 
that 40% of the fetuses who received 1 Gy were mentally 
retarded (I.Q. <70). They also concluded that mental 
retardation could be produced with exposures below 0.1 
Gy and that radiation-induced mental retardation was a 
stochastic effect (non-threshold effect). Clinical analysis, 
the application of the concept of biological plausibility 
and animal studies did not support the concept that 
radiation induce mental retardation was a stochastic 
effect. Reanalysis of the A-bomb data indicated that the 
threshold for radiation induced mental retardation was 
approximately 50 rad (0.5 Gy). There was no increased 
risk of mental retardation or decrease in I.Q. from 
exposures of 10 rad (0.1 Gy) or below.
3. Does fractionation and protraction of radiation 
decrease the magnitude of the reproductive and 
developmental risks? Animal studies were very helpful 
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in evaluating whether fractionation decreased the 
teratogenic and growth retarding effects of ionizing 
radiation. Fractionation and protraction of the radiation 
exposure reduced the developmental effects of the 
radiation. Developmental risks were reduced when 
diagnostic x-ray studies occurred over a period of days, 
occupational exposures occurred over a period of weeks 
to years and when flying at high altitudes occurred over 
a period of hours. 
4. Is there a period during pregnancy when radiation will 
result in an increased mortality but not an increase in 
malformations?  The “all or none” phenomenon was 
described in the 1950s. Irradiation of rats and mice 
with up to 1.5 to 2.0 Gy during the pre-implantation 
and pre-organogenesis stages resulted in embryo 
lethality; however, malformation rates in the surviving 
fetuses at term were similar to the controls; at this early 
stage of pregnancy, high exposures induced cell loss or 
chromosome abnormalities that most likely resulted in 
zygote death or malformations that were lethal. 
5. How vulnerable is the fetus to the oncogenic (cancer 
inducing) effects of radiation? This is the most 
controversial and difficult area to evaluate, because 
the epidemiological studies are not consistent. In 1999 
Boice and Miller published their interpretation of the 
data pertaining to the oncogenic risks of low-level 
intrauterine radiation. They noted, “Evidence for a 
causal association derives almost exclusively from 
case-control studies, whereas practically all cohort 
studies find no association, most notably the series 
of atomic bomb survivors exposed in utero. Learned 
debate continues as to the causal nature of low-level 
intrauterine radiation exposure and subsequent cancer 
risk. The association is not questioned, but the etiologic 
significance is. Different scientists interpreting the same 
data have different opinions as to the causal nature 
of the association and the possible level of risk.” The 
most recent publication based on the 60 year follow-up 
of the in utero population exposed to the A-bomb in 
Japan indicates that the embryo is actually less sensitive 
to the oncogenic effects of radiation than the child, 
with a suggested threshold at 20 rad (0.2 Gy). The 
population of in utero survivors numbers approximately 
1,500, which is a small population for oncogenic 
studies and this population is only in their 60s, so we 
have to wait another 20 years to finalize the risk of 
cancer among those who were exposed to the A-bomb 
as embryos. In the mean time, parents of patients who 
were exposed in utero to diagnostic radiation can 
be told that the oncogenic risk of those amounts of 
in utero radiation is very low.
We utilize the scientific information obtained from studies 
in these five areas to counsel patients concerning radiation 
risks during pregnancy. The willingness and persistence of 
scientists to debate the controversial aspects of this research 
and apply the best available scientific information to assist 
patients in turmoil about the risks of embryonic radiation to 
themselves and their offspring have saved thousands of lives 
and changed family histories.
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Do assisted Reproductive Techniques Increase  
the Risk of Birth Defects?  
Assisted Reproduction and Birth DefectsChapter 22
About 15% of couples meet the clinical definition of 
infertility by not becoming pregnant after trying for one year. 
In some cases, these couples are normal and just need more 
time, but in other cases, there is a problem for which medical 
attention may be helpful. Causes of infertility affect three 
general features of the reproductive process (Figure 22-1):
• Normal ova may not be ovulated, or ova may not be 
ovulated normally.
• Normal sperm may not be introduced into the female 
genital tract or may not survive once they are introduced.
• There may be an obstruction in the genital tract, 
preventing the ova and the sperm from reaching one 
another.
The following are some of many therapies in use to 
overcome these abnormalities.
• Hormones or hormone-like compounds that induce 
ovulation. 
• In vitro fertilization (IVF). This technique harvests ova 
from the ovaries through a needle placed into the ovary 
through the vagina. The ova are mixed with sperm in a 
laboratory dish. The resultant embryo is placed into the 
uterus through the cervix.
• Gamete intrafallopian transfer (GIFT) and Zygote 
intrafallopian transfer (ZIFT). These techniques are 
similar to IVF; however, in GIFT, the ovum and sperm 
meet before fertilization in the fallopian tube, rather than 
a laboratory dish. The fallopian tube is where the ovum 
and sperm would join under normal circumstances, but 
in GIFT, the ovum and the sperm are injected into the 
fallopian tube together, through a thin instrument inserted 
into the belly through a tiny incision. In ZIFT, the fertilized 
ovum, called a zygote, is placed into the fallopian tube. 
Thus, fertilization has occurred in the laboratory, but 
early development happens in the fallopian tube, which 
may provide a more natural environment.
• Intracytoplasmic sperm injection (ICSI). A spermatozoon 
is injected directly into the ovum using a microscopically 
tiny pipette. The technique is otherwise exactly like IVF. 
ICSI eases the job for the sperm by ferrying it across the 
zona pellucida, the membrane that surrounds the ovum.
It has now been 30 years since the first baby was born 
following assisted reproductive techniques or ART. The 
use of this technology has increased to the extent that to 
date over 1 million babies have been born following ART. 
However, there is concern that ART may increase the risk of 
an abnormal pregnancy. These concerns are based on two 
possibilities that the medications or physical procedures that 
are involved could injure a normal gamete or embryo, or that 
an abnormal gamete, ordinarily incapable of fertilization, 
will be helped to achieve fertilization and will give rise to a 
child with birth defects.
The good news for couples using these techniques is 
that little if any increase in birth defects has been shown to 
occur in the resulting children, although not all researchers 
agree on this point. Experimental animal studies support the 
safety of these techniques; also, animal breeding programs 
have used these assisted reproductive methods extensively 
for many years without an apparent increase in birth defects. 
The news is not entirely reassuring however; there may be 
other reproductive consequences. 
Figure 22-1. Photo courtesy of Shady Grove Reproductive Science 
Center, Rockville, MD.
These 8-cell human embryos were fertilized in vitro. 
They will soon be ready to place into the uterus.
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Possibilities include:
Miscarriage  
It has been suspected that some assisted reproductive 
techniques might increase miscarriages. Accurate 
miscarriage rates are almost impossible to determine 
because many miscarriages occur so close to the time of an 
expected period that a woman would never have suspected 
that she was pregnant. Miscarriage occurs in at least 30% 
of all pregnancies, but only about half of those pregnancies 
are recognized. In a group of women undergoing fertility 
treatments, detailed monitoring of hormone levels will catch 
even very early pregnancies, and an episode of bleeding 
will be correctly identified as a miscarriage. So the reason 
that miscarriage rates among women undergoing fertility 
treatments appear higher than in the general population 
may be because it is closer to the true rate. 
This argument notwithstanding, at least one ovulation 
inducing medication, called clomiphene, may increase the 
miscarriage rate slightly. Clomiphene stimulates maturation 
of the oocyte in the ovary. During maturation of the 
oocyte granulosa cells that surround the oocyte produce 
primarily estrogen. After ovulation, these cells produce 
primarily progesterone. Both estrogen and progesterone 
prepare the lining of the uterus for implantation of the 
fertilized egg. Clomiphene may alter the function of the 
granulosa cells so that hormone production is inadequate 
to support implantation. Under these circumstances, a 
fertilized egg might fail to implant or might implant poorly. 
How often clomiphene causes early miscarriage due to 
faulty implantation is unknown, but we do know that only 
half of women who ovulate in response to clomiphene 
are recognized to be pregnant. Stimulating ovulation 
with clomiphene clearly does not completely restore the 
reproductive system to normal.
Ectopic Pregnancy
Sometimes an embryo implants outside the uterus, 
usually in the fallopian tube. In early pregnancy, fingerlike 
projections called chorionic villi dig into the tissue where 
the embryo is implanted, in order to set up the placenta. 
When a pregnancy occurs outside the uterus, the invading 
villi can erode into blood vessels, causing bleeding that can 
be life-threatening. Ectopic pregnancies may result from 
scarred fallopian tubes that trap the fertilized ovum before 
it can pass freely into the uterus. It is not clear whether 
assisted reproductive techniques increase the risk of ectopic 
pregnancies, or whether these techniques are used in women 
who already have a higher rate of tubal damage.
Chromosome Abnormalities 
Abnormal chromosome numbers occur commonly 
in early pregnancies. In pregnancies that miscarry, about 
half have an abnormal number of chromosomes, which is 
presumed to be the reason for the subsequent miscarriage. 
A naturally-conceived pregnancy that miscarries very early 
would not be checked for chromosome abnormalities. It 
has been noted that chromosomal abnormalities appear 
to be more common in embryos created through assisted 
reproductive techniques that involve fertilization in the 
laboratory, compared to the general population; however, 
when embryos are placed into women without pre-testing, 
chromosome abnormalities at birth are not increased. It 
appears likely, then, that chromosomally abnormal embryos 
are largely eliminated by natural processes.
Imprinting Defects
Case reports have associated ICSI with an unusual group 
of genetic abnormalities called imprinting defects. Imprinting 
refers to the methylation of cytosine in GpC rich regions of 
the genome, and can change the way the DNA is read. 
Imprinting defects include Angelmann syndrome, associated 
with severe mental retardation, ataxia, and seizures, or 
Beckwith-Wiedeman syndrome, associated with macrosomia 
(an abnormally large body), omphalocele (a defect in the 
abdominal wall at the umbilicus) and other clinical features. 
DNA methylation occurs during the development of sperm 
and oocytes, and ICSI techniques are believed by some 
researchers to interfere with normal methylation. It is not 
known, however, whether imprinting abnormalities are 
increased by assisted reproductive techniques, or whether 
they are associated with the underlying infertility problems. 
Multiple Gestations
Hormone-like medications that induce ovulation may 
cause more than one egg to be released in a cycle, resulting 
in twins, triplets, and higher-order multiple gestations. The 
rate of twins in the general population is about 1%, but 
between 8 and 25% of pregnancies achieved with ovulation 
induction result in twins. The rate of triplets in the general 
population is about 0.01%. With some ovulation induction 
medications, this rate can reach a few percent. With optimal 
monitoring of the induced ovulation cycle quadruplets and 
higher do not occur very often. IVF, GIFT, and ZIFT have 
the potential for producing high order multiples (more than 
two babies at once) if more than one embryo or zygote is 
placed in the woman’s reproductive tract. Multiple embryos 
may be used in order to increase the chance that at least 
one of them will implant and develop. If four embryos are 
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placed in the uterus and all of them happen to implant, the 
result is quadruplets. Many fertility doctors now recommend 
implanting no more than one or two embryos at a time, in 
order to avoid multiples of a higher order than twins.
Although having many babies at one time may sound 
like an efficient way for a couple to complete its family, 
multiple gestations are associated with pregnancy risks, 
including increased birth defects. Perhaps the most important 
risk is prematurity, because the more babies there are in the 
uterus; the earlier in pregnancy the uterus will sense that it is 
overfull. Labor may start weeks before the babies are due. 
Prematurity is an important cause of death and disability in 
children arising from these pregnancies.
suggested Reading
Palermo GD, Neri QV, Takeuchi T, Rosenwaks Z. ICSI: where we 
have been and where we are going. Semin Reprod Med. 2009; 
27(2):191–201.
Manipalviratn S, DeCherney A, Segars J. Imprinting disorders and 
assisted reproductive technology. Fertil Steril. 2009; 91(2):305–15.
Basatemur E, Sutcliffe A. Follow-up of children born after ART. 
Placenta. 2008; 29 Suppl B:135–40.
23-62
Chapter 23
Ann P. Streissguth  
University of Washington
Seattle, Washington
What are the Effects of alcohol Use During Pregnancy?
Alcohol Use During Pregnancy
Thousands of research studies over the past 40 years 
have demonstrated that alcohol (ethanol) used during 
pregnancy is teratogenic. Prenatal exposure can cause 
growth deficiency, malformations, and neurobehavioral 
deficits. Whether a conceptus is affected depends on the 
dose, timing, and conditions of exposure. Different strains 
of mice respond differently to similar doses of alcohol, and 
it is very likely that women also differ in how alcohol intake 
affects offspring. Individual variations in offspring can also 
make a difference; even twins can be differentially affected. 
In general, dizygotic (non-identical) twins show more 
disparate responses to prenatal alcohol than do monozygotic 
(identical) twins.
There appear to be several mechanisms for the 
teratogenicity of alcohol. Alcohol has a directly toxic effect on 
the developing brain; it can kill brain cells and interfere with 
the transport of amino acids (the building blocks of proteins) 
and glucose (the main energy source for cells). Alcohol can 
also impair placental-fetal blood flow, causing hypoxia or 
disrupting the hormonal and chemical regulatory systems in 
the brain that control the maturation and migration of nerve 
cells.
The teratogenic properties of alcohol, our most frequently 
used “social” drug, came to attention originally through 
independent clinical observations in 1986 by Lemoine in 
France and in 1973 by Jones and Smith in Seattle. Noting 
a pattern of malformation, growth deficiency, and central 
nervous system effects in children of alcoholic mothers, the 
term Fetal Alcohol Syndrome (FAS) was coined in 1973 and 
drew immediate attention to alcohol as a teratogen. Four 
decades of research have increased recognition of the types 
of damage caused by prenatal alcohol and the long-term 
consequences. Our understanding of the breadth of prenatal 
alcohol damage derives from studies of children with Fetal 
Alcohol Syndrome (FAS), experimental animal models, and 
long-term prospective studies of diverse human populations. 
In general, larger doses cause greater effects. Both 
animal and human studies show that a “binge” dose (many 
drinks in a short time period) is particularly damaging for 
the conceptus. The brain appears to be the most vulnerable 
organ: brain effects are widespread, and can occur across 
a wide range of doses and patterns of exposure. In general, 
morphological (structural) abnormality occurs at the highest 
doses or highest peak doses, while behavioral deviations 
can occur at lower doses or lower peak doses. Direct cell 
death, aberrant neuronal migration and development, 
and disrupted neurochemical balance of the brain can 
result from exposure during all periods of embryonic and 
fetal development. The typical facial appearance of FAS, 
however, arises from exposure early in pregnancy.
Prospective epidemiologic studies link alcohol to 
increased risk of miscarriages, stillbirths, low birth weight, 
and increased neonatal morbidity. Alcohol abuse is often 
associated with poor nutrition, which can compound results. 
Experimentally, animal studies have shown that these adverse 
birth outcomes result from prenatal alcohol even when diet 
and rearing conditions have been controlled; poor diet and 
poor rearing conditions, however, can aggravate adverse 
effects.
Alcohol crosses the placenta, so that minutes after a 
pregnant woman consumes alcohol, the fetal blood alcohol 
level is similar to that of the mother. Alcohol can cause a 
temporary pause in fetal respirations. Autopsies of deceased 
children with FAS, imaging studies, and experimental animal 
Figure 23-1. The discriminating features of FAS are those on the left 
side. However, as the facial features often coarsen with puberty, 
not all adolescents and adults will retain these features. Graphic 
from Streissguth AP and Little. Alcohol, Pregnancy, and the Fetal 
Alcohol Syndrome, 2nd edition, Unit 5, Project Cork Slide Lecture 
Series, Dartmouth Medical School, available from Milner-Fenwick, 
Baltimore, 1994.
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studies have shown us that many brain regions, including 
the hippocampus, cerebellum, corpus callosum, and basal 
ganglia, are affected by prenatal alcohol. A large and 
compelling experimental animal literature links prenatal 
alcohol to disruptions in learning, memory, emotional 
responsiveness, and behavior. Associated brain-behavior 
deficits include optic nerve hypoplasia with impaired vision, 
reduced cerebellar size with impaired motor development 
and ability, decreased callosal size with hyperactivity, and 
decreased serotonin synthesis with impaired instinctive 
maternal behaviors. See Table 23-1 for the comparability 
of alcohol-induced behavioral problems in humans and 
laboratory animals.
The consequences of prenatal alcohol exposure can last 
a lifetime. Rodents exposed prenatally to alcohol have higher 
rates of sickness and early death. Some (but not all) studies 
have found that early growth deficits attenuate with time, at 
least in some individuals. Problems with maintaining attention 
and focus are not only measureable in day-old newborns, 
but also manifest throughout childhood, adolescence, and 
Figure 23-2. First child identified with FAS at birth, shown here on day 1, 8 months, 4 1/2 years, 8 years and 18 years. Note the short 
palpebral fissures (eye openings), thin upper lip, smooth philtrum (between upper lip and nose), and microcephaly. The first four photos 
from; CIBA Foundation book: “Mechanisms of Alcohol Damage in utero” Ciba Foundation Symposium 105, Pitman, London, 1984. 
TaBLE 23-1.
BEhaVIORaL EFFECTs FOLLOWInG PREnaTaL aLCOhOL EXPOsURE
hUMans anIMaLs
Hyperactivity, Reactivity Increased Activity, Exploration and Reactivit
Attention Deficits, Distractibility Decreased Attention
Lack of Inhibition Inhibition Deficits
Mental Retardation, Learning Difficulties Impaired Associative Learning
Reduced Habituation Impaired Habituation
Perseveration Perseveration
Feeding Difficulties Feeding Difficulties
Gait Abnormalities Altered Gait
Poor Fine and Gross Motor skills Poor Coordination
Developmental Delay (Motor, Social, Language) Developmental Delay
Hearing Abnormalities Altered Auditory Evoked Potentials
Poor State Regulation Poor State Regulation
From: Driscoll, Streissguth, & Riley. J. Stud. Alcohol 59:292–304. 1990.
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early adulthood. Learning problems (particularly in abstract 
thinking and arithmetic) are not easily measurable until early 
childhood, but have lifelong consequences. Some of the 
most marked behavioral deficits in humans are observed in 
adaptive behavior and “executive function” as measured by 
communication, socialization, problem-solving, and daily 
living skills.
Follow-up studies show that children with FAS do not fare 
well as they reach adolescence and early adulthood. They 
often cannot live independently, are impulsive, exhibit poor 
judgment, do not respond appropriately interpersonally, are 
frequently depressed, and often socially isolated. Lifespan 
studies of patients with FAS, or other fetal alcohol effects 
related to significant prenatal alcohol exposures, show a 
wide array of “secondary disabilities.”  These include social, 
behavioral, psychiatric, and legal problems that stem from 
the primary disability of prenatal brain damage from alcohol 
but may be complicated by the failure of an appropriate early 
diagnosis, the impact of high-risk environments associated 
with parental alcohol abuse, and the failure of society to 
adequately provide appropriate services to this population 
of disabled adolescents and adults.
FAS and other Alcohol-Related Neurodevelopmental 
Disabilities (ARND) represent many neurobehavioral deficits 
besides mental retardation. Epidemiologic studies in the U.S. 
and some Western European countries have revealed an 
FAS prevalence of at least 2 to 7 per 1000. The prevalence 
of a relatively new more inclusive term for patients with 
and without FAS facial features, “Fetal Alcohol Spectrum 
Disorders” (FASD), has been recently estimated at 2–5%.
The U.S. Surgeon General’s 1981 recommendation for 
“no alcohol use for women who are pregnant or considering 
pregnancy” was re-issued in 2005. Recently, France and 
England have issued comparable warnings. Bottle labeling, 
begun in the U.S. in 1989, is now commencing in France. 
In the past decade increasing international collaborations 
in fetal alcohol studies and increased identification of 
affected individuals has spurred prevention/intervention 
efforts and the development of local and national plans 
for identifying and serving affected families. In 2009 The 
World Health Organization (WHO) began developing the 
first global strategy on reducing health damage from alcohol 
abuse. Preventing FASD should be at the top of the list. 
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Stress is a term that can mean very different things under 
different circumstances. In toxicology, stress refers to any 
external challenge that disturbs the constancy of the internal 
environment, or homeostasis. This definition encompasses 
the neurochemical, physiological, and behavioral reactions 
to novel, dangerous, or upsetting situations. Stress isn’t 
necessarily bad; the endocrine and neural adaptations 
typically referred to as the “stress response” may cause a 
person to, for example, escape from the path of a moving 
car. However, these responses can be maladaptive in certain 
situations, especially in cases of chronic stress.
Stressors can be environmental conditions or events, 
including excessive heat or cold, trauma, noise, starvation, 
chemical exposures, or physical exertion. Stress can even 
include domestic violence or abuse, conflicts with family 
members, or a hostile work situation, and psychological 
stressors include anxiety and depression. Although a 
considerable amount of experimental animal research has 
been done on the topic, far fewer human studies have been 
attempted. Because women and their life situations differ 
widely, such studies are difficult to conduct and interpret. 
Laboratory animal studies, most often with rodents, 
have tested the effects of such stressors as physical restraint, 
hypothermia, electric shock, noise, visual stimuli, vibration, 
shipping, and crowding on development. Deprivation of food 
and water has also been used as a stressor, but the possible 
effects of malnutrition confound these studies. Studies in 
pregnant rodents have demonstrated that certain maternal 
stressors can increase the adverse effects of chemicals 
known to cause malformations or other manifestations of 
developmental toxicity. Moreover, it is also possible that the 
stress caused by maternally toxic exposures to chemicals 
might exacerbate the harmful effects of those chemicals on 
the embryo or fetus.
Numerous experimental animal studies have examined 
effects of maternal stress or excess glucocorticoids (hormones 
produced in response to stress) on the physiology (especially 
endocrine alterations) or behavior of the young at various 
times after birth. Some investigators have noted increases 
in the likelihood of disorders of cardiovascular function, 
glucose homeostasis, and anxiety related behaviors in the 
animal as an adult. Other investigators have noted mortality, 
decreased growth, or development of extra ribs in the 
embryo or fetus, and a few studies have reported stress-related 
malformations. These malformations include encephalocele 
and exencephaly (different degrees of defective development 
of the brain and skull) caused by failure of the neural tube to 
close normally during development of the embryo. 
There are clearly significant differences in susceptibility 
to maternal stress during development among species and 
even among strains of the same species. For example, it is 
generally easier to induce adverse effects of stress on growth, 
mortality, and anatomical development in mice than in rats. 
And in some strains of mice, maternal stress is associated 
with cleft palate, while other strains are unaffected.
Several human studies have attempted to evaluate the 
potential for effects of maternal stress on development. 
Various clinical studies have associated such an adverse 
environment during pregnancy with the development in 
the offspring of metabolic disorders and neuroendocrine 
dysfunction as well as an increased risk of psychiatric 
diseases in later life. Some studies have reported findings 
such as increased incidences of low birthweight or preterm 
delivery, and a few studies have found diminished scores on 
neonatal neurological examination. However, these human 
studies often have methodological shortcomings, including 
arbitrary measures of psychological stress or inappropriate 
comparisons between groups. These studies must also deal 
with possible biases, especially recall bias. Recall bias is 
attributable to selective memory. Women, who miscarried, 
gave birth prematurely, or who gave birth to abnormal 
Cleft palate (right) can be induced in fetuses 
of susceptible mouse strains by maternal stress 
during pregnancy.
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children may be more likely than women with normal 
pregnancies to remember events that they believe may have 
contributed to such outcomes. This differential reporting may 
occur even when the life experiences of the two groups were 
not truly different.
Confounding factors are also common in human 
studies. Stressful life events are typically more common in 
women of low socioeconomic status, and poverty itself can 
be a stressor. Stressed mothers are commonly younger, more 
likely to smoke, abuse alcohol or other drugs, or have poor 
nutrition; any of these exposures could affect the results of 
a study on development. Thus, compelling human evidence 
for stress-induced effects on the offspring has been difficult 
to obtain.
Although there has been much speculation, we know 
relatively little about mechanisms by which maternal stress 
could adversely affect pregnancy. The response to stress 
is a basic adaptive mechanism that is protective in times 
of crisis. Stress activates the sympathetic nervous system 
and results in the release of specific hormones, including 
catecholamines and glucocorticoids. In mice, it is the 
increase in glucocorticoids that appears to be the cause of 
stress-induced cleft palate (see Figure). Stressors may also 
alter activities of the immune, neural, and renal systems, 
as well as having additional endocrine effects. Any of these 
influences may, in turn, affect various aspects of a mother’s 
physiology and behavior. Further, epigenetic mechanisms 
are increasingly being invoked as likely causes of postnatally 
manifested effects on offspring.
Stress responses are complex and can vary depending 
on the stressor and species involved. Although adverse 
effects have been shown to occur in laboratory animals, 
determining possible mechanisms by which maternal 
stress might negatively affect human embryonic or fetal 
development has been problematic.
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What Is the Risk of Treating or not Treating a  
Pregnant Woman with antidepressants?
Chapter 25 Antidepressant Use During Pregnancy
The risk of major depression among women is highest 
during childbearing age with an estimated prevalence of 
up to 20% during pregnancy. Untreated depression during 
pregnancy is associated with several adverse reproductive 
outcomes, including cesarean or premature delivery, low birth 
weight, and neonatal intensive care admission. Furthermore, 
maternal stress has been linked in some studies to a higher 
rate of cranial neural-crest malformations, orofacial clefts 
and various other congenital anomalies.
Selective serotonin reuptake inhibitors or SSRIs account 
for over 80% of antidepressant prescriptions in the U.S. 
Commonly used SSRIs include fluoxetine (Prozac), sertraline 
(Zoloft), paroxetine (Paxil), and citalopram (Celexa). All 
share a similar mechanism of action in depression, but their 
chemical structures and pharmacokinetic properties vary. 
Although many studies of pregnancy outcome treat these 
drugs as a class, different SSRIs may actually affect the 
developing fetus differently. 
Data on human teratogenicity associated with maternal 
SSRI use during the first trimester of pregnancy are inconsistent. 
Most studies have limited sample sizes and power, and 
many of the associations found may be attributable to 
chance despite their nominal statistical significance owing 
to multiple comparisons made within the studies. Available 
epidemiological studies (Chapter 14) are of four main types: 
1. The majority of studies assessing risk of first trimester 
SSRI use are retrospective cohort studies based on linked 
administrative records (data bases from prescription 
records, insurance claims, hospital records, etc). 
Five of the 10 published studies based on this design 
show positive findings: In one study, maternal use of 
any SSRI early in pregnancy was found to be a risk 
factor for any congenital malformation or any heart 
malformation. In two studies, maternal paroxetine use 
in particular was found to be associated with such risk. 
An increased risk for septal heart defects was found in 
the infants of mothers who took sertraline or citalopram 
in early pregnancy in another study. Maternal fluoxetine 
treatment in combination with benzodiazepine 
therapy was associated with any congenital anomaly, 
while associations of maternal combined SSRI and 
benzodiazepine therapy or citalopram monotherapy 
with congenital heart defects were reported in one other 
study. Other cohort studies did not detect any significant 
association of congenital malformations in general (four 
studies) or any heart malformation (two studies) with 
maternal use during pregnancy of any SSRI (four studies) 
or of paroxetine in particular (one study).
2. Four exposure cohort studies have been performed 
through teratogen information services. One study 
found a significantly increased risk for cardiac anomalies 
among the infants of women treated with fluoxetine early 
in pregnancy. No significant association of maternal 
SSRI use during pregnancy and birth defects was found 
in the other three studies. 
3. One prospective population-based cohort study found 
an association of maternal paroxetine treatment during 
pregnancy with cardiovascular malformations in the 
infant. Another study of similar design found a significant 
increase in risk for cardiac defects with use of any SSRI.
4. Retrospective case-control studies have found a tripling 
of the frequency of right ventricular outflow tract 
heart defects among infants with maternal paroxetine 
treatment in early pregnancy and an increased frequency 
of maternal sertraline treatment among infants with 
cardiac septal defects or omphalocele. Increased risks 
for omphalocele were also found among infants whose 
mothers had been treated with any SSRI, and increased 
risks for right ventricular outflow tract heart defects were 
associated with paroxetine treatment in another study. 
The risks for many other birth defects analyzed were not 
increased. 
Other data suggest that maternal SSRI treatment late in 
pregnancy is associated with various neonatal complications, 
including symptoms of neonatal withdrawal and toxicity, 
premature delivery, low birth weight and persistent 
pulmonary hypertension of the neonate. Data on the risk of 
neurobehavioral and long-term cognitive problems among 
children of women who were treated with SSRIs during 
pregnancy are limited. Given the pharmacological effects of 
these medications on the developing brain, the possibility of 
functional abnormalities is one to be studied. 
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Bupropion is the next most commonly used antidepressant 
in the U.S. Congenital anomalies were reported in 3.6% 
infants of women identified prospectively to have taken 
bupropion in the first trimester and reported to a pregnancy 
registry (chapter 16) operated by the manufacturer. 
Congenital heart defects were observed in more than 1/3 
of these infants. Results from a more recent population-
based case-control study indicated a doubling of the risk for 
one particular kind of cardiac malformation (left ventricular 
outflow tract defects) among infants of mothers who used 
bupropion in the first trimester of pregnancy. Relatively little 
is known about the risks of newer antidepressants, such as 
selective norepinephrine reuptake inhibitors.
None of the antidepressant treatments during pregnancy 
is known to be associated with a high risk of birth defects 
in the infant. There is a lack of consistency among studies 
that suggests there may be additional explanations other 
than the drugs that contribute to those findings that are 
statistically significant. Any increase in risk, if it exists, is small 
and difficult to detect against a background risk of 2–3% of 
having a malformation identified at birth (or 3–4% identified 
by 1 year of age) in any pregnancy. 
The clinician must be aware of the concerns that a 
pregnant woman might have in taking a medication. 
Concern may be heightened as well, because discontinuation 
of antidepressant treatment during pregnancy may pose 
a substantial risk of relapse and consequent pregnancy 
complications. Clinicians can counsel pregnant women 
and those of childbearing age who require antidepressant 
treatment that some but not all studies suggest a slightly 
increased risk of malformations in children whose mothers 
take SSRIs or bupropion early in pregnancy, while at the 
same time highlighting the fact that these studies show most 
such babies are normal and that discontinuation of treatment 
may pose serious risks to the pregnancy. 
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What are the Effects of antiepileptic Drugs during Pregnancy?
Exposure to an anticonvulsant drug occurs in 1 in 250 
(0.4%) pregnancies. Since exposure to many of these drugs 
has been shown to be harmful to the fetus, this makes these 
medications the most common potentially harmful fetal 
exposures for pregnant women. The dilemma, however, is 
that diseases that require treatment with antiepileptic drugs, 
if untreated, often present risks for a pregnant woman and 
her fetus as well.
There are over 30 anticonvulsant drugs prescribed in the 
United States. Some drugs, like lamotrigine, valproate, and 
topiramate, are used for several medical conditions, such 
as preventing seizures, treating the symptoms of bipolar 
disorder, or preventing migraine headaches.
Human research studies have not been carried out 
on the fetal effects of each anticonvulsant drug. The 
information available has shown that the risks vary for each 
drug. Because of these risks, women with epilepsy (or other 
medical conditions) who take these medications are urged 
to meet with their physicians to discuss their treatment before 
beginning a pregnancy. The crucial issues are:
1. Does she need to take an anticonvulsant drug?
2. Is the medication she is taking more potentially 
dangerous to her unborn infant than another drug?
3. If she is taking two anticonvulsant drugs, can she 
eliminate one? The reason is that taking two is often 
more dangerous to the fetus than taking one.
4. Can she take a lower dose of the anticonvulsant?  There 
is a dose-response relationship for any medication, 
which means the lower the dose, the lower the risk to the 
fetus.
Potential fetal effects of anticonvulsant drugs
These effects have been identified for several drugs:
1. Major malformations: The range of effects has been 
for a doubling (for drugs like carbamazepine, phenytoin 
and lamotrigine) to a 4- to 6-fold increase (for 
phenobarbital and valproate). Specific malformations 
that are more common include cleft lip, cleft palate, 
heart defects, and spina bifida.
2. More subtle effects, including mid-face hypoplasia and 
digit hypoplasia, occur in some anticonvulsant-exposed 
infants. Systematic studies have shown that these 
physical features occur in 10 to 15% of infants exposed 
to phenytoin, phenobarbital, and carbamazepine. The 
child with these physical changes is more likely to have 
IQ deficits than the anticonvulsant-exposed infants who 
do not have these physical effects from the medication.
3. An increased frequency of low birth weight.
4. Lower intelligence and developmental delay. This 
effect has been most severe after exposure to the 
drugs valproate and phenobarbital. More subtle effects 
may occur after exposure during pregnancy to other 
anticonvulsant drugs. Studies to assess these potential 
effects are needed for most of the “new” anticonvulsant 
drugs which have been marketed since 1990.
Can the fetal effects of anticonvulsant drugs be prevented 
by folic acid supplements during pregnancy?
Very few systematic studies have addressed this important 
question. Studies of the occurrence of major malformations 
in women enrolled in pregnancy registries have shown that 
each of the mothers of affected infants was taking a vitamin 
(including folic acid) supplement. It is current practice to 
recommend to each woman taking an anticonvulsant drug 
to take a vitamin supplement that includes 4 mg folic acid 
per day. The hope is that this high dose could be beneficial. 
There is no evidence of a risk for harm to the fetus from this 
dose. 
Is there a genetic risk for the harmful fetal effects of 
anticonvulsant drugs?
Clinical studies have suggested that the pregnant 
woman who has taken an anticonvulsant drug and whose 
drug-exposed child has the physical abnormalities attributed 
to these drugs has a greater risk of having a second affected 
child. However, no systematic studies have been carried out 
to identify the presumed genetic basis for the harmful fetal 
effects of anticonvulsant drugs.
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Can Chemicals in the Environment That affect hormone  
Function Disrupt Development?
Chapter 27 Chemicals That Affect Hormone Function 
Hormones, including estrogens and androgens, regulate 
the expression of genes that play critical roles in guiding the 
development of organ systems in the embryo. Changes in 
either the amount or the timing of hormone exposure can 
lead to altered human development. For example, humans 
with a defect in the androgen receptor gene have androgen 
insensitivity syndrome; although they are genetically male, 
they look female, because androgens cannot activate the 
receptor to masculinize the reproductive tract during critical 
periods of prenatal development. 
Hormonally-active chemicals were first shown to have 
effects on development in humans in the early 1970s, when 
vaginal adenocarcinoma, a rare cancer, was shown to be 
linked to fetal exposure to diethylstilbestrol (DES). During 
the 1950s, the mothers of these young women had been 
given DES, a synthetic estrogen, in an effort to prevent 
miscarriage and preterm delivery. In Taiwan in 1979, many 
people consumed rice oil contaminated with high levels of 
polychlorinated biphenyls (PCBs) and dibenzofurans. The 
offspring of exposed women were smaller at birth and had 
delays in neurological development. Several more recent 
studies on PCBs have shown neurological effects in other 
populations exposed to lower amounts. Although we know 
that PCBs and related compounds can interact with various 
components of the endocrine system, the exact cause for 
the developmental disorders observed after these exposures 
is not known. In 1992, a publication of the proceedings of 
a conference organized by Theo Colborn concluded, “We 
are certain of the following:...A large number of man-made 
chemicals that have been released into the environment...
have the potential to disrupt endocrine systems of animals, 
including humans”. 
Chemicals that affect development through hormonal 
processes are called endocrine disruptors, endocrine 
modulators, or, simply, hormonally active substances. 
The International Programme on Chemical Safety, part of 
the World Health Organization (WHO), adopted the term 
endocrine disruptors and defined them as “exogenous 
substances that alter function(s) of the endocrine system 
and consequently cause adverse health effects in an intact 
organism, or its progeny, or (sub)populations.” Evidence 
supporting the endocrine disruptor hypothesis is derived 
from studies in wildlife living in contaminated environments, 
studies of livestock foraging on phytoestrogen-containing 
plants, laboratory animal studies, and reports of increasing 
rates of health effects in hormonally sensitive tissues, 
including tumors of the testes, breast, and prostate, birth 
defects that affect the reproductive tract (hypospadias and 
cryptorchidism), and diminished semen quality. 
The most convincing evidence to support the endocrine 
disruptor hypothesis has been obtained in laboratory 
experiments in which animals are exposed during critical 
developmental periods. Female rodents exposed as 
embryos or fetuses to a sufficient dose of an estrogenic 
chemical typically develop accelerated puberty and delayed 
preputial separation; males have reduced accessory sex 
gland weights and reduced sperm production. Exposures 
with anti-androgenic effects affect primarily male offspring, 
causing reduced anogenital distance, hypospadias, retained 
nipples, reduced testes and sex accessory gland weights, 
and reduced sperm counts. For example, in experimental 
animals, the DDT isomer o,p-DDT binds to the estrogen 
receptors and feminizes hormonally sensitive tissues, while 
the DDT metabolite p,p=-DDE demasculinizes development 
by binding to and inhibiting the androgen receptor. Other 
chemicals that disrupt development by endocrine-based 
modes of action include the fungicides vinclozolin, the 
plasticizer diethylhexylphthalate, a group of surfactants 
called alkylphenols, and 2,3,7,8-tetrachlorodibenzodioxin 
(commonly called dioxin or TCDD). Exposures that alter the 
function of the thyroid gland during development affect the 
Reprinted from Advances in Neonatal Care, Volume 
4, Stokowski LA, Hypospadias in the neonate, 206–
215. Copyright (2004), with permission from National 
Association of Neonatal Nurses.
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differentiation of central nervous system and sensory organs 
(e.g., hearing). In rodents, testis size is inversely proportional 
to the thyroid status in the neonate. Many of the effects of 
hormone disruption are not obvious at birth but become 
apparent on the functional level as the individual matures.
Organizations that have reviewed the evidence 
concerning the impact of endocrine disruptors in the 
environment on human health have generally concluded 
that additional research is needed before cause-and-effect 
determinations can be made with any degree of confidence. 
The link between exposure to endocrine disruptors and effects 
in humans is largely based on the concurrent rise in the use of 
many chemicals with hormonal activity and the increase over 
time in certain health outcomes that have at least a partial 
endocrine basis. However, data on the impact of low level 
environmental exposures on the rates of endocrine-sensitive 
health outcomes have been conflicting and there are some 
who do not believe that human endocrine disorders are 
caused by low level environmental exposures. The Endocrine 
Society was one of the most recent organizations to weigh 
in on the controversy, when it released a position paper that 
made a number of recommendations regarding research to 
increase our understanding of the effects of endocrine active 
chemicals and advocated involvement of individual and 
scientific society stakeholders in fostering changes in public 
policy and awareness of the issue. 
The United States Congress included in the Food 
Quality Protection Act of 1996 a provision that the U.S. 
Environmental Protection Agency begin a program to screen 
and test chemicals for ability to interact with the estrogen, 
androgen, and thyroid hormone activity. This program, 
which is arguably the largest testing program to be adopted 
since the 1970s, will provide a much more comprehensive 
evaluation of the chemicals that can interfere with endocrine 
mediated processes. The latest information on the status 
of this requirement can be found at: http://www.epa.gov/
endo/pubs/edspoverview/index.htm.
One of the most controversial contemporary issues 
relates to the plasticizer bisphenol A (BPA), which is produced 
in very large quantities and used in a number of consumer 
products. BPA binds to the estrogen receptor, although its’ 
potency is several orders of magnitude less than that of 
estradiol, the most active human estrogen. While traditional 
toxicology studies have shown that BPA is a weak estrogen in 
exposed animals, other studies have reported adverse effects 
in tissues at very low, environmentally relevant concentrations. 
Similar low dose findings have also been reported for the 
phthalate plasticizers. These types of findings have fueled the 
concern that exposures to endocrine disrupting chemicals 
well below those previously considered safe can cause harm 
to the developing fetus. Recently, the National Institute of 
Environmental Health Sciences (NIEHS), a part of NIH, has 
launched a $30M grant program (http://www.niehs.nih.
gov/news/releases/2009/bisphenol-research.cfm) in an 
attempt to clarify whether current human exposure to BPA 
affects development.
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Is herb Use during Pregnancy a Reason for Concern?
Chapter 28
Women commonly use medicinal herbs during 
pregnancy; the National Birth Defects Prevention Study 
found that 99.4% of 4239 women reported herbal use 
during pregnancy primarily in the first trimester. Teas made 
from raspberry leaf (Rubus idaeus) are used throughout 
pregnancy in many cultures, and teas made from ginger 
(Zingiber officinale), peppermint (Mentha x piperita), or 
spearmint (Mentha spicata) are common folk remedies 
for morning sickness. Some midwives incorporate herbs 
into their practices, including oral or topical oil of evening 
primrose (Oenethera biennis) to speed cervical ripening, or 
a mixture of blue cohosh (Caulophyllum thalictroides) and 
the unrelated black cohosh (Cimicifuga racemosa) to treat 
stalled labor. 
The most common herb intentionally ingested by 
pregnant women is red raspberry leaf even though there 
is no evidence that raspberry leaf eases morning sickness 
or labor; a placebo-controlled clinical trial of raspberry 
leaf extract administered from 32 weeks gestation until 
labor found no significant differences between groups in 
pregnancy outcomes.
Dried ginger root, commonly used for morning sickness, 
has been tested in numerous clinical trials in doses up to 
1 g/d and appears to be effective. No adverse pregnancy 
outcomes have been linked to ginger, and reproductive 
toxicology studies of ginger in rats have identified no 
problems. Rates of major malformations were no higher in 
54 women who took St. John’s wort (Hypericum perforatum) 
during pregnancy than for a comparator group.
Evening primrose oil, a source of gamma-linolenic 
acid, may be used in an effort to soften the cervix; it is 
more commonly topically applied than ingested orally. In 
a clinical trial, orally ingested evening primrose oil from the 
37th gestational week until birth did not shorten gestation or 
decrease the overall length of labor. 
Not all herbs are benign. Licorice, an herb that is used 
medicinally but is consumed most commonly in the form 
of candy or chewing gum, appears to shorten gestation in 
humans. A questionnaire study in Finland, where licorice 
candy consumption is so common that participants could 
be separated into low, medium, and high-exposure 
groups, found that heavy exposure to licorice (more than 
500 mg/ glycyrrhizinic acid per week) slightly shortened 
gestation and more than doubled the risk of delivering a baby 
before 38 weeks. Birth weight and head circumference were 
unaffected. A study of offspring in this cohort at age eight 
found dose-related cognitive defects and attention problems 
in eight-year- olds exposed to high levels of licorice in utero. 
Maternal use of blue cohosh (Cimicifuga racemosa) in 
high doses has been associated with cases of stroke, heart 
attack, and hypoxic-ischemic symptoms in exposed infants. 
Blue cohosh rhizomes contain several vasoconstrictive 
compounds, including methylcytisine, caulosaponin and 
caulophyllosaponin. A woman who took blue cohosh in an 
effort to induce abortion developed tachycardia, abdominal 
pain, vomiting, and muscle weakness, symptoms consistent 
with toxicity mediated through the nicotinicacetylcholine 
receptor. 
Lack of adequate regulation of herbal products in the 
United States complicates the use of herbs. Herbal products 
may contain different herbs than are stated on the label, be 
adulterated with other drugs, or be contaminated with heavy 
metals or bacteria, some of which might cause adverse 
effects during pregnancy. Misidentification of an herb was 
associated with neonatal hirsutism in a baby born with hair on 
its forehead, pubic hair, swollen nipples and enlarged testes. 
The mother had taken a product that purportedly contained 
eleuthero, also called Siberian ginseng (Eleutherococcus 
senticosis) throughout pregnancy and during lactation. In a 
two-generation rat study, Eleutherococcus senticosis caused 
Thomas G. Barnes @USDA-NRCS PLANTS
Database/Barnes, T.G. & S.W. Francis. 2004, Wildflowers
and ferns of Kentucky, University Press of Kentucky.
Reprinted with permission.
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no adverse effects on reproductive performance. Subsequent 
analysis of the product taken by the mother showed that the 
herb consumed was actually Chinese silk vine (Periploca 
sepium), which is contraindicated during pregnancy. 
Surveys of pregnant women and midwives have not 
revealed reckless use of problematic herbs. Some alarmist 
articles in the medical literature include lists of plants to 
avoid in pregnancy, but these lists often include plants 
that are never used in pregnancy, never used medicinally, 
or never ingested intentionally except by those attempting 
suicide. Such lists are not helpful to clinicians.
On the other hand, the safety of many herbs commonly 
used during pregnancy has not been established. Even where 
some data in humans exist, no studies specifically designed 
to pick up adverse reproductive effects have been performed 
to date. There are many unknowns about the safety of herbs 
in pregnancy. The popularity of some herbs makes further 
research an important public health issue. 
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Does Maternal Diabetes or Obesity Increase the  
Risk of having a Child with a Birth Defect?
Maternal Diabetes, Obesity, and Risk of Birth DefectsChapter 29
Given the increasing frequency of diabetes and 
obesity among women of childbearing age in recent 
years, understanding the effects of these disorders on the 
embryo or fetus is critical. Many epidemiologic studies using 
different study designs have provided strong evidence for 
maternal pregestational diabetes (type 1 and type 2) as a 
risk factor for numerous types of birth defects, and results 
from experimental animal studies have supported these 
epidemiologic findings. In most studies, the overall risk for 
birth defects among infants of diabetic mothers is about two 
to four times that of infants of non-diabetic mothers. The 
degree of increased risk varies by the type of birth defect 
and by whether a defect is “isolated” or occurs with other 
unrelated major birth defects (“multiple”) (Figure 29-1). For 
certain rare birth defects, such as sacral agenesis, the risk 
among diabetic mothers is estimated as more than 100 
times higher than among non-diabetic mothers, whereas the 
increase in risk for other defects is more modest and the risk 
is not at all increased for a few defects. Women who achieve 
strict control of their blood glucose before conception can 
substantially reduce their risk for having an infant with a birth 
defect to that approaching the risk in the general population. 
Although diabetes is a well-recognized risk factor for birth 
defects, the mechanisms by which the increased risk occurs 
are not well understood. Better understanding of these 
mechanisms could provide strategies for intervention among 
women with poorly controlled diabetes and is an important 
area for future research.
The risk for having an infant with birth defects associated 
with gestational diabetes, diabetes that is first diagnosed 
during pregnancy, is more controversial. Some studies have 
shown an increased risk for certain birth defects among 
women with gestational diabetes, while others have not. 
Some studies have suggested that gestational diabetes may 
present a higher risk for women who are obese. Given the 
timing of gestational diabetes (with onset after the critical 
period of development of most organs), some investigators 
have suggested that the increased risk for birth defects 
observed in some studies might be due to inclusion of 
women who actually have pregestational diabetes in whom 
1The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control 
and Prevention.
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Figure 29-1. Graph showing adjusted odds ratios and 95% 
confidence intervals for the association between maternal 
pregestational diabetes and types of birth defects—cardiac and 
non-cardiac, and infants with isolated defects and with defects 
occurring with other major unrelated birth defects (multiple 
defects). Data are from National Birth Defects Prevention Study 
(NBDPS); of note, not all cardiac or non-cardiac birth defects are 
eligible for inclusion by the NBDPS. (Correa et al., 2008)
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Figure 29-2. Graph showing summary odds ratios and 95% 
confidence intervals from a meta-analysis examining the 
association between maternal obesity and neural tube defects. 
This meta-analysis demonstrated a dose-response relationship 
between degree of overweight or obesity and odds of neural tube 
defects. (Rasmussen et al., 2008)
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the diagnosis was not made until undergoing screening for 
gestational diabetes during the second or third trimester of 
pregnancy. Of note, in the United States, about one-third of 
diabetes goes undiagnosed.
Many studies have shown that women who have a baby 
with a neural tube defect, such as spina bifida or anencephaly, 
are more likely to be obese, suggesting that obesity is a 
risk factor for these defects. In addition, a dose-response 
relationship has been observed; that is, the risk appears be 
higher as the degree of overweight or obesity increases. In 
a recent meta-analysis, odds ratios for having a pregnancy 
affected by a neural tube defect were 1.22 for overweight 
women, 1.70 for obese women, and 3.11 for women who 
were severely obese (Figure 29-2), compared with women 
of normal weight (an odds ratio of 1.0 would indicate no 
increased risk). An increase in the risk of other defects has 
also been suggested, with the most convincing evidence for 
congenital heart defects in which a meta-analysis identified 
an odds ratio of 1.30 (95% confidence intervals 1.12–1.51), 
suggesting a modestly increased risk. Although several defects 
appear to occur more frequently among obese women, one 
defect, gastroschisis (a defect in which the intestines and 
sometimes other organs protrude through a defect in the 
abdominal wall), appears to occur less frequently.
The reasons for the association between maternal obesity 
and certain birth defects are not known. One possible reason 
is that women who are obese might have different nutritional 
requirements than women who are of normal weight. Lower 
levels of serum folate, have been associated with some types 
of birth defects and also have been observed among obese 
women, providing some evidence for this hypothesis. Another 
possible reason is that obese women may have metabolic 
abnormalities (e.g., increased levels of insulin or estrogen) 
that may increase the risk for birth defects. Another possibility 
might be related to undiagnosed diabetes. Women who are 
obese are more likely to have pregestational diabetes, a 
known risk factor for birth defects. In most previous analyses 
of the association between obesity and birth defects, women 
known to have pregestational diabetes have been excluded, 
but it is possible that some women with pregestational 
diabetes were not diagnosed before pregnancy and thus 
were inadvertently included, potentially raising the observed 
risk associated with obesity. Finally, there may be other 
differences in obese women (e.g., related to diet or physical 
activity) that may increase the risk for birth defects. 
In summary, maternal prepregnancy diabetes is a 
well-recognized risk factor for birth defects, but the effects 
of gestational diabetes are less well understood. Maternal 
obesity is associated with increases in several types of birth 
defects, with the evidence being the strongest for neural 
tube defects and perhaps congenital heart defects. Better 
understanding of these conditions and how they increase 
the risk for birth defects is essential to the development of 
strategies to decrease risks for birth defects to infants born to 
women with these conditions.
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Most infections that a woman contracts during 
pregnancy do not harm the developing embryo or fetus. 
However, a few infectious diseases can kill an embryo, 
fetus, or newborn, cause birth defects, trigger a premature 
delivery, or inhibit fetal growth. Only eight infectious agents 
are generally considered to increase the risk of birth defects 
in humans. These include six viruses: the rubella virus, 
Venezuelan equine encephalitis virus, cytomegalovirus, 
varicella zoster virus, herpes simplex viruses, and lymphocytic 
choriomeningitis virus; one bacterium, Treponema pallidum; 
and one protozoal parasite, Toxoplasma gondii.
Rubella virus causes German measles. An exposed 
fetus may develop a congenital rubella syndrome, which 
includes cardiovascular defects, microcephaly (abnormally 
small head), microphthalmia (abnormally small eyes), 
cataracts, glaucoma, retinopathy, mental retardation, 
growth retardation, motor impairment, an enlarged liver and 
spleen, and skin rash. The risk of birth defects from rubella 
exposure during the first trimester of pregnancy may be as 
high as 85 percent. Exposure between weeks 13 and 18 of 
pregnancy has about a 25 percent risk of birth defects. There 
is little risk of birth defects after the 18th week of pregnancy. 
The incidence of congenital rubella syndrome has decreased 
dramatically since the introduction of the rubella vaccine.
Venezuelan equine encephalitis virus is related to the 
rubella virus. First trimester infection can cause spontaneous 
abortion of the embryo or fetus. Fetal infection during the 
second or third trimester of pregnancy may cause severe 
damage to the brain and fetal death. The virus also causes 
brain and eye malformations in rhesus monkeys infected 
during gestation.
Cytomegalovirus (CMV) can cause serious effects in 
babies infected anytime during pregnancy. About 5 to 10 
percent of infected infants show serious effects at birth. 
Even if infants appear normal at birth, 10 to 15 percent 
develop handicaps within a few years. Adverse effects of 
CMV include microcephaly, cerebral atrophy, enlarged 
cerebral ventricles, enlarged liver and spleen, intracranial 
calcifications, chorioretinitis (an inflammation of the choroid, 
the thin pigmented vascular coat of the eye, and the retina), 
skin lesions, blindness, hearing loss, mental retardation, 
intrauterine growth retardation, and neurologic dysfunctions.
Varicella zoster virus is related to cytomegalovirus and 
herpes simplex viruses. Varicella zoster causes chickenpox 
(varicella), and reactivation of the virus causes shingles 
(herpes zoster). A fetus infected during the first 20 weeks 
of pregnancy has about a one percent risk of developing 
congenital varicella syndrome. Newborns with the syndrome 
may have atrophy of the cerebral cortex, enlarged cerebral 
ventricles, nerve fiber abnormalities, microcephaly, 
mental and psychomotor retardation, learning disabilities, 
cataracts, microphthalmia, chorioretinitis, hypoplastic 
(underdeveloped) limbs and digits, intrauterine growth 
retardation, and scarring of the skin.
Graphics from www.teratology.org.
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Herpes simplex viruses (HSV) cause blisters and ulcers of 
the skin and can infect the central nervous system, eyes, and 
liver. HSV Type 1 usually produces cold sores around or in 
the mouth, whereas HSV Type 2 usually affects the genitalia, 
causing genital herpes eruptions. When a woman is infected 
with herpes for the first time during a pregnancy, the fetus 
can be severely affected. HSV can cause microcephaly, 
hydrocephaly, hydranencephaly (absence of the cerebral 
hemispheres), porencephaly (cavities in the brain), intracranial 
calcification, microphthalmia, chorioretinitis, skin aplasia 
(failure of skin to develop), skin lesions, and psychomotor 
retardation. The most serious effects appear following 
infection during the third trimester, but abnormalities can 
occur from infection any time during pregnancy. Many 
effects are likely due to disruption of existing structures rather 
than malformation. Most HSV abnormalities are caused by 
the Type 2 virus, but some are caused by the Type 1 virus.
Lymphocytic choriomeningitis virus (LCMV) is acquired 
from exposure to infected rodents and causes lymphocytic 
choriomeningitis virus syndrome. About one-third of fetuses 
infected during pregnancy die, and about 85 percent 
of surviving infants have serious problems including 
microphthalmia, cataracts, chorioretinitis, scarring and 
atrophy of the eyes, macrocephaly (abnormally large head), 
hydrocephaly, and microcephaly due to dysplasia or atrophy 
of the cerebral cortex. Congenital LCMV mimics congenital 
cytomegalovirus and congenital toxoplasmosis.
Treponema pallidum is the bacterium that causes 
syphilis. A fetus can contract congenital syphilis anytime 
during pregnancy. Untreated syphilis infection during early 
pregnancy causes up to 40 percent of pregnancies to end 
in spontaneous abortion, fetal death, or perinatal death. 
Congenital syphilis can cause fetal hydrops (abnormal 
accumulation of fluid in the entire body), hydrocephaly, 
defects of the teeth and skeleton, enlargement of the liver 
and spleen, vision loss, hearing loss, mental retardation, 
hemiplegia (paralysis of one side of the body), and skin 
lesions and scarring.
The protozoan parasite Toxoplasma gondii causes 
toxoplasmosis. Infants infected during pregnancy may 
develop hydrocephaly, microcephaly, macrocephaly, 
cerebral calcifications, enlarged liver and spleen, vision loss, 
hearing loss, mental retardation, cerebral palsy, seizures, 
neurologic problems, encephalitis, chorioretinitis, and 
inflammation of multiple organs. The highest risk for severe 
effects occurs with maternal infection between 10 and 24 
weeks of gestation. Up to 40 percent of fetuses infected 
during the first trimester of pregnancy develop severe effects.
Human birth defects have been reported to occur in 
association with other infectious agents including HIV, 
parvovirus B19 (which causes fifth disease), Borrelia 
burgdorferi (which causes Lyme disease), cocksackie virus, 
Epstein-Barr virus (which causes infectious mononucleosis), 
influenza viruses, mumps virus, Mycoplasma, and Salmonella. 
However, there is presently insufficient evidence to conclude 
that the infections caused the congenital abnormalities.
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how Does nutrition Influence Development
Chapter 31 Nutrition Effects on Development
A growing fetus needs food. Severely restricted intake of 
calories or protein can cause decreased fertility, fetal death, 
premature delivery, and growth restriction. Deficiencies 
in some essential minerals or vitamins increase the risk of 
malformations and other adverse pregnancy outcomes.
Extreme caloric restriction leads to irregular menstrual 
periods or amenorrhea (lack of menstruation), both of which 
decrease fertility. During the last six months of World War 
II, a Nazi-occupied area of the Netherlands was completely 
cut off from food supplies, in retaliation for a Dutch rail 
strike supporting the Allies. The average daily food ration 
decreased from 1400 calories to less than 600 calories 
(almost exclusively from bread and potatoes) during the 
last two months. Women who were pregnant or became 
pregnant during this famine suffered an excess of premature 
deliveries, very low-birth weight infants, and infant deaths. 
Similar poor outcomes were reported during the siege of 
Leningrad. The ”fetal origins of adult disease” hypothesis 
holds that under-nutrition during fetal life, infancy, and 
early childhood followed by a rapid increase in body mass 
index can increase the risk of chronic diseases such as 
coronary heart disease, hypertension, and type 2 diabetes, 
underscoring the importance of good maternal nutrition.
Deficiencies in certain micronutrients cause congenital 
malformations in animals, including humans. The relationship 
between iodine deficiency, goiter, and cretinism, a neurologic 
disorder characterized by severe mental retardation, was 
identified during the nineteenth century and represents the 
earliest observation of the interconnection of diet and birth 
outcome. While iodine supplementation (primarily in the 
form of iodized salt) has eliminated goiter and cretinism 
in developed countries, about 1.6 billion people (24% 
of the world population) still suffer from iodine deficiency 
disorders. Iodine deficiency during pregnancy also can 
cause fetal death, severe growth restriction, abnormal bone 
development, and varying degrees of mental impairment.   
Vitamin A deficiency was first shown to be teratogenic in 
swine in the 1930s. Warkany and his colleagues extended 
these findings by detailing the defects that vitamin A 
deficiency produces in virtually every organ system of the 
rodent. More recently, vitamin A has been shown to be 
critical in establishing anterior–posterior body axis patterns in 
the embryo. Sporadic reports in the literature have linked eye 
abnormalities and other adverse birth outcomes to severe 
maternal vitamin A deficiency. Malformations induced by 
vitamin A deficiency in humans are rare, but in developing 
countries, vitamin A deficiency remains the leading cause of 
visual impairment and blindness. Even though it is important 
to get enough vitamin A during pregnancy, too much vitamin 
A can also be teratogenic (discussed in the last paragraph 
of this chapter).
Deficiencies in many B vitamins adversely affect 
development. In animals, riboflavin, niacin, folic acid, and 
pantothenic acid deficiencies cause structural malformations; 
pyridoxine and thiamine deficiencies increase embryonic 
mortality and decrease fetal growth. Folate deficiency induced 
by a folic acid antagonist, causes structural malformations 
in animals. The neural tube defect rate among offspring 
of women taking folic acid supplements at the time of 
conception is reduced by as much as 50% compared to that 
among unsupplemented pregnancies (chapter 32). The U.S. 
Public Health Service recommends that all women receive 
400 mg of folic acid daily, and since January, 1998, all 
grain products are required to be fortified with folic acid at a 
level designed to provide an additional daily intake of 100 
mg/day folic acid. It is controversial whether supplemental 
folate overcomes the effects of subclinical deficiency in the 
pregnant woman or a metabolic problem of the embryo. 
Low maternal Vitamin B12 status can lead to neurological 
developmental delay and megaloblastic anemia in the 
offspring and has been reported to be an independent risk 
factor for the occurrence of neural tube defects.  
Blickstein I. Normal and abnormal growth of multiples.
Seminars in Nematology 2002; 7(3): 177-185. Reprinted
with permission.
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Choline has been deemed an essential nutrient as the 
body cannot always produce enough to meet its needs. 
Choline functions in the synthesis of membrane phospholipids 
and the neurotransmitter acetylcholine and participates in 
methylation reactions including DNA methylation, which 
can affect gene expression. In experimental animals, low 
choline intake during late pregnancy alters brain structure 
and function whereas in utero choline supplementation can 
improve cognitive performance or behavioral tests in the 
offspring. Long chain polyunsaturated fatty acids, such as 
docosahexaenoic acid (DHA) found in fatty fish, have also 
garnered interest. Reports from animal and human studies 
suggest a possible relationship between DHA and visual 
acuity in the offspring.
Low maternal vitamin D status is associated with 
reduced infant growth, neonatal hypocalcemia, and 
poor bone mineralization. Vitamin D can be obtained 
from diet, supplements and is generated in the skin from 
7-dehydrocholesterol upon UVB radiation. Dark skin, 
concealing clothing, sunscreen use, and northerly latitudes 
can limit sunlight exposure and reduce vitamin D synthesis. 
Recently, a high prevalence of maternal hypovitaminosis 
D has been identified internationally, fueling the concern 
that vitamin D deficiency is an increasing public health 
problem. Vitamin E deficiency in rats produced litters in 
which approximately 30% of pups had brain anomalies 
(exencephaly or hydrocephalus). However, there is no 
evidence that vitamin E deficiency is teratogenic in humans. 
In contrast, vitamin K deficiency in humans (usually as a 
result of therapy with warfarin, an oral anticoagulant) results 
in a high percentage of miscarriage and prematurity. Infants 
have characteristic bone abnormalities, optic atrophy, and 
mental retardation.
Zinc deficiency is teratogenic in animals, affecting the 
development of virtually every organ system. After only 24 
hours of dietary deficiency, plasma zinc decreases by 40%, 
and only a few days of deficiency during the embryonic 
period can produce malformations. Offspring of women 
with acrodermatitis enteropathica, a genetic disorder of 
zinc absorption, have a higher rate of malformations. 
Epidemiological studies also suggest a relationship between 
zinc deficiency and central nervous system malformations in 
humans. Although severe zinc deficiency is uncommon in 
developed countries, mild deficiency is common: the average 
dietary intake is only about half of the Recommended Daily 
Allowance (RDA) for pregnant and lactating women. Also, 
some drugs, chemicals, and physiological or environmental 
stressors can significantly alter zinc metabolism. These 
two facts, along with the observation that even transitory 
zinc deficiency can have adverse effects, suggest that 
unrecognized, subclinical zinc deficiency may play a role in 
some human embryonic morbidity.
The adverse effects of copper deficiency during 
pregnancy have been shown in numerous species, including 
humans. Copper-deficient lambs exhibit neonatal ataxia and 
myocardial atrophy. The effects of prenatal copper deficiency 
in humans have been reported in offspring with Menkes’ 
disease, an X-linked disorder of copper metabolism. These 
infants have mental retardation and severe cardiovascular 
and connective tissue defects that generally cause death by 
three years of age. Many of the defects can be linked to 
decreased activity of copper-requiring enzymes. Copper-
chelating drugs, including D-penicillamine, used to treat 
Wilson’s disease (a genetic copper overload condition) and 
rheumatoid arthritis can induce copper deficiency in humans.
Vitamins may be good for you, but more is not 
necessarily better. Megadoses of vitamins may be harmful 
in some instances. In animal models, an excess of vitamin 
A is teratogenic, affecting the development of many organs. 
The expression of many genes responsible for establishing 
the embryonic body pattern is controlled by retinoic acid, the 
active form of vitamin A. Vitamin A levels are tightly controlled 
in the embryo; excess vitamin A can overwhelm these control 
mechanisms, leading to abnormal development. It is likely 
that vitamin A excess would be teratogenic in humans, but 
the minimum teratogenic dosage is not clear. The latest 
thinking is that this level is more than 30,000 International 
Units (IU)/day; the RDA for pregnancy is 2567 IU/day). The 
Teratology Society, in a position paper on vitamin A issued 
in 1987, reasonably advocated that vitamin A intake in 
pregnant women be restricted to the RDA.
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Chapter 32 Folic Acid and Birth Defects
Whether taking folic acid around the time of conception 
could prevent birth defects of the brain and spinal cord known 
as neural tube defects (NTDs) was highly controversial until 
the publication of two landmark studies in the early 1990s, 
one by Czeizel and Dudas, and the other by the Medical 
Research Council. These studies proved conclusively that 
folic acid could dramatically reduce the risk of NTDs and led 
the U.S. Public Health Service (USPHS) to recommend that all 
women of childbearing age capable of becoming pregnant 
take 400 micrograms of folic acid daily. It is unfortunate that 
this recommendation was followed by only 30–40 percent of 
American women. The USPHS soon recognized that another 
strategy was needed to get folic acid to all women at risk and 
began fortifying enriched cereal grains (bread, pasta, rice) 
with 140 micrograms of folic acid per 100 grams of grain.
The impact of this effort has not been easy to measure. 
In the U.S. most NTDs are diagnosed prenatally and many 
pregnancies are terminated without being identified in vital 
records. Thus, looking at rates of NTDs reported on birth 
certificates results in missing many cases. In Canada, which 
has a very similar fortification program, more information is 
available on prenatally diagnosed cases. The rates before 
and after fortification in various countries are shown in 
Figure 32-1. Comparing rates in U.S. and Canadian studies 
showed that the drop in rates was greater in areas where 
ascertainment was more complete. As shown in the figure, 
the drop in rates is also related to the starting rate; higher 
risk populations show greater reductions, probably due to a 
combination of factors: some populations have low folate 
diets and some are genetically at high risk. A demonstration 
project in China showed that northern China, for example, 
had far higher NTD rates than southern China, probably 
because folate containing foods were scarce in the north. 
Newfoundland had higher rates than most areas of Canada, 
probably because the Irish and Scottish background of the 
inhabitants put them at high risk because of genetic factors.
It is not clear how much of a reduction in rates should 
have been seen. The Medical Research Council trial found 
a 72% decrease in NTD rates but the confidence interval 
extended from 29% to 88% and the women in the trial were 
not typical because all had a history of previous affected 
children. Other trials did not have a sufficient number of 
subjects to determine what the expected benefit should 
be. Case control studies generally showed around a 50% 
reduction in risk in those who took folic acid-containing 
vitamins. Case control studies, however, compared women 
who elected to take folic acid containing vitamins to women 
who did not. This design could introduce a bias in that 
vitamin takers could be more health conscious in general. 
Thus, it is uncertain exactly what the target reduction is.
The actual drop in NTD rates since fortification began 
averages around 40 to 50% (Figure 32-1). This drop is 
consistent with the effect expected based on the case control 
studies. It is also consistent with the effect predicted by 
modeling based on giving women various doses of folic acid 
to determine how much was needed to reach blood folate 
levels known to be protective against NTDs. 
Are there more folic acid-preventable NTDs? A recent 
publication by Mosley et al. indicates that there may not 
be. The investigators interviewed women who had an NTD 
1This research was supported by the Intramural Research Program, Eunice Kennedy Shriver, National Institute of Child Health and Human Development
Figure 32-1 Legend. Change in neural tube defect (NTD) 
prevalence rates following mandatory fortification of food with 
folic acid in selected populations. Ascertainment of cases varies 
by area; some include prenatally as well as postnatally diagnosed 
cases. Therefore, the denominator may be births or pregnancies.
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affected child and women who had unaffected children. 
They found that women who had an affected child were not 
significantly less likely to have used folic acid supplements. 
Their data suggest that, because folic acid supplement use 
was not a factor, the amount of folic acid in fortified food is 
sufficient to prevent folate-related NTDs. Although it is well 
known that some NTDs occur for reasons unrelated to folic 
acid (chapter 7), such as genetic syndromes and obesity, it is 
not completely clear what the minimum NTD rate achievable 
by folic acid is.
Older case control studies suggested that 
periconceptional use of multivitamins containing folic acid 
might reduce the risk for defects other than NTDs. These 
findings led a number of investigators to compare other 
defect rates pre and post-fortification. The results are mixed: 
some reports show a significant decline in congenital heart 
defects (atrial septal defects, conotruncal and other severe 
defects), diaphragmatic hernia, isolated cleft palate, pyloric 
stenosis, limb defects, and omphalocele. Other reports, 
however, have failed to confirm these findings, suggesting 
that the positive results could be chance findings. The failure 
to find consistently lower rates of other defects since the 
institution of food fortification may well mean that only NTDs 
are preventable by folic acid at the levels present in fortified 
food. 
It is important to note that there is considerable debate 
over other benefits and risks of food fortification. Food 
fortification can almost eliminate folate deficiency. Hopes 
that folic acid could prevent cardiovascular disease by 
reducing homocysteine, a known marker for cardiovascular 
disease, have not been realized as shown in many clinical 
trials. Moreover, some, but not all, trials have found an 
increase in cancers or pre-malignant conditions in subjects 
who received folic acid. This finding has raised concerns 
that folic acid may be promoting the growth of cancerous 
or pre-cancerous lesions. There is hope that as data from 
other folic acid trials become available, this question will be 
resolved.
Folic acid has been a major success story. Food 
fortification with folic acid is one of very few modalities that 
can actually prevent a serious birth defect. Much more needs 
to be learned about the other benefits and risks associated 
with food fortification with folic acid.
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Can In Utero Exposures Program an Increased Risk For 
Diseases Decades Later In Life? 
Chapter 33
In the early 1990’s, David Barker and 
his colleagues studied the relationship 
between the incidence of coronary 
heart disease and birth weight in a 
population of adult men and women in 
Hertfordshire, England. They found an 
inverse correlation between the incidence 
of coronary heart disease and birth 
weight—the lower the weight at birth, the 
higher the risk of coronary heart disease 
in adulthood. Importantly, this was not 
simply a problem of low birth weight or 
premature birth, as the inverse relationship 
was evident among full-term births within 
a normal birth weight range (i.e., 5–10 
pounds). Subsequent studies by this group 
and others expanded the range of adult 
diseases inversely correlated with birth 
weight to include hypertension, diabetes, 
and obesity. These are components of the 
metabolic syndrome, and all contribute to 
increased risk of coronary heart disease. 
Since that time, a number of studies 
around the world have corroborated 
these findings. The “Barker hypothesis” 
postulates that organs and metabolic pathways undergo 
programming during embryonic and fetal life, which 
determines the set points of physiological and metabolic 
responses that carry into adulthood.
A corollary hypothesis, the thrifty phenotype hypothesis, 
focused on maternal and fetal nutrition as the basis for the 
observed inverse relationship between birth weight and risk of 
adult disease. This hypothesis states that during the prenatal 
(and perhaps early postnatal) period, the developing child 
can adapt to a low nutrient environment by permanently 
altering its metabolism to become more efficient at storing 
and using nutrients. The developing organism is making 
metabolic adaptations for a life of low nutrient availability, as 
predicted by its developmental environment. This “predictive 
adaptive” response would be advantageous if, indeed, the 
undernutrition experienced during development continued 
throughout life.
But what if this developmental prediction of the adult 
world is wrong? What if prenatal undernutrition is followed 
by a postnatal environment of adequate or excess nutrition? 
The ability to efficiently use and store nutrients is now a 
maladaptation, one that will favor accumulation of excess 
energy stores, putting the individual at risk for obesity along 
with insulin resistance, hyper-insulinemia, and hypertension. 
A mismatch (Figure 33-1) between the developmental 
environment and the environment in later life may be a key 
factor in increasing the risk of developing the metabolic 
syndrome in childhood or later in life. At present it is not 
clear what, if any, role the prenatal environment has played 
in the rampant increase in the incidence of childhood-onset 
obesity and diabetes seen in developed countries in the past 
few decades.
Studies in laboratory animals, including rats, mice, and 
sheep, have recapitulated the findings in human epidemiology 
studies. Pregnant rats either underfed or fed a low-protein 
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Figure 33-1. The mismatch hypothesis. Predictive adaptive responses to the prenatal 
environment (developmental programming) produce a birth phenotype adapted to a 
similar postnatal environment (e.g., nutrient deprived). Developmental programming 
probably occurs in part by epigenetic alterations to the DNA. If the postnatal environment 
does not match the prenatal environment, the individual is maladapted and may be at 
increased risk of diseases later in childhood or adulthood. Adapted from Gluckman and 
Hanson, 2008.
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diet during pregnancy have offspring that are more prone 
to obesity, hyper-insulinemia, and elevated blood pressure 
than are offspring of pregnant rats fed a nutritionally 
complete diet. Offspring of rats on the deficient diets are 
born smaller but tend to catch up to their normally-fed 
controls by weaning and then are more likely to become 
obese, hyper-insulinemic, and hypertensive, especially if fed 
a high-fat diet after weaning. Likewise, offspring of pregnant 
ewes fed a low protein diet demonstrate insulin resistance 
and elevated blood pressure. Vascular reactivity is elevated 
and the number of nephrons in the kidney is reduced in 
these offspring; both conditions contribute to elevated blood 
pressure. The periods of development most sensitive to 
the long-term effects of undernutrition have not been well 
defined in humans or animals.
There is mounting evidence that some chemical 
exposures during development may have some of the 
same long-term effects that undernutrition has on health. 
Chemicals, including phthalates, bisphenol A, organo-
tins and diethylstilbestrol, have been called environmental 
obesogens because developmental exposures to these 
chemicals can induce obesity in offspring. These chemicals 
may alter energy balance through their ability to interfere 
with fatty acid metabolism and/or nuclear receptor signaling 
in adipocytes and other cells. The developmental period 
may be particularly sensitive to such effects because the 
environment during development can determine life-long 
metabolic patterns in the individual. Recently, a variety 
of chemical exposures during pregnancy in rats has been 
demonstrated to lead to elevated blood pressure.
What are the mechanisms by which undernutrition, 
toxicant exposure, or other adverse developmental 
environments permanently affect health? Alterations of the 
hypothalamic-pituitary-adrenal axis may be a common 
mechanism underlying fetal programming. Plasma cortisol 
levels in adulthood are correlated with birth weight and 
risk of developing the metabolic syndrome. Levels of 
glucocorticoids in the fetus can be elevated by under- 
nutrition and other stressful insults that have programming 
effects. These changes in hormone levels are paralleled by 
altered expression of glucocorticoid receptors and affect 
expression of enzymes, ion channels, and transporters 
regulated by the glucocorticoids. Thus, these endocrine 
changes may be both the cause and the consequence of 
intrauterine programming.
The molecular basis for developmental programming 
is likely to be epigenetic modification of DNA. Epigenetic 
changes are those that alter the expression of genes without 
altering the genetic sequence of the genes. Two prominent 
forms of epigenetic changes are DNA methylation and 
histone modifications. For example, extensive methylation of 
cytosine nucleotides in gene promotors tends to turn genes 
off, and this silencing of genes can be permanent. Conversely, 
acetylation of histones (proteins associated with the DNA) 
can open the structure of the chromatin and enhance 
gene expression. There are periods during gametogenesis 
and embryonic development during which the methylation 
pattern of the genome is largely erased and re-established, 
and there are probably other developmental periods during 
which particular genes important for regulating growth 
and metabolism may be epigenetically altered, leading to 
developmental programming. Insights into these processes 
are emerging rapidly.
So yes, the in utero environment can affect life-long 
health, and a healthy start lasts a lifetime. A society 
devoted to the study of the Developmental Origins 
of Health and Disease (DOHaD) has a Web site with 
further information for those interested in this area: 
http://www.mrc.soton.ac.uk/dohad/.
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Adduct—A compound formed by a chemical addition 
reaction.
ADME—Absorption, Distribution, Metabolism and 
Excretion; the four functions that determine the fate of a 
chemical or drug in the body. 
Agenesis—Usually occurring at birth, the absence or 
partial development of an organ or body part.
Allantois—The extraembryonic membrane formed early 
in development as an outpouching of the yolk sac into 
the area of the future umbilical cord. It is the site of blood 
formation for the embryo and the blood vessels of the 
allantois become the umbilical artery and veins.
Allele—Alternative form of a gene. Alleles are usually 
found in pairs at a specific site on a chromosome.
Alpha fetoprotein—A protein produced by fetal tissues. 
An abnormally high amount of this protein in the amniotic 
fluid or maternal serum may signal a neural tube defect,  
or other abnormal opening in the fetus.
Amino acid—One of a group of organic compounds 
containing an amino group and a carboxyl group which 
are the building blocks of protein.
Amniocentesis—A procedure in which a small amount of 
amniotic fluid is removed and analyzed to detect genetic 
abnormalities of the fetus.
Amnion—The extraembryonic membrane that lines the 
amniotic cavity (sac).
Amniotic cavity—The fluid filled cavity that surrounds the 
developing embryo.
Anencephalus (anencephaly)—Congenital absence of 
the upper part of the brain and the flat bones of the skull. 
See also Exencephaly.
Angiotensin converting enzyme (ACE) inhibitors—A 
class of drugs that inhibit the proteolytic enzyme that 
converts angiotensin I into angiotensin II; used to treat high 
blood pressure.
Aneuploidy—An abnormal number of chromosomes.
Anotia—Congenital absence of the ears.
Antepartum—Before birth.
Anterior—A descriptive term meaning situated in the front.
Anti-mitotic—Refers to inhibition of cell division.
Apoptosis—Programmed cell death; a type of cell death 
in which the cell uses its own specialized machinery to kill 
itself.
ARND—Alcohol Related Neurodevelopmental 
Disabilities—A spectrum of functional neurologic 
(behavioral) defects resulting from in utero exposure 
to alcohol.
Ataxia—A loss of voluntary muscle coordination.
ATPase—An enzyme that hydrolyzes ATP to ADP and 
phosphate.
Atrophy—Wasting or decrease in size of a tissue or organ.
B
Basal ganglia—Several large clusters of nerve cells, 
including the corpus striatum and the substantia nigra, 
deep in the brain below the cerebral hemispheres; 
participate in the regulation of motor performance.
Bioinformatics—The science of managing and analyzing 
large amounts of biological data using advanced 
computing techniques, especially in genomics.
Biotransformation—The conversion of a compound from 
one form to another by the actions of enzymes.
Blastocyst—An early stage of the embryo; a fluid-filled 
cavity surrounded by a single celled membrane, the 
trophoblast, and containing the inner cell mass, which will 
become the embryo. 
Blastulation—The process by which the early embryo 
transforms from a solid mass of cells, the morula, to the 
blastocyst.
C
Caspase—A member of a group of protease enzymes that 
mediate apoptosis. 
Cataract—Partial or complete opacity (clouding) of the 
lens of the eye; a common cause of blindness but curable 
by surgery. 
Catecholamine—One of a group of hormones (e.g. 
epinephrine) that affects the sympathetic nervous system.
Caudal—A descriptive term meaning towards the tail; 
inferior.
Cerebellum—A part of the brain that is important for 
a number of cognitive and motor functions, including 
balance and coordination of movement. 
Cerebral cortex—The layer of unmyelinated neurons (the 
gray matter) forming the cortex of the cerebrum.
Cerebrum—The largest part of the brain important for 
integration of motor, sensory, and other mental functions, 
such as thought, reason, emotion, and memory.
Glossary
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Cerebral palsy (spastic paralysis)—A condition resulting 
from brain damage before, at, or shortly after birth, that is 
marked by lack of muscle control. 
Cerebrospinal fluid—The fluid that fills the spaces in and 
around the brain and spinal cord.
Chondrocyte—A cartilage cell. 
Chorioallantoic placenta—The placenta developed  
from the allantois and chorion; establishes a nutritive and 
excretory connection between the blood of the fetus and 
that of the mother.
Chorion—The outermost membrane enclosing the fetus. 
Chorionic villus—Any of the tiny extensions from the 
chorion that contain fetal blood vessels and combine with 
the uterine tissue to form the placenta.
Chorioretinitis—Inflammation of the choroid layer behind 
the retina of the eye.
Chromatin—Genetic material composed of DNA and 
proteins that condense to form chromosomes.
Chromosome—An organized structure of genes formed 
from condensed chromatin. In humans, there are 46 
chromosomes and 2 sex chromosomes (an X or Y).
Cleft palate—A congenital fissure along the midline of the 
hard palate.
CNS—Central nervous system: The brain and spinal cord, 
olfactory bulbs and optic nerves.
Conceptus—An embryo or fetus.
Congenital—Present at birth.
Corpus callosum—A band of white neural tissue that joins 
the left and right hemispheres of the cerebrum.
Cranial—Relating to the cranium or skull; also a term used 
for directionality meaning towards the head.
Cranial placodes—Thickenings in the surface ectoderm of 
the embryo associated with the future eye and ear regions.
Craniosynostosis—Premature fusion of the cranial bones 
leading to abnormal head shape.
Cretinism—A developmental disorder caused by deficiency 
of thyroid hormone, and characterized by severe mental 
retardation, sometimes resulting from maternal iodine 
deficiency.
Cryptorchidism—Failure of the testes to descend into the 
scrotum.
Cytotrophoblast—The inner cellular layer of the 
trophectoderm (trophoblast); part of the mammalian 
placenta. 
D
Developmental Neurotoxicity—Adverse effects on the 
development of the nervous system.
Diploid—Having a pair of each type of chromosome.
Distal—Farther or farthest from the center or trunk.
Down Syndrome—A disorder caused by an extra 
chromosome 21 (trisomy 21) and characterized by mental 
retardation and distinguishing physical features. 
Dysmorphia (also dysmorphic, dysmorphogenesis)—
A descriptive term, often referring to a birth defect, that 
indicates a difference in appearance of a body part or 
organ.
E
Ectoderm—The outermost layer in an embryo which will 
develop into the skin and nervous system.
Encephalitis—Inflammation of the brain.
Encephalocele—Protrusion of brain tissue through a 
fissure or defect in the skull.
Endocrine—Belonging to the endocrine glands or their 
secretions.
Endocytosis—A process by which extracellular materials 
are taken into cells.
Endoderm—The innermost layer of an embryo that will 
develop into the lining of the digestive tract and respiratory 
tract.
Endometrium—The inner lining of the uterus that is shed 
during menstruation.
Embryo—The developing organism from the stage after 
gastrulation when the central long axis appears until all 
major anatomical structures are present. In humans, this is 
from about the second week after fertilization to about the 
end of the seventh week of pregnancy.
Epiblast—The primitive ectoderm of the early embryo. 
Epididymis—The tightly-coiled, thin-walled tube that 
conducts sperm from the testis to the vas deferens.
Epigenetic—Refers to changes in gene expression that 
are not the result of changes in the DNA sequence. The 
changes are stable and potentially heritable.
Epoxide hydrolase—A detoxification enzyme that modifies 
epoxides by adding a molecule of water and converts them 
to a molecular structure that can be more rapidly excreted. 
Epstein-Barr virus—The herpes virus that causes infectious 
mononucleosis.
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Estriol—One of the three naturally occurring forms of 
human estrogen. It is produced in significant amounts 
during pregnancy.
Ethanol—Ethyl alcohol. 
Exencephaly—An open brain resulting from failure of 
the neural tube to close. In humans this is followed by 
degeneration of the brain, resulting in anencephaly.
External genitalia—The external sex organs.
Extracellular matrix—A non-cellular mesh of fibrous 
proteins and carbohydrate molecules (glycosaminoglycans) 
in body tissue that helps maintain and support the cells of 
that tissue.
Extraembryonic membranes—Membranes that surround 
the embryo; the chorion, yolk sac, allantois, and amnion.
F
Fetal alcohol syndrome—Characteristic facial changes 
and impaired mental development resulting from maternal 
alcohol intoxication during pregnancy.
Fetus—An unborn baby from the 8th week after 
conception until birth.
Folic acid—A B vitamin involved in DNA synthesis that is 
essential for growth and reproduction.
Frontonasal dysplasia—Also known as median cleft face 
syndrome, a rare craniofacial disorder.
G
Gamete—A sex cell. In higher animals, a sperm or an 
egg.
Gastroschisis—A malformation in which the intestines and 
sometimes other organs protrude through a defect in the 
abdominal wall.
Gastrulation—A stage of embryo development in which 
a two-layered embryo (ectoderm and endoderm) develops 
a third layer (mesoderm) through the movement of specific 
cells. 
Gene—A hereditary unit of DNA that codes for a protein, 
found in a specific location on a chromosome. Each 
human chromosome contains many thousands of genes. 
Genital folds—The embryonic structure that will 
differentiate into the penis in boys or the labia in girls.
Genome—All the genetic material in the chromosomes of 
an organism.
Genomics—The study of genes and their function.
Genotype—The genetic make-up of an individual. 
Expressions of genotype result in the phenotype which is 
how the individual looks. In the case of a recessive gene, 
such as that for albinism, persons who carry one albino 
gene and one normal allele and persons who carry two 
normal alleles, have the same (normal) phenotype, but 
different genotypes.
Germ cells—Sperm and egg cells and their precursors. 
GIFT (Gamete Intrafallopian Transfer)—A technique 
to treat infertility by fertilizing an egg in the laboratory and 
placing the resulting embryo into the fallopian tube. The 
embryo is expected to travel through the fallopian tube and 
implant in the uterus much as it would have had natural 
fertilization occurred.
Glaucoma—A disease caused by increased pressure of the 
fluid within the eye, resulting in damage to the optic nerve; 
advanced disease is a common cause of blindness.
Glial cell—A kind of connective tissue cell in the brain 
and spinal cord. Glial cells provide structural support and 
nourishment to nerve cells.
Glucocorticoids—A class of hormones, including cortisol, 
produced by the adrenal glands. Glucocorticoids mediate 
a response to stress and affect protein and carbohydrate 
metabolism.
Glycolysis—The breaking down of glucose, a simple 
sugar, to produce energy.
Growth hormone releasing factor—A hormone, made 
in the hypothalamus, that causes the pituitary to release 
growth hormone. Growth hormone is involved in growth 
and in energy metabolism.
h
Haploid—Having only one of each chromosome (see 
diploid). 
HCG (human chorionic gonadotropin)—A hormone 
made by those cells of the embryo that form the placenta. 
HCG is the hormone that is detected by pregnancy tests.
Hepatosplenomegaly—Enlargement of the liver and 
spleen.
Hippocampus—A portion of the brain, located in each 
temporal lobe, and associated with memory.
Hirsutism—Hair growth in excessive amounts and in 
unusual places.
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Holoprosencephaly—A birth defect in which the 
embryonic forebrain fails to divide completely into the 
cerebral hemispheres; results in varying degrees of mental 
impairment and abnormal development of the eye, nose, 
and lip.
Hormone—A chemical messenger produced by one organ 
and transmitted through the blood to initiate or alter the 
function of another organ or tissue.
Hydranencephaly—A rare condition in which the brain’s 
cerebral hemispheres are replaced by sacs filled with 
cerebrospinal fluid.
Hydrocephalus—Accumulation of excess cerebrospinal 
fluid within the ventricles of the brain; head enlargement 
and brain damage may occur.
Hypoblast—The innermost of the three primary germ 
layers, adjacent to the blastocyst cavity, which develops into 
the endoderm. 
Hypospadias—A birth defect in which the urethra opens 
on the underside of the penis instead of at its end.
Hypoxia—Lack of oxygen that may lead to tissue damage. 
Hydrops—Accumulation of fluid in body tissues or cavities.
I
ICSI (Intracytoplasmic sperm injection)—An infertility 
treatment in which the sperm is injected through the 
membrane of the egg into its cytoplasm.
Implantation—The embedding of the early embryo in the 
lining of the uterus.
Imprinting (Genetic)—Differential expression of a gene, 
depending on whether it was transmitted through the sperm 
or the egg; thought to be regulated by attachment of 
methyl groups to the DNA, and by chromatin structure.
Ischemia—Loss of blood flow that may lead to tissue 
damage.
Isotretinoin—A vitamin A-like medication (13-cis retinoic 
acid).
IVF (in vitro fertilization)—Fertilization outside the body, 
used as a treatment for infertility.
k
Karyotype—A picture of an individual’s chromosomes, 
arranged in order from largest to smallest, to make it easier 
to look for extra, missing, or rearranged chromosome 
material.
Ketoacidosis—Abnormally high levels of ketones and 
acids in the blood; may occur in a diabetic person who 
does not get enough insulin. 
L
Leydig cells—Cells in the testes that produce testosterone 
in the presence of luteinizing hormone (LH).
Leprosy—A disease caused by infection with the bacterium 
Mycobacterium leprae, often affecting the skin and nerves 
and causing body parts to become deformed.
LOAEL (Lowest Observed Adverse Effect Level)—
In a toxicology study, the lowest tested dose that produces 
detectable damage.
Luteinizing hormone (LH)—A hormone made by the 
pituitary gland that acts on the ovary to control egg 
maturation and triggers ovulation and acts in the testes for 
the production of testosterone.
Lysosome—A cell organelle that contains enzymes for 
intracellular digestion of proteins and other molecules.
M
Macrosomia—An abnormally large body or body part.
Malformation—A structural defect due to abnormal 
development.
Meiosis—The cell division used to make germ cells 
from body cells. The diploid number of chromosomes is 
reduced to a haploid number; for example, in humans with 
46 chromosomes, meiosis results in germ cells with 23 
chromosomes each.
Membrane—A thin layer of tissue separating or 
connecting structures or organs.
Mendelian inheritance—Passing of genetic traits from 
parents to offspring, as expected when they are determined 
by single genes.
Meningomyelocele—A birth defect following failure of the 
neural tube to close; results in protrusion of a sac of nerve 
tissue and its covering membranes. 
Mesoderm—A middle layer of cells in the embryo, lying 
between the ectoderm and the endoderm.
Metabolism—The chemical processes necessary for life 
that occur in the body. 
Metallothionein—A protein in the body that binds metals 
such as zinc.
Methylation—Attachment of a methyl group to a 
molecule. Methylation of DNA is an epigenetic event that 
alters gene expression which affects cell function.
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Microarray—A two dimensional display, typically on 
a glass, filter, or silicon wafer, upon which hundreds of 
DNA or protein samples are deposited or synthesized in 
a high-density matrix, in a predetermined spatial order, 
allowing them to be tested with labeled probes in a 
high-throughput, parallel manner. Used to study how 
large numbers of genes interact with each other and how 
a cell’s regulatory networks control vast batteries of genes 
simultaneously.
Micromass culture—A laboratory technique in which 
dispersed cells of an embryonic organ such as the brain are 
allowed to reaggregate in culture.
Minimata disease—A syndrome of mental deficiency and 
neurologic impairment caused by exposure of a fetus to 
methylmercury.
Mitochondria—Cellular organelles that generate ATP 
molecules, the chemical energy source for the body.
Mitosis—Cell division that creates two genetically identical 
daughter cells by duplicating the genetic material of a 
parent cell.
Microcephaly—A small head.
Microphthalmia—A small eye.
Morphogen—A chemical message that directs tissue 
development in the embryo. An example of this has been 
described during development of the limbs. 
Morphological—Pertaining to structure or form. 
Morula—an early multi-celled stage of the embryo from 
which the blastocyst is formed.
MSAFP—Maternal Serum Alpha-Fetoprotein. Alpha-
fetoprotein is a protein made in the fetus that normally 
leaks, in small amounts, into the mother’s circulation. If 
there is an abnormal opening in the fetus, such as a neural 
tube defect, larger amounts appear in the mother’s serum, 
providing a screening test for such fetal anomalies.
Multicotyledonary placentation—Formation of a 
placenta with many lobes 
Multifactorial inheritance—The transmission of a trait 
from parents to offspring that is determined by multiple 
genetic and environmental factors, each with a small effect.
Mutagen—An agent that increases the mutation rate.
Mutation—A permanent change in the genetic material.
Mycoplasma—A kind of minute microorganism that 
sometimes causes disease in humans.
Myelination—Coating of certain nerve fibers with a fatty 
sheath that enhances nerve signal transmission.
Myocarditis—Inflammation of the heart muscle. 
Myositis—Inflammation of muscle.
n
Necrosis—Abnormal cell or tissue death.
Neural—Pertaining to nerves.
Neural crest—A band of cells on either side of the neural 
tube. Cells from these regions migrate to form parts of the 
nervous system, face, skin, and heart.
Neural plate—A flat area in the middle of the early 
embryo that will roll up to form the neural tube.
Neural tube—The embryonic tube that becomes the brain 
and spinal cord.
Neurobehavioral—Pertaining to the function of the 
nervous system as it relates to behavior.
Neuroendocrine—Pertaining to the nervous and 
endocrine systems in anatomical or functional relationship.
Neuron—A nerve cell.
Neuropore—An opening at the cranial or caudal end of 
the neural tube before it completes closure.
Neurulation—The formation of the neural plate and its 
rolling up into the neural tube.
NOAEL (No Observed Adverse Event Level)—In a 
toxicology study, the highest dose used that fails to produce 
evidence of damage.
Nucleotide—One of the basic building blocks of DNA and 
RNA, consisting of a nitrogenous base, a phosphate group, 
and a sugar molecule.
O
Omphalocele—The abnormal presence of abdominal 
contents in the umbilical cord. It results from failure of the 
normal withdrawal of the intestines from the cord into the 
abdomen during development.
Oocyte—A female germ cell in the ovary; precursor of the 
ovum. 
Organogenesis—Formation and development of organs.
Orofacial cleft—The failure of the lip or palate to fuse 
properly.
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P
Palate (secondary)—The roof of the mouth, consisting of 
the hard palate, soft palate, and uvula. 
Pharmacogenetics—The study of single gene interactions 
with drugs. 
Pharmacogenomics—The study of the relationship 
between an individual’s genetic make-up (genome) and 
drug response. 
Phenotype—How an individual looks as a function of their 
genetic make up (see genotype).
Phenylketonuria—A recessively inherited condition in 
which metabolism of an amino acid, phenylalanine, is 
blocked; increased phenylalanine in the infant causes nerve 
and brain cell damage, and mental retardation.
Phocomelia—A birth defect with hands and feet 
attached to underdeveloped limbs; this and other severe 
malformations are associated with prenatal thalidomide 
exposure.
Pinocytosis—The engulfment of liquid droplets by a cell 
through minute invaginations of its membrane.
Placenta—The organ that is formed in pregnancy from 
both fetal and maternal tissues and functions in the growth 
and protection of the fetus.
Pluripotent—Able to differentiate into a variety of cell 
types; examples are the ovum and embryonic stem cells.
Polydactyly—The presence of extra fingers or toes.
Polymorphism—The occurrence of two or more 
genetically different forms of a gene in the same 
population, where the less frequent form has a frequency of 
1% or more.
Porencephaly—A cystic cavity in the brain; may result from 
brain tissue destruction or maldevelopment.
Posterior—A descriptive term meaning situated at the 
back.
Post-implantation—Occurring after the early embryo 
embeds into the lining of the uterus.
Postpartum—After birth.
Prader-Willi syndrome—A condition resulting from a 
deletion in chromosome 16; it is associated with short 
stature, mental retardation, small hands and feet, obesity, 
overeating, and underdeveloped gonads.
Pre-Implantation—Occurring before the early embryo 
embeds in the lining of the uterus.
Progesterone—A steroid hormone produced in the ovary 
by the corpus luteum; essential for the maintenance of 
pregnancy.
Protein kinase—An enzyme essential for protein 
phosphorylation; often involved in the signal transduction 
pathways activated by stressors.
Proteomics—Analysis of protein expression and function.
Psychomotor retardation—Retardation of both mental 
and motor development.
Q
QSAR—Quantitative Structure Activity Relationship; the 
study of the relationship of the structure of a chemical to its 
biological effect.
R
Receptor—A cell component that combines with a drug or 
other substance and thereby alters cell function.
Retinoid—A group of compounds that includes many 
metabolites of vitamin A.
Retinopathy—Disease of the retina, the innermost layer of 
the eye that receives and transmits images.
s
Sacral agenesis (caudal regression syndrome)—
Absence or significant underdevelopment of the lower part 
of the spine and lower limbs. This congenital malformation 
is associated with maternal diabetes.
Salmonella—Gram negative rod shaped motile bacteria, 
some of which cause intestinal inflammation.
SARS—Severe Acute Respiratory Syndrome; a respiratory 
illness caused by a coronavirus.
Sertoli cells—Somatic cells within the seminiferous tubule 
which support germ cell development and form tight 
junctions to create the blood testis barrier.
Signal Transduction—Within a cell, any process by which 
one kind of signal or stimulus is converted to another.
SiRNA—Short or Small interfering RNA molecules that 
decrease the expression of a specific gene by degrading its 
messenger RNA.
Somatic—Pertaining to the body (excludes reproductive 
cells).
Somatomedin—A growth factor produced by the liver 
upon stimulation by somatotropin that acts directly on 
cartilage cells to stimulate skeletal growth. 
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Somatotropin—A hormone produced in the pituitary 
gland the acts in the liver to produce somatomedin.
Somite—One of paired, segmented blocks of mesodermal 
cells on either side of the neural tube of the embryo which 
give rise to connective tissue, bone, muscle, and the dermis 
of the skin.
Spermatid—A haploid male germ cell resulting from the 
division of a spermatocyte; the precursors of spermatozoa.
Spermatocyte—A male germ cell arising from the division 
of a spermatogonium during meiosis.
Spermatogonium—An undifferentiated male germ 
cell located close to the basement membrane of the 
seminiferous epithelium in the testis; gives rise to 
spermatocytes.
Spina bifida—A defect in which part of the vertebral 
column is absent, allowing the spinal membranes and 
sometimes the spinal cord to protrude; a result of failure of 
the neural tube to close.
Steroid—Any of a number of hormones with a common 
molecular structure that regulate body functions.
Syncytiotrophoblast—The layer of trophoblast cells that 
invades the endometrium during implantation.
Syndactyly—Fusion or webbing of fingers or toes.
T
Tay-Sachs disease—A recessively inherited disease, in 
which a deficiency of hexosaminidase A causes abnormal 
storage of a ganglioside. There is progressive mental 
deterioration and early death.
Teratogen—An agent that may induce abnormal embryo/
fetal development when administered during pregnancy.
Teratology—The study of malformations or serious 
deviations from the normal type in organisms. It is 
the branch of science concerned with the production, 
development, anatomy, and classification of malformed 
fetuses.
Teratogenesis—The process by which birth defects arise.
Teratogenetics—The study of how genes and teratogens 
interact to cause birth defects.
Tetralogy of Fallot—A complex congenital heart disease 
involving four abnormalities: a ventricular septal defect, 
pulmonary stenosis, right ventricular hypertrophy, and an 
overriding aorta, which means that the aorta lies directly 
over the ventricular septal defect.
Thalidomide—A sedative, antinauseant, and hypnotic 
drug that causes abnormalities of limbs, heart, ear, and 
craniofacial structures when taken by pregnant women.
Threshold dose—The dose at which an agent has begun 
to have an effect.
Thrombocytopenia—An abnormally low number of 
platelets in the blood.
Toxoplasmosis—A disease caused by the protozoon 
Toxoplasma gondii. Infants infected during gestation may 
have hydrocephaly, microcephaly, encephalitis, cerebral 
palsy, mental retardation, loss of vision, deafness, and 
other problems.
Transcripts—Messenger RNAs that carry the genetic 
information from DNA to the ribosome to produce protein.
Transgenic organism—An organism derived by the 
transfer of one or more genes from another organism.
Trimester—A period of three months; human pregnancy is 
divided into three trimesters.
Triple screen—A combination of three tests (levels of 
MSAFP, estriol and HCG) which, if abnormal, indicate that 
the health of the fetus may be at risk.
Trisomy 18—The presence of an extra chromosome 18; 
Edwards syndrome.
Trisomy 21—The presence of an extra chromosome 21; 
Down syndrome.
Trophoblast—The outer layer of flattened cells forming the 
wall of the blastocyst.
U
Ultrasound—Sound waves of frequency higher than the 
range audible to the human ear used to delineate body 
structures by measuring the reflected waves.
Urogenital—Relating to the organs of the urinary and 
genital tracts.
V
Vas deferens—The tube that conveys sperm from the 
epididymis to the ejaculatory duct.
Ventral—On the belly side of the trunk; in humans, to the 
front of the body.
Ventricular septal defect—A defect in the wall dividing 
the two ventricles of the heart.
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W
Whole embryo culture—A technique in which embryos 
undergoing organogenesis are cultured in vitro.
Williams syndrome—A syndrome resulting from a 
deletion in chromosome 7, which is associated with an 
elf-like face, mental retardation, short stature, and cardiac 
abnormalities.
X
X-linked—Refers to a gene that is located on one of the 
sex chromosomes, which is carried by the female in a 
double dose (XX) and the male in a single dose (XY). 
Xenobiotic—A compound that is foreign to a living 
organism. Examples of xenobiotics include drugs, 
carcinogens or compounds that have been introduced into 
the body.
Y
Yolk sac—A fluid filled sac on the ventral side of the early 
embryo. Important in the transfer of nutrients during the 
second and third weeks of development.
Z
ZIFT (Zygote Intrafallopian Transfer)—The transfer of an 
in vitro fertilized zygote into the fallopian tube.
Zona pellucida—The membrane that encloses the mature 
ovum. 
Zygote—The fertilized ovum.
